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Abstract

Genetic Dissection of Quantitative Trait Loci for Substances of Abuse
By Jo Lynne Harenza, M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2013.

Major Director, Michael F. Miles, M.D., Ph.D.,
Professor, Pharmacology and Toxicology and Neurology
It has been reported that an individual’s initial level of response to a drug might
be predictive of his or her future risk of becoming dependent, thus basal gene
expression profiles underlying those drug responses may be informative for both
predicting addiction susceptibility and determining targets for intervention. This
dissertation research aims to elucidate genetic risk factors underlying acute alcohol and
nicotine dependence phenotypes using mouse genetic models of addiction.
Phenotyping, brain region-specific mRNA expression profiling, and genetic mapping of a
recombinant inbred panel of over 25 mouse strains were performed in order to identify

xxii

quantitative trait loci (QTL) harboring candidate genes that may modulate these
phenotypes. Previous BXD (B6 x D2) behavioral studies performed in our laboratory
identified an ethanol-induced anxiolysis-like QTL (Etanq1) in the light dark box (LDB).
We hypothesized that genetic variation within Nin (a gene within the Etanq1 support
interval involved in microtubule-anchoring) may modulate anxiolytic-like responses to
acute ethanol in the LDB as well as other preclinical models of anxiety, the elevated
plus maze (EPM), and marble burying (MB) task. Molecular studies have allowed us to
confirm cis regulation of Nin transcript levels in the NAc. To elucidate potential
mechanisms mediating Etanq1, the pharmacological tools, diazepam and HZ166 (a
benzodiazepine derivative) were utilized to interrogate whether GABAA receptor
activation modulates ethanol’s anxiety-like behaviors in the LDB. We show that the LDB
phenotype, percent time spent (PTS) in the light following a brief restraint stress, is not
being modulated through direct activation of GABAA α2/α3 receptor subunits. To
genetically dissect Etanq1 as well as parse the ethanol anxiolytic-like phenotype, we
have assayed 8 inbred strains, selected based on genotypes at Nin, in various
preclinical models of anxiety. Principal components analysis of these behavioral data
suggests that the gene(s) modulating the ethanol anxiolytic-like component in the LDB
do not overlap with similar phenotypes in the elevated plus maze (EPM), nor the MB
phenotype. Furthermore, site-specific delivery of an sh-Nin lentivirus into the NAc of D2
mice revealed that Nin may modulate one LDB endophenotype, latency to enter the
light side of the LDB, which loaded as a part of the “anxiolysis” principal component.
These data strongly imply that basal neuronal Nin expression in the NAc is important for
acute ethanol anxiolytic-like behavior, perhaps through a novel mechanism involving

xxiii

synaptic remodeling. In separate behavioral QTL mapping studies, we hypothesized
that genetic variation regulating expression of Chrna7 modulates the reward-like
phenotype, conditioned place preference (CPP), for nicotine. We provide evidence for
genetic regulation of Chrna7 across the BXD panel of mice and through
pharmacological and genetic behavioral studies, confirm Chrna7 as a quantitative trait
gene modulating CPP for nicotine in mice. Microarrays, followed by network analyses,
allowed us to identify a genetically co-regulated network within the nucleus accumbens
(NAc), differentially expressed in mice null for Chrna7, which was similarly correlated in
the BXD panel of mice. Our network and molecular analyses suggest a putative role for
Chrna7 in regulating insulin signaling in the NAc, which together, may contribute to the
enhanced sensitivity to nicotine observed in strains of mice that lack or have low mRNA
levels of Chrna7 in the NAc. Overall, this research has elucidated and confirmed new
genetic risk factors underlying alcohol and nicotine dependence phenotypes and has
enabled a better understanding of the neurogenomic bases of alcohol and nicotine
addiction. Future studies that further investigate the signaling pathways and/or gene
interactions involving Nin and Chrna7 may lead the field to new candidates for
pharmacotherapies that may be tailored for use in individuals with susceptible
genotypes. Supported by NIAAA grants P20AA017828 and R01AA020634 to MFM,
NIDA T32DA007027 to WLD, and NIDA R01DA032246 to MFM and MID.

Chapter 1 - Introduction

Alcohol and nicotine are two of the most widely abused drugs in the world,
accounting for nearly 8 million deaths globally and $5 million of the drug abuse-related
socioeconomic burden of the United States each year (World Health Organization,
2011). Risk for developing various aspects of drug addiction, such as tolerance and
dependence, is determined by a combination of interactions among an individual’s
genetic makeup, environment, and neuroadaptations that occur following acute and
repeated drug exposure. Alcohol and nicotine dependence each have estimated
heritabilities ranging between 30-60% (Heath, 1997; Cloninger, 1981; Swan, 1997;
Kendler, 1999; Heath, 1993; True, 1999), thus, a strong genetic component influences
these traits. Furthermore, these complex interactions manifest themselves
heterogeneously among individuals, and as such, there remains a need to understand
the biological and genetic bases of risk for developing different stages of the disease at
the level of the individual.
In order to dissect neuronal and genetic mechanisms underlying substance use
disorders, it is essential to acknowledge that drug addiction occurs through a
progression of cycles, which lead to an evolution of neurogenomic changes that
ultimately hijack the brain’s executive function center such that control over drug-taking
is lost (Koob, 2010). In one such model for the progression from acute to chronic drug
use, the first stage begins with drug-induced activation of the mesocorticolimbic reward
1

circuit, which consists of the ventral tegmental area (VTA), ventral striatum or nucleus
accumbens (NAc), and prefrontal cortex (PFC). See Figure 1.1 for a schematic of the
neurocircuitry in this pathway. Similar to natural rewards, such as food, liquids, and sex,
most drugs of abuse, including alcohol and nicotine, increase firing of dopaminergic
neurons from the VTA to increase synaptic concentrations of the excitatory
neurotransmitter, dopamine, in the NAc following acute use (DiChiara, 1988).
Interestingly, our laboratory found that in response to a single administration of a
modest dose of ethanol in mice, over 300 genes’ expression levels were significantly
altered in this reward circuit (Kerns, 2005), demonstrating the sensitivity of the central
nervous system to one dose of a drug. In fact, a single exposure to cocaine in mice has
been shown to excite dopamine neurons in the VTA and result in subsequent activation
of AMPA and NMDA receptors which persisted for at least five days (Ungless, 2001),
suggesting that acute drug use can result in at least short-term synaptic plasticity in the
mesolimbic reward pathway. It follows then, that repeated drug use, which progressively
activates this reward circuit, results in a variety of neuroplastic changes in the VTA and
NAc, leading to recruitment of feedback circuits in the dorsal striatum (consisting of the
caudate and putamen). Repeated activation of the ventral-dorsal striatal loop is thought
to lead to habit formation and drug-seeking automaticity, which are key drivers of
compulsive behaviors (Koob, 2010). Eventually, these neuroadaptations may lead to
compulsive drug use and loss of executive function maintained by the frontal cortex
structures, leading to poor decision-making and addiction. Once in full-blown addiction,
periods of abstinence are characterized by negative withdrawal symptoms, thought to

2

Figure 1.1 - Neuronal projections involved in mediating effects during the acute
and reinforcing stages of substance abuse disorders. Sagittal representation of a
rat brain depicting the neuronal circuitry implicated the early stages of drug addiction.
(VTA=ventral tegmental area, AC=anterior commissure, N.Acc=nucleus accumbens,
FC=frontal cortex, C-P=caudate putamen, AMG=amygdala, BNST=bed nucleus of the
stria terminalis, VP=ventral palladium, ARC=arcuate nucleus, LH=lateral hypothalamus,
Snr=substantia nigra pars reticula, RPn=reticular pontine nucleus, LC=locus coeruleus.
Image adapted from (Koob, 2010).

3

result from the gain-of-function of stress systems, such as the extended amygdala
circuit. Thus, a negative affective state caused by dysregulation of neurocircuitry often
leads to successive episodes of drug use to curb these symptoms (Koob, 2010).
Furthermore, in those aspiring to quit, the combination of both a loss of control and
enhanced negative emotional state often prevents rehabilitation, as the nervous
systems of these addicted individuals have essentially been “re-wired” (Figure 1.2). In
fact, 70% of adult smokers aspire to quit smoking, but only 4-7% are successful without
medication and just 25% of those using current cessation therapies are able to abstain
from smoking for six months (American Cancer Society, 2013). The high rates of
relapse are thought to result from difficulty in managing cravings and withdrawal
symptoms (National Institutes of Health, 2008). Additionally, alcoholics frequently selfreport anxiety as a motive for initiation of drinking (Brown, 1991; Pohorecky, 1991) and/
or a reason for relapse. Accordingly, alcohol’s ability to relieve anxiety is thought to
contribute to multiple facets of the alcohol use disorder, including the initiation of
drinking, the progression to excessive drinking by attempting to curb withdrawal-induced
anxiety, and consequently, recidivism (Spanagel, 1995; Pandey 2003; Sloan, 2003).
Thus, understanding the neurogenomic basis of the acute behavioral responses to
drugs of abuse may be important in uncovering new drug targets and/or lead to new
therapeutic strategies for intervention.
The major foci of this dissertation are to genetically dissect acute behavioral
responses to ethanol and nicotine using mouse models of ethanol-induced anxiolysis
and nicotine reward. It is important to note that in many cases of substance abuse
disorders, individuals also have occurrences of psychiatric illness and/or an additional
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substance use disorder. In fact, co-morbidities between nicotine and alcohol use
disorders (Dani, 2005) as well as between anxiety disorders and alcohol addiction exist
(Swendsen, 1998). However, these interactions are beyond the scope of and were not
assessed for this body of work. Rather, behavioral responses and genes underlying
each substance abuse disorder were interrogated independently. We hypothesize that
uncovering genes modulating or altered in response to such behaviors may lead to a
better understanding of the cycle of addiction and as will be discussed in the next
section, may be predictive of chronic use of the same drug. The studies herein have
elucidated and confirmed a role for two candidate genes in these behaviors, Ninein
(Nin) as a potential modulator of an acute ethanol anxiolytic-like phenotype, and Chrna7
for an acute nicotine reward-like phenotype. Furthermore, each acute phenotype
correlates to chronic behavioral responses to the same drug, suggesting that Nin and
Chrna7 are important players in the early cycles of alcohol and nicotine addiction,
respectively. Additional studies described within this dissertation have investigated the
mechanism by which the basal expression levels of each of these genes might influence
an acute drug response in the behavioral assays tested. This work has therefore
uncovered novel candidate genes and as will be discussed, potential signaling
pathways underlying acute ethanol and nicotine phenotypes within the NAc, a key brain
region involved in the acute responses to drugs. Overall, this work has elucidated two
potential genes whose basal NAc expression levels suggest a new pool of individuals
who may be more sensitive than others to the acute effects of alcohol or nicotine. Thus,
future studies investigating the downstream molecular consequences of altered basal
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expression of Nin and Chrna7 may further elucidate the pharmacological mechanisms
of acute ethanol-induced anxiolysis and nicotine reward, respectively.
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Chapter 2 - Background and Significance

Role of acute drug responses in alcohol addiction
Marc Schuckit, a pioneer in the alcohol field, made early observations that in
families with a history of alcoholism, an individual's initial response to moderate doses
of alcohol, measured as perceived intoxication (Schuckit, 1980) and/or the degree of
body swaying (Schuckit, 1994), was correlated inversely with his/her later risk for
becoming an alcoholic. Using the Subjective High Assessment Scale (SHAS), 21-25
year-old male sons or siblings of alcoholics were assessed for blood alcohol
concentration (BAC) and subjective “high” at multiple time points following consumption
of a 20% solution of ethanol, dosed by kilogram of body weight. Although there was no
overall difference in BAC compared to controls, males from alcoholic families reported
significantly different feelings on 22 of the 38 subjective measures probed. Principal
components analysis (PCA) performed using responses to both low and high doses of
ethanol in these same groups of men allowed identification of two major independent
factors contributing to roughly 60% of the variance: subjective feelings on the SHAS
after a high dose of ethanol (46%) and cortisol levels combined with sway responses
after both high and low doses of ethanol (14%) (Schuckit, 1988). These analyses
reproducibly allowed the prediction of whether the subject came from a family with a
history of alcoholism or not. Furthermore, a longitudinal study performed when these
men were 31-35 years of age revealed that 56% of men originally documented as
8

having low subjective responses to alcohol developed alcoholism, regardless of family
history, compared to only 14% of those who had high initial levels of response and this
difference was statistically significant (Schuckit, 1994). Thus, sons of alcoholics as well
as comparison subjects developed alcoholism, therefore, these studies suggest that
uncovering the genetic and/or molecular mechanisms underlying the initial response to
alcohol might allow us to predict one’s susceptibility to becoming alcoholic later in life.
These observations may not be unique to alcoholism. In fact, substance abuse
studies in rodents have begun to uncover acute phenotypic responses which may
predict chronic drug intake. For example, a study in male Long Evans rats tested
whether hypothermic responses to the exposure to a 3-hour vapor of the widely-abused
inhalant, nitrous oxide (N2O), could predict later tolerance to the drug. Rats that
developed acute tolerance to the hypothermic effects of N2O, that is, experienced a low
level of response to the inhalant, developed full tolerance to repeated bouts of N2O,
while the group that was sensitive to the acute hypothermic effects of N2O did not
develop chronic tolerance (Ramsay, 2005). Furthermore, preliminary investigation of
acute and chronic drug responses across a recombinant inbred panel of mice indicate
that certain initial drug phenotypes do correlate to chronic phenotypes for the same
drug. Additionally, these relationships are not always inverse. Specifically of note for this
dissertation, an acute nicotine reward-like phenotype correlates positively to an
anxiolytic-like phenotype following chronic nicotine administration (Figure 2.1, a) and an
acute ethanol-induced anxiolytic-like phenotype was found to correlate positively to
ethanol drinking behaviors using a two-bottle choice paradigm (Figure 2.1, b). The
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Figure 2.1 - Correlation between acute and chronic drug phenotypic responses in
mice. Using publicly available datasets from the GeneNetwork web resource, Pearson
correlations across the BXD RI panel reveal that acute responses to nicotine and
ethanol might predict chronic phenotypic responses to the same drugs. Panel a, a
nicotine preference phenotype (GN Record ID 14803) significantly correlates positively
with a chronic nicotine anxiolytic-like response (GN Record ID 15575) as measured
using an elevated plus maze. Pearson’s multiple r=0.483, adjusted r=0.3801, p=0.0415,
n=23, outliers removed. Panel b, acute ethanol’s anxiolytic-like phenotype (GN Record
ID 10964) measured using the light-dark box shows a near significant positive
correlation with daily ethanol consumption using a two-bottle choice paradigm (GN
Record ID 12623). Pearson’s multiple r=0.4569, adjusted r=0.3951, p=0.0652, n=17.
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details of these exact phenotypic responses to nicotine and ethanol will be described
later in this section.
Anxiety has been reported to play a key, yet complex, role in multiple aspects of
alcoholism, such as the initiation of drinking behavior, reinforcement, withdrawal effects,
and relapse (Spanagel, 1995; Pandey, 2003; Pohorecky, 1991; Pohorecky, 1991;
Colombo, 1995; Stewart, 1993). Human studies have observed a high prevalence of
anxiety symptoms among alcohol-dependent individuals (Schuckit, 1990) and a higher
than expected rate of anxiety symptoms in the individuals one year post-abstinence
(Schuckit, 1990; Brown, 1991), suggesting that both genetic predisposition for higher
anxiety levels and pharmacodynamic neuroadaptations resulting in increased anxiety
levels during abstinence periods following chronic use influence drinking behavior. This
complex cycle is depicted in Figure 2.2. One human study reported that increased
“state” anxiety (as measured by a tension-anxiety scale) was correlated with increased
drinking behavior (Sloan, 2003). Additionally, a study in Wistar rats reported that
increased basal anxiety resulted in increases in drinking behavior and preference
(Spanagel, 1995). Although a solid link between ethanol’s acute anxiolytic effect and
later drinking behavior has not been established in rodent models, genetic correlations
we have performed do suggest a possible link. Thus, there remains a need for
understanding the complex relationship between anxiety and alcohol.
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Figure 2.2 - Model of the involvement of anxiety in alcohol addiction disorders.
Flow diagram depicting the multiple stages of alcohol use in which anxiety levels play a
role in drinking behaviors. An individual may be genetically predisposed to high basal
anxiety levels, leading to initiation of and social drinking behaviors. Alternatively,
engaging in social and/or intermittent drinking behaviors to relieve anxiety may promote
detrimental pharmacodynamic effects in the brain of susceptible individuals. Both
possibilities may lead to continued drinking, followed by abstinence periods in which
anxiety levels rise and drinking is repeated to relieve anxiety. Repetition of this cycle
results in neuroadaptations, leading to chronic drinking and when compulsion and loss
of control ensue, addiction. Adapted from (Pandey, 2003).
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Brain regions and neurotransmitters involved in “anxiety”.
!

Anxiety is often diagnosed clinically as a sense of apprehensiveness or panic

despite the absence of an immediate threat (Lieb, 2005) and many forms of anxiety
disorders exist. Functional MRI (fMRI) studies performed on human subjects diagnosed
with anxiety disorders confirmed two brain regions commonly associated with anxiety as
it relates to fear response and suppression, the amygdala and ventral prefrontal cortex
(vPFC), respectively (Indovina, 2011). The amygdala receives sensory input from the
hippocampus, thalamus, and executive cortices (eg, PFC) through its basolateral and
lateral nuclei, termed the basolateral amygdala (BLA), and subsequently, integrates this
information into a signal which it sends to the central amygdala (CeA), bed nucleus of
the stria terminalis (BNST), and NAc via glutamatergic efferents (McCool, 2010).
Collectively, the CeA, BNST, and NAc are referred to as the “extended amygdala”.
Furthermore, optogenetics studies in mice have recently dissected the microcircuitry of
the amygdala to find that activation of BLA glutamatergic terminals in the CeA result in a
reversible anxiolytic-like response in the elevated plus maze and open field preclinical
anxiety tests, while inhibition of this projection produced an anxiogenic-like response in
the same assays (Tye, 2011). Thus, the involvement of the amygdala in anxiety-related
emotional states is well-accepted.
!

Interestingly, fMRI studies in which personalized stressful imagery relating to past

experiences was shown to healthy subjects, revealed significant increases in activation
of the medial prefrontal cortex (mPFC), anterior cingulate, striatum, substantia nigra,
thalamus, caudate, putamen, and hippocampus (Sinha, 2004), indicating a role for the
striatal-limbic-prefrontal circuits in response to emotional distress. In support of this,
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eQTL mapping studies in the Miles laboratory implicate genes within the nucleus
accumbens (NAc) as potential modulators of anxiolytic-like phenotypes following acute
ethanol administration (Putman, 2008; Wolen, 2012). Though generally thought to be
the “reward” and reinforcement” center of the brain, rather than perceiving “anxiety”,
studies have shown a neuroanatomical circuit link between the amygdala and the NAc.
As mentioned earlier, the NAc is a component of the extended amygdala circuit. In fact,
in monkeys and mice, the amygdala was found to contain projections to multiple regions
of the striatum, including the NAc (Russchen, 1985; Novejarque, 2011). Thus, activation
of these projections in response to an anxiogenic-like or anxiolytic-like stimulus, such as
a saline or ethanol injection, likely triggers signaling events in the NAc, which may have
been captured by microarray gene expression profiling performed following behavioral
testing in the LDB (Putman, 2008).
!

Alcohol has numerous molecular targets in the central nervous system, many of

which have also been linked strongly to anxiety, making it difficult to dissect ethanol’s
anxiolytic mechanism. These include many of the systems discussed below, but a larger
weight has been placed on the gamma-aminobutyric acid receptor subunit A (GABAA)
system, as that is the focus of Chapter 5.

Gamma-aminobutyric acid (GABA)
It has been well-established that ethanol, similar to benzodiazepines,
barbiturates, anesthetics, and neurosteroids, is a positive allosteric modulator of GABAA
receptors, potentiating GABAergic neurotransmission (Sieghart, 1994; Rudolph, 1999;
Kumar, 2004). Since cross-tolerance exists between chronic ethanol and
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benzodiazepines or barbiturates and these classes of drugs are often used to treat
alcohol withdrawal and anxiety (Kumar, 2004), GABAA receptors have long been
implicated in the interplay between alcohol and anxiety (Enoch, 2008; Ducci, 2007; Low,
2000; Griebel, 2000; Buck, 2001). GABAA receptors are heteropentameric ligand-gated
ion channels most commonly comprised of 2α, 2 β, and 1ϒ subunits. Diazepam has
been the prototypical anxiolytic used in research because of its anxiolytic effects
observed clinically (Chouinard, 1983). Diazepam act as an agonist at α1, α2, α3, α5, β,
and ϒ2 subunits of GABAA receptors with comparable affinities (Mohler, 1977;
Braestrup, 1977). Studies using mice with a point mutation in the α1 subunit (H101R),
rendering the subunit diazepam-insensitive (Rudolph, 1999), revealed that the α1
subunit controls the sedation and anti-convulsant effects of diazepam (Rudolph, 1999),
but not anxiolytic effects. Later, studies linked the α2 subunit to anxiolysis through
generation of two additional GABAA subunit mutants, the α2(H101R) or α3(H126R),
rendering them diazepam-insensitive (Low, 2000; Crestani, 2001). PTS in the light side
of a LDB increased dose-dependently versus control following low doses of diazepam
(0.5, 1, and 2 mg/kg, p.o.) in both WT and α3 mutants, but not α2 mutants. PTS in the
open arms of the EPM following a low dose of diazepam (2mg/kg, p.o.) was significantly
increased in WT and α3 mutants, but not α2 mutants, suggesting that diazepam’s
anxiolytic effect is mediated through GABAA α2 subunits, but not α3 (Low, 2000).
However, TP003, a GABAA α3 selective agonist, produced anxiolytic-like effects in a rat
unconditioned model and a non-human primate conditioned model of anxiety,
demonstrating that α3 subunits do play a role in anxiolysis (Dias, 2005). In rhesus
monkeys, the specific GABAA α2/α3 agonist, HZ-166, produced an anti-conflict
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response similar to diazepam without locomotor suppression effects (Fischer, 2010).
Furthermore, multiple human studies, through the Collaborative Study on the Genetics
of Alcoholism (COGA) dataset and independent samples, have identified strong
evidence of association between alcohol dependence and Gabra2, the gene encoding
the GABAA α2 subunit (Edenberg, 2004; Pierucci-Lagha, 2005; Covault, 2004; Dick,
2006; Fehr, 2006; Lappalainen, 2005; Soyka, 2008). Therefore, we chose to interrogate
the GABAA receptor system, hypothesizing that ethanol might be eliciting its anxiolyticlike effects, PTS and PDT in the light side of the LDB, through this system.

Corticotrophin-releasing hormone (CRH)
A large body of literature consists of evidence of the involvement of the “stress”
hormone, corticotrophin-releasing hormone, CRH (aka, corticotrophin releasing factor,
CRF), in both anxiety and alcohol use disorders. CRH, secreted by the hypothalamus in
response to a stress stimulus, activates its receptors, Crhr1 and Crhr2, on the anterior
pituitary glands. This triggers the release of a second neurohormone, adrenocorticotrophic hormone, ACTH, which binds to and activates its receptors on the adrenal
glands, finally leading to the release of the neurosteroid, cortisol in humans or
corticosterone in rodents. Cortisol has widespread effects on the body, but its major role
is to counteract the stress response and attempt to return the body to homeostasis.
Once this is achieved, cortisol can negatively regulate its own production through
inhibitory feedback loops at the level of secretion of both CRH and ACTH. This
biochemical pathway is known as the hypothalamic-pituitary-adrenal (HPA) axis. Mice
lacking a functional Crhr1 gene displayed dampened HPA axis activation to acute stress
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and showed significant decreases in latency to enter and increases in time spent in the
center of an open field compared to wild-type mice, indicating overall decreases in basal
anxiety-like levels in these mice (Smith, 1998; Timpl, 1998). Furthermore, these same
Crhr1 knockout mice demonstrated a significantly reduced anxiogenic-like phenotype
following withdrawal from a forced ethanol-drinking paradigm, as indicated by more time
spent in the light side of the LDB compared to wild-type mice (Timpl, 1998). Additionally,
administration of the pharmacological Crhr1 antagonist, CP-154,526, in the Balb/c
mouse strain resulted in significant increases in time spent in the light side of the LDB
compared to vehicle-treated mice, however, did not cause increases in percent time
spent in the open arms of the EPM (Griebel, 1998). In contrast to these studies which
generally support a role for Crhr1 in anxiety-like behaviors, experiments targeting Crhr2
suggest that it has a role in mediating anxiolytic-like responses. Following LDB and
EPM testing, Kishimoto and colleagues found that Crhr2 knockout mice spent less time
in both the light and open arms, respectively, compared to their wild-type counterparts
(Kishimoto, 2000). Furthermore, Crhr2 knockout mice showed hypersensitive stress
responses, as evidenced by significantly higher levels of plasma corticosterone after
both 2 and 10 minutes of restraint stress (Bale, 2000). Pharmacogenetic experiments, in
which antisense mRNA oligonucleotides, designed against either Crhr1 or Crhr2, were
infused into the lateral ventricle of male Wistar rats, revealed some interesting findings
related to the role of these receptors in stress- and anxiety-related behaviors. Four days
following infusion, mice were immersed into a social defeat challenge to engage
anxiogenic-like behaviors and immediately tested in the EPM. Infusion of the Crhr1
antisense sequence resulted in increases in anxiolytic-like responses, supporting
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aforementioned observations, however infusion of the Crhr2 antisense sequence did not
alter defeat-induced anxiogenic-like responses (Liebsch, 1999). Following a forcedswim test, used to assess stress-coping behavior, rats with the Crhr2 antisense
oligonucleotides showed increased immobility, but no differences were found in rats
infused with the Crhr1 antisense sequence (Liebsch, 1999). The authors concluded that
perhaps Crhr1 is involved in mediating the affective aspect of stress, while Crhr2 is
involved in stress-coping mechanisms.
In addition to its role in stress and anxiety, genetic variation within the CRH
system has been associated with alcohol addiction phenotypes. Genome-wide
association studies using the COGA dataset have identified a single nucleotide
polymorphism (SNP) in Crhr1 that is significantly associated with alcohol dependence
(Chen, 2010). Another study found that increased incidences of stressful life events in
individuals with homozygous C alleles for the Crhr1 SNP, rs1876831, were significantly
associated with an earlier age of drinking initiation and higher consumption of alcohol
when exposed to stress. Additionally, individuals with an A allele for rs242938 also
showed significantly higher levels of alcohol consumption following stress (Schmid,
2010). Thus, the CRH system is not only involved in stress and anxiety emotional
states, but also may be important in modulating responses to both acute and chronic
ethanol.

Neuropeptide Y (NPY)
NPY is an endogenous 36 amino acid peptide found at its highest CNS
concentrations in the basal ganglia, amygdala, and nucleus accumbens, suggesting its
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importance in motor function and/or anxiety-related emotion (Adrian, 1983). NPY acts at
four different receptors, NPY Y1, NPY Y2, NPY Y3, and NPY Y5, but its anxiolytic-like
properties are thought to be elicited through the NPY Y1 receptor (gene name, Npy1r).
Early studies by Markus Heilig and colleagues showed that infusion of low doses of
NPY into the lateral ventricle of male albino rats significantly increased preference for
the open arms of the EPM following the Montgomery conflict test, which was used to
raise anxiety levels prior to testing (Heilig, 1989). As expected, high doses of NPY
resulted in decreases in locomotor activity. Additional intracerebroventricular (i.c.v.)
infusion studies in rodents found that NPY produced anxiolytic-like responses in
punished responding (Heilig, 1992) and fear-potentiated startle (Broqua, 1995) anxiety
models. NPY knockout mice displayed anxiogenic-like phenotypes in the open field test
and acoustic startle tests (Bannon, 2000), further supporting the notion that NPY
promotes anxiolytic-like behaviors. Intra-amygdalar infusions of NPY into the basolateral
(BLA), but not central (CeA), amygdala resulted in anxiolytic-like response in the social
interaction test. Furthermore, the BLA anxiolytic-like effect was reversed with an NPY
Y1-selective antagonist but not its inactive enantiomer (Sajdyk, 1999).
Genetic variation within the NPY gene and its receptors have been associated
with alcohol dependence phenotypes in both model organisms and human studies. For
example, loss-of-function of Npr-1 (an NPY-like receptor gene) in the nematode model
organism, Caenorhabditis elegans, resulted in a faster rate of development of an
ethanol acute functional tolerance phenotype (Davies, 2004). In humans, two SNPs
upstream of the Npy2r gene, rs4425326 and rs6857715, were significantly associated
with alcohol dependence and two intronic and one promoter SNP within Npy5r were
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significantly associated with withdrawal-induced seizures using the COGA dataset
(Wetherill, 2008). Overall, this subset of the many studies investigating the NPY system
not only demonstrates its involvement in anxiety-related behaviors and ethanolresponsive phenotypes, but also suggests that the interactions are complex.

Cannabinoid (CB) Receptors.
Evidence exists linking the endogenous cannabinoid (EC) system with both
anxiety as well as the rewarding and reinforcing aspects of drugs of abuse, including
ethanol. The EC system consists of two receptors, CB1 and CB2, activated by the
endogenous cannabinoids, anandamide (AEA) and 2-arachidonylglycerol (2-AG)
(Rinaldi Carmona, 1996). Specifically, the CB1 receptor (gene name, Cnr1) has been
implicated in anxiolytic-like as well as ethanol-responsive behaviors in rodent and
human studies. Hungund and colleagues reported differences in both CB1 receptor
density and affinity in the brains of C57BL/6J and DBA/2J mice, strains which display
multiple divergent responses to ethanol. B6 mice exhibit a 25% lower density, but
greater affinity of CB1 receptors than D2 mice (Hungund, 2000). As B6 mice voluntarily
consume ethanol and D2 mice typically avoid it (McClearn, 1959), these results may
suggest a relationship between CB1 signaling and drinking behavior. Moreover, Cnr1
knockout mice display reduced ethanol self-administration (Wang, 2003) and preference
(Vinod, 2008), but increased basal anxiogenic-like phenotypes in the LDB, EPM, and
social interaction assays (Uriguen, 2004). Cnr1 knockouts also failed to display
increases in anxiolytic-like responses the clinically-prescribed anxiolytics, bromazepam
(a benzodiazepine) and buspirone (a 5HT1A partial agonist), compared the wild-type
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strains in the LDB test (Uriguen, 2004). Behavioral pharmacology studies targeting the
CB1 receptor reported an increased anxiogenic-like phenotype in the an outbred strain
of mice, CD-1, tested in the EPM, open field (OF), and elevated T-maze models of
anxiety following administration of a low dose of CB1-selective antagonist, SR141716
(Thiemann, 2009). These findings may suggest a role for activation of CB1 receptors in
mediating acute anxiolytic-like phenotypes and/or chronic ethanol drinking behaviors.

Behavioral models for assessing acute phenotypic responses to drugs
Preclinical anxiety assays
!

The rodent model of anxiety from which this project stemmed is the light-dark box

(LDB) due to its predictive validity in assessing select benzodiazepines known to be
anxiolytic in humans (Crawley, 1980; Borsini, 2002; Hart, 2010). Mice have an innate
aversion to light, so when faced with a choice between light (or white) and dark (or
black) chambers (diagrammed in Appendix A1), they spend more time (Costall, 1989)
and travel a greater distance (Onaivi, 1989) in dark side of the LDB. Conversely,
following administration of clinically-prescribed anxiolytic drugs such as benzodiazepines, mice will spend significantly more time or explore more in the light side of
the box, thus this preference for the light side is routinely interpreted as anxiolytic-like
(Crawley, 1980; Blumstein, 1983). In support of this, when given an acute dose of
ethanol, a drug known to cause anxiolysis in humans, mice spend a significantly greater
amount of time and travel a greater distance in the light side of the LDB compared to
mice pretreated with saline. Accordingly, our laboratory has identified that these two
phenotypic responses to ethanol, percent time spent (PTS) and percent distance
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traveled (PDT) in the light are complex traits which are tightly genetically correlated to
each other (Putman, 2008) and a major portion of this dissertation focused on
elucidating the genetic variants underlying these phenotypes in mice.
A second major preclinical model of anxiety utilized throughout the experiments
presented herein is the elevated plus maze (EPM), in which four arms in the shape of a
cross, two with walls and two without walls, are elevated from the ground (diagrammed
in Appendix A2). In this assay, clinically efficacious anxiolytic drugs which increase in
the time spent on the open arms and/or number of entries into the open arms have
given the EPM predictive validity as an assay measuring “anxiety” (Pellow, 1985; Hart,
2010). However, alternative interpretations of phenotypic responses in this assay
include measurement of fear-related, avoidance, conflict, and/or risk-taking behavior.
Furthermore, this particular assay may measure some aspect of stress, as mice
exposed to only the open arms of the maze show increases of plasma corticosterone
levels (Fernandes, 1996), a hormone produced in response to stress-induced activation
of the hypothalamic pituitary adrenal axis. Additionally, male DBA/2J mice exposed to
social defeat stress show decreases in time spent in the open arms (Rodgers, 1993).
A third experimental model utilized in a portion of the experiments is marble
burying (MB) behavior, however, its translation to a particular affective human condition
is widely debated. In this assay, a cage is filled with bedding and 20 marbles are placed
in an evenly-spaced grid and the number of marbles buried during a test session is
recorded. The earliest record of this test reported its utility in discriminating major versus
minor tranquilizers such that administration of major tranquilizers resulted fewer marbles
buried, likely due to locomotor suppression effects (Broekkamp, 1986). Later, the test
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was suggested to model anxiety under the premise that rodents tend to bury novel or
noxious objects using both conditioned and unconditioned methods. For example, rats
buried novel glass marbles (Poling, 1981) as well as drinking spouts containing tobasco
sauce, but not those containing water or a palatable saccharin solution (Wilkie, 1979).
Additionally, the clinically-prescribed anxiolytics, diazepam, alprazolam, chlordiazepoxide, and buspirone, all decreased marble burying at doses that did not
suppress locomotor activity in C57BL/6J mice (Njung'e, 1991; Nicholas, 2006),
supporting its predictive validity in assessing anxiolytic-like phenotypes in rodents.
Interestingly, marble burying was also significantly reduced following anti-depressant
(paroxetine, fluoxetine, and citalopram), anti-psychotic (haloperidol and chlorpromazine), opiate (morphine), stimulant (D-amphetamine), and muscarinic AChR
antagonist (atropine) administration at doses which did not significantly decrease
locomotor activity (Nicholas, 2006). These studies suggest that the marble burying test
might be measuring some factor common to each of the affective states mentioned.
As suggested above, “anxiety” is not a unitary phenomenon, but rather, is
comprised of multiple dimensions including, but likely not limited to, fear, suppression of
novelty-seeking, general activity, avoidance, stress, and/or decision-making when faced
with conflict (Henderson, 2004; Turri, 2001; Clement, 2007; Brigman, 2009; Rodgers,
1995), making interpretation and generalization of phenotypic responses across assays
challenging. Furthermore, it has been shown that the phenotypes measured by each
behavioral assay are made up of unique combinations of these dimensions (Turri,
2001), contributing to the overall phenotypic response. Even more striking, an early
factor analysis study determined that anxiolytic-like activity on the open arms of the
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EPM with ledges loaded onto one factor, while activity on arms without ledges loaded
onto another (Fernandes, 1996). Thus, the genetic variants driving these complex
phenotypes are highly sensitive to the assay, its construction, environmental factors,
and dimensions of multiple assays may both overlap and be distinct.

Rodent models of reward
As described earlier, most substances of abuse activate the mesolimbic
dopamine pathway, which results in rises in extracellular dopamine levels to promote
signaling events leading to the perception of reward. One way this is modeled in rodents
is through a Pavlovian conditioned stimulus choice test, known as conditioned place
preference (CPP). The premise behind CPP is that pairing a rewarding drug with one
type of environment, called the conditioned stimulus, would result in an increased
preference for that environment in the absence of the drug. This test has been used in
animals since the early 1940s to model the appetitive reward-like properties of drugs of
abuse (Spragg, 1940; Rossi 1976). It is important here to note that although originally
morphed together, “reward” and “reinforcement” are independent stages of the drug
addiction cycle. In fact, CPP and drug self-administration were originally thought to be
isomorphic models of drug reward, however, that idea is no longer generally supported.
Rather, it is commonly accepted that self-administration models “reinforcement” and
CPP models “reward” (and may be influenced by other factors such as novelty-seeking
and memory), thus each assay measures different components of drug preference or
drug-seeking behavior in animals (Bardo, 2000). As mentioned in the previous section,
multiple factors play a role in rodent phenotypic responses and CPP is especially
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sensitive to environmental influences (Buccafusco, 2009). In the CPP paradigm used
herein, mice received cage enrichment every other day during the week prior to testing.
The apparatus consists of white and black chambers differing in floor texture, either
white mesh or black rod, representing two different environments (for a schematic, see
Appendix A3). For three days, drug injections are paired with one chamber and vehicle
injections are paired with the other and on the fourth day, mice are placed into the
apparatus and preference to the drug is interpreted as an increase in time spent in the
compartment previously paired with the drug (Kota, 2007). A portion of this dissertation
work utilizes the CPP paradigm to genetically map nicotine preference phenotypes
across a recombinant inbred panel of mice. We hypothesize that elucidating the genetic
underpinnings of nicotine CPP may lead to discovery of novel neural pathways that play
a role in reward (Bardo, 2000).

Quantitative Trait Loci (QTL) Mapping
Two of the most commonly used and fully sequenced inbred strains of mice are
C57BL/6J (B6) and DBA/2J (D2) due to excellent breeding ability, heartiness, and
longevity (Silver, 1995). Inbred strains are powerful genetic tools because of their
homozygosity at all loci, allowing behavioral and molecular investigation and trait
comparisons between laboratories and/or several years apart, ceteris paribus (Crabbe,
1999). B6 and D2 mice are highly polymorphic, containing over 4 million single
nucleotide polymorphisms (SNPs) between the two strains alone (Walter, 2007; Walter,
2008), and they show divergent phenotypic responses to multiple drugs of abuse
(Jackson, 2009; Elmer, 2010; Fish, 2010; Van der Veen, 2007). Therefore, the B6 and
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D2 strains were used as progenitors of the BXD recombinant inbred (RI) panel for use
in genetic mapping of quantitative traits. Briefly, B6 and D2 mice were outcrossed to
produce an obligate heterozygous F1 generation. F1 siblings were intercrossed to
produce an F2 generation in which B6 and D2 alleles recombine at random loci across
the genome. F2 siblings were intercrossed and the progeny of this mating were inbred
for 20+ generations to create a mosaic of B6 and D2 haplotypes along every
chromosome with homozygosity at nearly every locus (Taylor, 1978). Each resulting
BXD RI strain has a unique, fixed combination of B6 and D2 haplotype blocks, in which
over 14,000 polymorphic SNP and microsatellite markers have been extensively
genotyped (Williams, 2001; Wang, 2003). To nearly double the number of recombination
events per strain and subsequently, the resolution of mapping, advanced-intercross RI
(ARI) strains were developed by randomly intercrossing (non-brother-sister and noncousin matings) mice starting with BXD F2 mice for 9-14 generations, followed by at
least 20 generations of inbreeding (Peirce, 2004). Thus, the BXD panel of mice provides
a powerful tool for quantitative trait loci (QTL) analysis and has been used extensively to
map QTL for genetically-driven traits, such as ethanol-responsive phenotypes (Buck,
2001; Demarest, 1999; Phillips, 2010; Grisel, 2002; Christensen, 1996; Crabbe, 1999;
Yoneyama, 2008; Crabbe, 1998; Radcliffe, 2000), physiological measures (Grisel, 2002
Porcu, 2011; Jellen, 2012; Kirstein, 2002), as well as anxiety-related phenotypes
(Bailey, 2008; Yalcin, 2004), for example. In addition to B6 and D2, most of the inbred
mouse strains in use today have been SNP-typed and indel-typed (insertion/deletion) by
multiple groups (Frazer, 2007; Yalcin, 2011; Keane, 2011) within the past few years,
making mice a valuable tool in the genetics field.
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Using expression genomics in drug abuse research
By obtaining phenotype data (behavioral or other) from BXD RI and ARI panels
of mice, QTL can be quickly mapped using the online resource, WebQTL (Wang, 2003).
Like behavioral traits, mRNA (or even protein) expression levels, if genetically driven,
can be mapped as quantitative traits (Damerval, 1994; Schadt, 2003). These are
referred to as expression QTL (eQTL) and are predicted to underlie complex traits
(Damerval, 1994; Sladek, 2006). Genetic regulation of eQTL may be either cis (local) or
trans (distal), such that genes with eQTL regulated in cis map to a location within 20Mb
(~10cM) of the eQTL peak and those regulated in trans map elsewhere in the genome
(Doss, 2005; Sladek, 2006). Thus, cis eQTL result from genetic variation such as SNPs
or structural variants within or near the gene itself and as such, are thought to be the
primary drivers of complex traits (Doss, 2005; Sladek, 2006; Fehrmann, 2011). For
example, cis-modulation of hippocampus mRNA expression of the Per3 gene in the
BXD panel was found to be the result of an indel variant within the Per3 gene which
controls its transcript abundance by altering the binding of a transcription factor at that
site (Wang, 2012). Another study discovered that tandem repeat variation within the
promoter region of the CTSB gene was causative for its cis-regulation in neurons and
white blood cells (Borel, 2012). Other possibilities include variation within the 3‘UTR
leading to increased or decreased miRNA binding at the seed region, intronic or exonic
variation at splicing, enhancer, or insulator sites leading to altered alternative splicing or
altered promotor activity. Alternatively, trans eQTL result from genetic variation at a
locus distal to the eQTL peak, for example, variation within a transcription factor or distal
enhancer or miRNA, and may represent secondary or tertiary effects that may converge
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on downstream genes or pathways (Fehrmann, 2011). Thus, by correlating behavioral
QTL (bQTL) with eQTL from the same samples, candidate quantitative trait genes
(QTGs) can be prioritized for testing if a cis eQTL is present in the same tissue where
the gene’s expression significantly correlates to the phenotype (Sladek, 2006;
Hitzemann, 2004). The major premise of this dissertation utilizes this integration of
phenotypic data from BXD RI strains and corresponding genomic data, termed
“genetical genomics”, in such a way to identify and test QTGs influencing acute ethanol
and nicotine traits. This approach is illustrated in Figure 2.3.

Acute ethanol-induced anxiolysis QTL 1, Etanq1
The ethanol studies discussed herein originated from work performed by Dr.
Alexander Putman from the Miles Laboratory. Using the LDB preclinical model of
anxiety, 27 BXD strains were tested for an anxiolytic-like response to acute ethanol,
measured as PTS or PDT in the light. Nearly every strain tested showed significant
increases in these phenotypes compared to saline treatment, indicating that these
phenotypes contribute to the anxiolytic-like properties of ethanol. Furthermore, the strain
distributions for these phenotypes were continuous, indicative of quantitative traits. QTL
mapping of these two acute ethanol phenotypes identified overlapping significant
behavioral QTL (bQTL) on chromosome 12 and suggestive QTL on chromosome 1,
suggesting that the major gene(s) influencing PTS and PDT might lie on chromosome
12. The support interval for the bQTL on chromosome 12, deemed Etanq1 (ethanolinduced anxiolysis QTL 1), ranged from 53.9–71.6Mb and contained over 100 genes
(Putman, 2008). As it is impractical to test such a large number of genes in the mouse,
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Figure 2.3 - Flowchart of the “genetical genomics” approach to identifying
quantitative trait genes. For this dissertation work, genetic mapping of an acute
nicotine reward-like phenotype across the BXD RI panel was performed. Expression
data from the mesolimbic dopamine reward pathway (PFC, NAc, and B) were used for
eQTL analysis and correlations to bQTL in order to prioritize candidate genes. For the
acute ethanol anxiolytic-like phenotype, previous studies from our laboratory took this
approach and candidate genes were narrowed to four, one of which will be a focus this
dissertation.

29

Dr. Aaron Wolen from the Miles Laboratory sought to narrow this support interval by
testing additional strains from the ARI BXD population. As mentioned previously, these
BXD strains were created in such a way to introduce significantly more recombination
events than existed in the original panel of BXDs. By selecting strains with
recombinations within the original support interval, Dr. Wolen successfully narrowed the
Etanq1 support interval to a 3.5Mb region on chromosome 12, 69.1–72.6Mb, thus
reducing the number of candidate genes for investigation to 48 genes (Wolen, 2012).
Four hours following behavioral testing of each cohort of BXDs, mice were
sacrificed and brain regions from the mesolimbic dopamine reward pathway, VMB, NAc,
and PFC, were used for mRNA expression profiling by microarrays (Wolen, 2012).
Previous studies performed by our laboratory have shown that this four hour time point
captures a genomic profile of signal transduction events that occurred in response to
drug administration (Kerns, 2005). At this time point, an array of early, intermediate, and
late gene expression changes in response to ethanol can be detected. Additionally,
neuroadaptations occurring in response to the behavioral testing may also be captured.
These expression data were then subjected to eQTL analysis and by using a geneticalgenomics approach to identify relationships between bQTL and eQTL, candidate genes
were characterized and prioritized for interrogation. Chapter 5 focuses on the
interrogation of one such gene, Ninein.
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Chapter 3 - Etanq1 Correlation with Anxiolytics Targeting GABAA
Introduction
Risk for developing alcoholism is determined by the combination of genetic
predisposition, environment, and neuroadaptations that occur following acute and
chronic exposure to alcohol. Early twin studies estimated heritability for alcohol
dependence risk ranging around 60% (Heath, 1997), thus a significant genetic
component determines one’s susceptibility to this disease. Human studies have also
observed a high prevalence of anxiety symptoms among alcohol-dependent individuals
(Schuckit, 1990) and a higher than expected rate of anxiety symptoms in the individuals
one year post-abstinence (Schuckit, 1990; Brown, 1991). In fact, one study reported
that increased “state” anxiety (as measured by a tension-anxiety scale) was correlated
with an increase in drinking (Sloan, 2003). In support of this, a study in Wistar rats
reported that increased basal anxiety resulted in increases in drinking behavior and
preference (Spanagel, 1995). As alcoholics frequently report anxiety as motivation for
drinking (Koob, 1997; Brown, 1991; Schuckit, 1990), we hypothesize that alcohol’s
ability to relieve anxiety may contribute to initiation of drinking behavior and/or relapse in
an attempt to curb withdrawal-induced anxiety. However, the genes and receptor
systems involved in ethanol-induced anxiolysis are poorly understood, thus, there
remains a need for understanding this complex interplay between anxiety and alcohol
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so that future preventions and/or treatments might aid in the treatment of alcohol use
disorders.
Our laboratory has previously identified and confirmed a quantitative trait locus
(QTL), Etanq1, across the BXD genetic mapping panel of mice for two anxiolytic-like
phenotypes following acute ethanol administration (for background, see Chapter 2).
These phenotypes, percent time spent (PTS) and percent distance traveled (PDT) in the
light side of a light-dark box (LDB) have been used preclinically to predict the efficacy of
anxiolytic drugs (Crawley, 1980; Blumstein, 1983). Thus, this model for measuring
anxiolytic-like behavior in rodents is well-accepted. We sought to determine whether
acute ethanol is mediating this anxiolytic-like response through the GABAA system, a
receptor system known to be involved in both anxiolysis and alcohol use disorders (See
Chapter 2). We asked whether the commonly prescribed anxiolytic agent and known
target of the GABAA receptor system, diazepam, would produce similar responses to
ethanol in BXD strains in the LDB paradigm used herein. Since the BXD strains showed
a continuous distribution for the Etanq1 phenotypes, we predicted that strains with
extreme phenotypes for their ethanol responses would have similar responses to
diazepam if Etanq1 was being elicited through direct activation of GABAA α1, α2, α3, α5
receptors. Additionally, as it is believed that the GABAA system elicits its anxiolytic
responses through agonism of GABAA α2/α3 subunits of the receptor, we utilized a
selective GABAA α2/α3 agonist, HZ166 (a benzodiazepine derivative) in the same way.
We hypothesized that if Etanq1 is being modulated through direct agonism of GABAA
α2/α3 subunits, PTS and PDT in the light following HZ166 administration would result in
a mimicking of ethanol’s responses observed in selected BXD strains. Surprisingly, we
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show that the LDB phenotypes, PTS and PDT in the light following ethanol treatment
are not being modulated through direct activation of GABAA α1, α2, α3, α5 receptors.
Thus, the PTS and PDT phenotypes might result from activation of an alternate receptor
system known to be involved in anxiolysis or Etanq1 may be acting through a novel
mechanism.

Materials and Methods
!

Mice and Husbandry Conditions. For all studies, male mice were used, housed

2-4 per cage, and allowed at least a one-week acclimation period to the vivarium
following shipment to Virginia Commonwealth University (VCU). Mice were maintained
on a 12-hour light/dark cycle with ad libitum access to standard rodent chow (Harlan,
7012) and tap water. All mice were 8-12 weeks old at time of testing. C57BL/6J and
DBA2/J mice were obtained from Jackson Laboratories (Bar Harbor, ME) and Hsd, ICR
(CD-1) mice were obtained from Harlan Laboratories (Indianapolis, IN). Mice were
housed with Teklad aspen sani-chip (Harlan, 7090A) or Teklad corn cob (Harlan, 7092)
bedding, where noted.
!

Drugs. For LDB studies, a 1.8g/kg of ethanol dose was administered using a

10% ethanol (w/v) stock solution dissolved in a 0.9% physiological saline vehicle. This
dose was chosen based on previous LDB studies in our laboratory (Putman, 2008).
Diazepam dose response curves were performed using the following doses, 0, 0.5, 1.0,
5.0, and 10.0 mg/kg in a vehicle of 5% Tween 80 in 0.9% saline. HZ-166 ((8-ethynyl-6(2’-pyridine)-4H-2,5,10b-triaza-benzo[e]azulene-3-carboxylic acid ethyl ester) dose
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response curves were performed using the following doses, 0, 0.3, 1.0, 3.0, 10.0, and
30.0 mg/kg in a vehicle of 0.5% methylcellulose in 0.9% saline. For pain-stimulated
stretching experiments, 0.56% acetic acid was administered in 0.9% saline, ibuprofen
was administered at a dose of 30mg/kg in 0.9% saline, and HZ-166 was administered at
16mg/kg in 0.5% methylcellulose. Diazepam, HZ-166, acetic acid, ibuprofen and their
respective vehicles were all administered at a volume of 0.1mL per 10g of mouse mass
and all drugs, including ethanol, were administered intraperitoneally. Diazepam was
obtained from Sigma Aldrich and HZ-166 was obtained from the University of Wisconsin
(Di Lio, 2010; Cook, 2009).
!

Light Dark Box. In order to determine whether the Etanq1 phenotypes, PTS and

PDT in the light side of the LDB, are driven by activation of receptor subunits known to
be involved in anxiolytic phenotypes observed in humans, we first performed doseresponse curves in the LDB in both B6 and D2 mice for the GABAA α1, α2, α3, α5agonist, diazepam, and the GABAA α2/α3-selective agonist, HZ-166. We hypothesized
that if in B6 and D2 mice, ethanol’s phenotypes, PTS and PDT in the light, were being
mediated primarily through activation of one or more of these receptor subunits, that for
one or more of these drugs, one of the doses tested would also produce significant
increases in PTS and PDT in the light compared to vehicle-treated mice in the same
mouse strains, B6 and D2. Next, studies comparing ethanol’s phenotypic responses in
BXD strains with high and low PTS/PDT in the light to those same phenotypes following
administration of a dose of diazepam or HZ-166 which significantly increased these
phenotypes in B6 and D2 mice would allow us a better understanding of which receptor
systems through which Etanq1 may be acting.
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!

One hour prior to behavioral testing, mice were moved to the behavior room,

cages were changed, and the light-dark box chambers were turned on, such that mice
were allowed to habituate to the testing environment. For those mice receiving restraint
stress, mice were placed into a 50mL conical tube on top of a full cage of bedding for 15
minutes. For ethanol positive control studies, immediately following the restraint stress,
mice were injected i.p. with either ethanol, saline, or another vehicle, returned to their
home cage for 5 minutes, and then placed into center of the LDB, facing the dark side,
and allowed to roam for 10 minutes. Studies used either house lights (100mA) or
stimulus lights (170mA) within the light-dark box and are indicated for each experiment.
Due to the longer half-lives of diazepam and HZ-166, mice received an i.p. injection of
one of these drugs or their respective vehicles, 15 minutes later, were placed into tubes
for a 15 minute restraint stress, and then immediately placed into the center of the LDB,
facing the dark side, and allowed to roam for 5 minutes. A brief stress was performed to
both ensure that all mice were at similar baseline “anxiety” levels at the start of
behavioral testing and to minimize within-group variability. All light-dark box experiments
were performed during the light cycle between the hours of 0800 and 1300.
!

Acetic Acid Pain-Stimulated Stretching. In order to determine whether HZ-166

was pharmacologically active, we tested the compound in an acute model of
inflammatory pain in D2 mice. Previous studies have reported its efficacy in other
models of inflammatory and neuropathic pain (DiLio, 2010), thus we hypothesized that it
would decrease the number of pain-stimulated stretches following an acetic acid
stimulus. Ibuprofen, a non-steroidal anti-inflammatory drug, was used as a positive
control.
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!

Mice were administered a blinded pretreatment of methylcellulose (MeC), saline

(Sal), ibuprofen (Ibu), or HZ-166 (HZ), and 30 minutes later, injected with 0.56% acetic
acid (AA). The number of pain-stimulated stretches was tallied over 20 minutes and
percent inhibition of stretching was calculated by setting the average number of
stretches for the Sal group to 100%. All stretching behavioral experiments were
performed during the light cycle between the hours of 1000 and 1500.
!

Statistical Analyses. All data are presented as the mean ± SEM. Oneway

ANOVAs testing treatment as the factor were performed. A Tukey’s HSD post-hoc at an
alpha=0.05 determined statistical significance between two groups. For LDB and AA
experiments, only differences between vehicle and any doses were reported.

Results
Acute ethanol produces significant increases in PTS and PDT in the light side of the
LDB in B6, D2, and CD-1 (ICR) mice without decreasing locomotor activity.
!

Previous dose-response studies in our laboratory have determined that restraint

stress, followed by a 1.8g/kg dose of ethanol administered 5 minutes prior to testing,
elicited a significant increase in PTS and PDT in the light without decreasing TLA in both
B6 and D2 mice. Figure 3.1, a-c, depicts replication of these studies in B6 and D2 mice
housed on sani-chip bedding, and expansion to the outbred strain, CD-1 (ICR) housed
on corncob bedding. Additionally, in B6 mice, ethanol significantly decreased the latency
to enter the light and increased the total number of transitions between the light and
dark compartments, supporting historical criteria for an “anxiolytic-like” drug in the LDB.
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Figure 3.1 - Ethanol-responsive behaviors in the light dark box in B6, D2, and ICR
mice. Following a brief restraint stress, acute ethanol significantly increased the PTS
(a) and PDT (b) in the light side of the LDB compared to within-strain saline-treated
mice in all three strains tested, validating the LDB model of anxiolytic-like behavior for
ethanol in these strains of mice. Ethanol significantly decreased both jumping behavior
(j) and the latency to enter the light (i) in B6 and ICR mice and showed a trend for
decreased latency in D2 mice. All three strains also showed significant increases in the
percent stereotypies in the light (g), even though ICR mice demonstrated fewer overall
stereotypies following ethanol treatment (f). Only D2 and ICR mice showed significant
increases in TLA (c) and percent rearing in the light (e). Ethanol-treated B6 mice
demonstrated fewer total rears (d), but a greater number of transitions between the light
and dark compartments (h). Finally, ethanol-treated ICR mice had fewer transitions in
between the light and dark compartments (h) and an overall lower mean speed (k)
(*p<0.05, oneway ANOVA, n=5-8/gp).
37

Furthermore, although the total number of rears was significantly decreased in ethanoltreated B6 mice, there was a non-significant trend for an increase in percent of rears in
the light, suggesting that the majority of the exploratory rearing behavior occurred in the
light, supporting the notion of increased exploration in the light in B6 mice treated with
acute ethanol. In D2 mice, ethanol significantly increased TLA and both the percent
stereotypic counts and percent rears in the light, and showed a trend for decreasing
latency to enter the light compared to vehicle-treated mice. In the ICR mice, ethanol
significantly affected all measures tested. Ethanol significantly increased PTS, PDT,
TLA, percent rearing in the light, percent stereotypies in the light, and significantly
decreased total transitions, total stereotypies, jumps, speed, and latency to enter the
light compared to vehicle-treated mice.

Acute diazepam treatment does NOT mimic acute ethanol phenotypes elicited by B6
and D2 mice in the LDB.
!

An initial diazepam dose-response using restraint stress and house lights was

performed in D2 mice housed on sani-chip bedding (Figure 3.2). Doses lower than 2mg/
kg were chosen because previous studies in our laboratory had observed locomotor
suppression in D2 mice at 2mg/kg (data not shown). Doses of 1.0, 1.25, and 1.5mg/kg
significantly decreased the latency to enter the light compared to vehicle-treated mice,
which supports what “anxiolytic” doses of drugs routinely show in the LDB. No other
significant differences were found between vehicle and diazepam treatments even
though there are trends for increased PTS and PDT at the aforementioned doses.
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Figure 3.2 - Diazepam light-dark box dose-response curve in D2 mice that
underwent a brief restraint stress. At the doses tested, diazepam failed to produce
significant increases in PTS and PDT traveled in the light side of the LDB in D2 mice (ab). The only phenotypes which doses of diazepam significantly differed vehicle were
latency to enter the light (i) and speed (k). At 0.5, 1.0, and 1.25 mg/kg diazepam, D2
mice demonstrated significantly lower latencies to enter the light and the 1.25mg/kg
dose of diazepam significantly lowered speed (*p<0.05, oneway ANOVA, Tukey’s HSD,
n=4-7/gp).
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!

A diazepam dose-response in B6 mice housed on corn cob bedding using

restraint stress and house lights revealed that 5 and 10mg/kg of diazepam significantly
decreased TLA, total transitions, TotRears, and jumps compared to vehicle-treated
mice. Also in B6 mice, 5mg/kg diazepam significantly decreased the percent of rears in
the light and 10mg/kg significantly decreased mean speed compared to the vehicle
group, suggesting an overall decrease in general activity, perhaps due to the sedative
effects of diazepam at these higher doses (Figure 3.3). Under these same conditions in
D2 mice, diazepam significantly increased PTS in the light at 5mg/kg (Figure 3.4), but
significantly decreased TLA and total stereotypies at 10mg/kg and showed a trend for
decreased TLA at 5mg/kg, suggesting possible sedative effects at the 5 and 10 mg/kg
doses as observed in B6 mice.

Restraint stress does not mask the ability to detect anxiolytic-like phenotypes of
diazepam in the LDB.
!

Since our LDB protocol utilizes a brief restraint stress unlike common protocols in

the literature, we attempted to produce diazepam dose-response curves without
restraint stress, with stimulus lights, in D2 mice housed on corn cob bedding. Diazepam
significantly decreased multiple locomotor phenotypes, TLA, total transitions, total
stereotypies, jumps, and mean speed at both 5 and 10mg/kg and also significantly
decreased percent rearing in the light at 10mg/kg. Diazepam did not significantly
increase any phenotype compared to vehicle-treated D2 mice, thus, collectively, these
data suggest that diazepam is causing locomotor suppressing effects at high doses (5
and 10mg/kg), thereby masking our ability to detect “anxiolytic-like” effects as defined
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Figure 3.3 - Diazepam light-dark box dose-response curve in B6 mice that
underwent a brief restraint stress. At the doses tested, diazepam failed to produce
significant increases in PTS and PDT traveled in the light side of the LDB in B6 mice (ab). The doses of 5 and 10 mg/kg significantly decreased multiple phenotypes (denoted
with *), indicative of overall suppression of activity (*p<0.05, oneway ANOVAs, Tukey’s
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by increases in PTS and PDT in the light at the doses tested (Figure 3.4).

Acute HZ-166 treatment does NOT mimic acute ethanol phenotypes elicited by B6 and
D2 mice in the LDB.
!

An initial HZ-166 dose-response in B6 mice using restraint stress, house lights,

and a 5 minute homecage period, failed to produce significant changes all LDB
phenotypes compared to vehicle-treated mice (Figure 3.5). In fact, vehicle-treated mice
showed high mean PTS and PDT (38% and 36%, respectively). Therefore, in attempt to
increase the “stress”/”anxiety” of the light side to avoid ceiling effects, dose-response
studies were performed in B6 and D2 mice with stimulus lights and without the 5 minute
homecage period. As shown in Figure 3.6, these experimental manipulations did not
lower vehicle levels for PTS and PDT in the light and additionally, failed to produce
significant within-strain differences from vehicle-treated mice at all doses tested.
Interestingly, vehicle levels for mean PTS and PDT in B6 mice increased to 49% and
42%, respectively, suggesting no preference for either side of the light-dark box prior to
drug treatment.

HZ-166 pretreatment attenuates pain-stimulated stretching in a model of acute
inflammatory pain.
!

At a dose of 16mg/kg, HZ166 significantly decreased pain-stimulated stretching

behavior compared to its vehicle group (Figure 3.7). At a dose of 30mg/kg, the positive
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control, ibuprofen, significantly decreased writhing behavior compared to its vehicle
group.
!

Based on these initial dose-response experiments, diazepam and HZ-166 were

not tested in BXD strains in the LDB. Furthermore, literature studies do not provide
strong evidence of the behavioral efficacies of acute diazepam in B6 mice in the lightdark box assay, as variety of factors differ among studies, including, strain, age, lightdark box construction, pretreatment time, dose, vehicle, and phenotype interpreted as
anxiolytic-like. Thus, inter-laboratory comparisons are quite difficult.

Discussion
!

In the present studies, we sought to determine whether Etanq1 was acting

through activation of the GABAA α1, α2, α3 α5 or GABAA α2, α3 by comparing
phenotypes produced by acute ethanol in the LDB to those produced by diazepam, and
HZ-166, respectively. Since acute ethanol produced phenotypes in the LDB predictive of
its role as an “anxiolytic” drug, other known anxiolytic drugs whose mechanisms of
anxiolytic action have been discovered were chosen for comparison. Diazepam is used
clinically to treat anxiety and anxiety disorders, while HZ-166 was chosen based on
literature studies providing preclinical evidence that agonism of the GABAA α2, α3
subunits reduces anxiogenic-like behaviors in multiple models of anxiety in multiple
species (Fischer, 2010; Atack, 2006). Surprisingly, however, we were unable to attain
dose-response curves for PTS and PDT in the light for any of the three drugs in B6 and
D2 strains of mice using our light-dark box protocol.
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A number of studies have demonstrated an “anxiolytic-like” effect for diazepam in
multiple preclinical models of anxiety, especially in C57BL/6J mice. However, each
study may use a different experimental design, a different substrain of C57BL/6 mice, a
different drug vehicle, as well as report different phenotypes which they consider to be
“anxiolytic-like”, thus making inter-laboratory comparisons quite difficult. Bouwknecht
and Paylor argue that in addition to monitoring an increase in time spent in an aversive
area (eg, light side of the LDB, open arms of the EPM, center of the OF), one must also
monitor locomotor measures such as total distance traveled, number of transitions, etc
(Bouwknecht, 2004). Here, we demonstrate that acute ethanol significantly increased
PTS and PDT in the light without decreasing total distance traveled. Perhaps most
importantly, ethanol decreased the latency to enter the light in all three strains,
suggesting that ethanol is acting as an anxiolytic-like drug in the LDB.
Furthermore, it has been well-established that the starting position of the animal
greatly affects the PTS in the light outcome, yet little attention is given to these details in
publications. For example, placing two different groups (treatments or genotypes) of
mice into the light side of the LDB can cause one of two responses, freezing, which
would increase time spent in the light (in an “anxious” strain) or an immediate escape to
the dark side but then explores readily, thereby decreasing percent time spent in the
light (in a “non-anxious” strain). However, when starting the same mice in their “safe
zone”, the mouse that previously froze in the light chooses to spend more time in the
dark side and the mouse that immediately escaped to the dark still spends the same
amount of time in the light. Thus, it is recommended that a mouse always be started in
its “safe zone” when assaying anxiety-related behaviors (Bouwknecht, 2004), which is
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what was done herein. In fact, the premier papers describing the LDB and its predictive
validity for assessing diazepam’s anxiolytic-like properties started B6 mice in the light
side and used activity counts and the number of transitions to draw conclusions about
anxiolytic-like properties of the drug (Crawley, 1980; Blumstein, 1983). These measures,
one can argue, may actually represent exploratory/locomotor-related phenotypes, rather
than anxiolytic-like phenotypes.
One very intriguing reason for the lack of increase in PTS and PDT in the light
following diazepam observed in our studies may be the result of a novel polymorphism
in the gene for the GABAA α2 subunit, Gabra2, in B6 mice that occurred sometime
between 1976 and 1990. Gabra2 expression is cis-modulated across multiple brain
regions (hippocampus, amygdala, striatum, and cortex) and platforms (microarray and
RNA-Seq), with low expression always associated with the B allele in multiple RI
crosses (Mulligan, 2012). Between B6 and D2 mice, the Gabra2 locus is identical by
descent except for eight indels and nine SNPs within intronic or intergenic regions, thus
it is likely that one or more of these variants is responsible for the large differences in
expression observed (Mulligan, 2012). The publications reporting phenotypes that
support diazepam’s anxiolytic-like actions in B6 mice in preclinical assays of anxiety
were largely published in the 1970s and 1980s. From these studies, one would predict
that D2 mice would be responsive to the anxiolytic-like effects of diazepam. In our
studies, we showed that diazepam in D2 mice did not produce significant increases in
PTS or PDT in the light under the conditions of enhanced lighting without restraint
stress and while we did observe significant increases in PTS in the light with restraint
stress, we saw concurrent locomotor suppression, thus the sedative side effect of
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diazepam complicated interpretation of these results. Interestingly, our first D2
diazepam dose-response study showed trends for increased PTS and PDT in the light
without locomotor suppression effects, yet at some of these same doses in the later
study, this was not observed. The only difference in these two studies was the type of
bedding on which mice were housed. To date, no one has studied the effects of different
bedding types on the anxiolytic-like responses of diazepam in preclinical models of
anxiety and often, the type of bedding is not reported. However, it has been reported
that changing an animal’s bedding and essentially its environment for all, if not most, of
its adult life, does alter behavioral outcomes (Blom 1996; Ras, 2002; Homma, 2009).
Perhaps testing a larger number of mice, housed on sani-chip bedding, may reveal
significant increases in PTS and PDT at some of the lower doses (0.5-1.5mg/kg) of
diazepam in D2 mice.
Finally, most published studies on diazepam use a vehicle containing between
2-10% ethanol, which we have shown produces significant increases in PTS and PDT in
the light along with decreased latency to enter the light on its own. Thus, we argue that
those studies be interpreted with caution.
In an attempt to bypass the locomotor sedative effects of diazepam due to
agonism at the GABAA α1 subunit, we tested both B6 and D2 mice with a GABAA α2, α3
- selective agonist, HZ-166. Based on the Gabra2 expression studies mentioned earlier,
we predicted to see increases in PTS and PDT in the light in D2 mice following
administration of HZ-166. However, we failed to produce dose response curves in either
strain with this drug. Testing HZ-166 in a pain-stimulated stretching assay validated that
the drug does have pharmacological activity at both the time-point and within the dose
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range tested. Interestingly, PTS and PDT in the light levels in vehicle-treated mice
ranged from 36-49%, suggesting that 0.5% methylcellulose treatment lowered basal
“anxiety” levels to a point where mice did not prefer one side over the other, thus leaving
a small window of detection for possible increases in PTS and PDT in the light.
Interpretation of these studies may be compromised due to a ceiling effect of the
vehicle, thus more experiments, perhaps utilizing an alternate vehicle, would need to be
performed in order to draw conclusions about the anxiolytic-like action of HZ-166.
!

Overall, although the dose-response studies were largely negative in of

themselves, they do provide insight for mechanism of action of Etanq1. First, Etanq1 is
genetically driven by acute ethanol’s ability to significantly increase PTS and PDT in the
light side of the LDB, but not genetically driven by locomotor activating effects of ethanol
across the BXD panel. Second, diazepam, HZ-166, and buspirone, drugs whose
specific mechanisms of anxiolytic action have been well-documented, failed to produce
coincident increases in PTS and PDT in the light. Therefore, we can conclude that
Etanq1 is not being driven primarily through activation of one of the following receptor
subunit systems alone, GABAA α1, α2, α3 α5 or GABAA α2, α3. It is entirely possible
that small effects at one or more of these subunits may have a cumulative effect on PTS
and PDT in the light, however, mixed dosing regimens would need to be performed in
order to answer those questions. The more likely scenario is that Etanq1 may be acting
through another receptor system known to be involved in eliciting anxiolytic responses,
such as the CRF, neuropeptide Y, the endocannabinoid system, or through a novel
mechanism yet to be discovered.
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Alternatively, these studies may imply that ethanol’s influence on the PTS and
PDT phenotypes is not driven primarily by “anxiolysis”. The LDB gained predictive
validity for assessing anxiolytic drugs based on the ability of clinically known anxiolytics
to significantly increase the time spent in the light, increase exploratory behaviors in the
light such as rearing, and/or decrease the latency to enter the light (Crawley, 1980;
Blumstein, 1983; Costall, 1989). Perhaps PTS and PDT are measuring something other
than “anxiolysis” in these strains of mice, such as disinhibition or risk-taking behaviors.
Nonetheless, these studies demonstrate the complexity of Etanq1 and beg for additional
experiments to interrogate its mechanism of action.
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Chapter 4 - Etanq1 Correlation with Other Behavioral Models of “Anxiety”
Introduction
Risk for developing alcoholism is determined by the combination of genetic
predisposition, environment, and neuroadaptations that occur following acute and
chronic exposure to alcohol. Due to the complex and heterogenous nature of
alcoholism, there is a need to understand the biological and genetic bases of risk for
disease-related endophenotypes. Alcoholics frequently report anxiety as motivation for
drinking and we hypothesize that alcohol’s ability to relieve anxiety may contribute to
initiation of drinking behavior. However, the genes and receptor systems involved in
ethanol-induced anxiolysis are poorly understood, as ethanol acts at multiple receptor
systems in the central nervous system (Spanagel, 2009). A number of previous studies
have attempted to “genetically dissect” endophenotypes across multiple preclinical
assays measuring basal “anxiety” levels (Flint, 2003; Henderson, 2004; Fernandez,
2002; Turri, 2001; Clement, 2007; Brigman, 2009; Rodgers, 1995) in order to genetically
map loci underlying “anxiety”. With these studies, it has become clear that the
responses measured in behavioral assays are made of multiple components and thus
influenced by multiple genes. As such, phenotypic responses to drugs which have
considerable heritability are expected to be influenced polygenically. The studies by
Flint, Turri, and others cited above provide evidence that studying “anxiety” is rodents is
complex and when adding a new variable such as a drug, it may be necessary to
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dissect phenotypic responses to drugs in the same way in order to elucidate genes
modulating these behaviors.
Our laboratory has previously identified and confirmed a quantitative trait locus
(QTL) across the BXD panel for the percent time spent (PTS) and percent distance
traveled (PDT) phenotypes in the light-dark box (LDB), deemed Etanq1 (Putman, 2008).
We hypothesized that acute ethanol might be mediating its anxiolytic-like responses
through the same mechanism across the LDB and EPM, as we show that it reproducibly
produces significant increases in PTS and PDT in the light and open arms in multiple
strains of mice and both assays are constructed such to test unconditioned responses
to a drug. To dissect Etanq1 as well as parse the ethanol anxiolytic-like phenotype, we
have assayed six BXD strains (and their progenitors, B6 and D2), selected based on
haplotypes within the Etanq1 support interval, and eight inbred strains in various
preclinical models of “anxiety”. Principal components analysis of these behavioral data
suggests that the gene(s) modulating the ethanol anxiolytic-like component in the LDB
do not overlap with those same phenotypes in the elevated plus maze (EPM), nor a
marble burying (MB) phenotype. Dissecting complex phenotypes may allow us to
uncover novel genes and/or mechanisms, thus leading to new targets for alcohol use
disorders.

Materials and Methods
!

Mice and Husbandry Conditions. For all studies, male mice were used, housed

2-4 per cage, and allowed at least a one-week acclimation period to the vivarium
following shipment to Virginia Commonwealth University (VCU). Mice were maintained
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on a 12-hour light/dark cycle with ad libitum access to standard rodent chow (Harlan,
7012) and tap water. All mice were 8-12 weeks old at time of behavioral testing, each of
which were performed during the light cycle between the hours of 0800 and 1300.
C57BL/6J, DBA2/J, AKR/J, NOD/ShiLtJ, 129S1/SvImJ, C3H/HeJ, and Balb/cByJ mice
were obtained from Jackson Laboratories (Bar Harbor, ME) and BXD mice were
obtained from the University of Tennessee Health Sciences Center (Memphis, TN). Mice
were housed with Teklad aspen sani-chip (Harlan, 7090A) or Teklad corn cob (Harlan,
7092) bedding, where noted.
!

Drugs. For all behavioral studies, a 1.8g/kg of ethanol dose was administered

intraperitoneally (i.p.) using a 10% ethanol (w/v) stock solution dissolved in a 0.9%
physiological saline vehicle. This dose was chosen based on previous LDB studies in
our laboratory (Putman, 2008).
!

Restraint Stress. For the majority of studies herein, a brief (15 minute) restraint

stress was performed to both ensure that all mice were at similar baseline “anxiety”
levels at the start of behavioral testing and to minimize within-group variability.
!

Light Dark Box. The LDB (Med-Associates, St. Albans, VT) consists transparent

square box of dimensions 10.75" L x 10.75" W x 8" H with a black insert which divides
the chamber into two equally sized chambers. The entire apparatus is contained within
a sound-attenuating chamber. Mice were placed into a 50mL conical tube on top of a full
cage of bedding for 15 minutes. Immediately following the restraint stress, mice were
injected i.p. with either ethanol or saline, returned to their home cage for 5 minutes, and
then placed into center of the LDB, facing the dark side, and behaviors were recorded
for 10 minutes. Studies used house lights (100mA) within the light-dark box.
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!

Elevated Plus Maze. The EPM (Hamilton Kinder, San Diego, CA) consists of four

black arms in a cross shape raised 30.5” from the ground. Each arm is 15” L x 2” W and
the apparatus contains with center section measuring 2” L x 2” W. The closed arms
have 6” black walls and the open arms do not have walls. For mice receiving restraint
stress, mice were placed into a 50mL conical tube on top of a full cage of bedding for 15
minutes. Immediately following the restraint stress, mice were injected i.p. with either
ethanol or saline, returned to their home cage for 5 minutes, and then placed into center
of an EPM, facing one of the open arms, and allowed to roam for 5 minutes. The open
arm that each mouse faced to begin the assay was randomized and balanced within
treatment groups. If mice did not receive restraint stress, they were administered either
ethanol or saline i.p., placed into their home cage for 5 minutes, and then placed into
the center of the EPM and allowed to roam for 5 minutes. If a mouse fell or jumped off
of the maze, it was placed back into the center facing the opposite open arm from which
it fell. The number of falls was counted as a separate phenotype.
!

Marble Burying Task. A large rat cage was filled 1/3 with sani-chip bedding and

cages were shaken such that the surface of the bedding was flat. 20 marbles were
arranged evenly into a matrix of 5 rows x 4 columns (See Appendix A3). Mice received a
15 minute restraint stress (as described previously), were injected i.p. with either
ethanol or saline, returned to their home cage for 5 minutes, then were placed in the
cages below the grid in the middle of grid and allowed to roam for 5 minutes. Marbles
must have been buried at least 50% with bedding in order to be counted in the total
number of marbles buried. The total number of marbles buried was converted to a
percent of marbles buried.
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!

Statistics. Using JMP and/or R, A twoway ANOVA, followed by a Tukey’s HSD

post-hoc was performed for all behavioral studies to determine the presence of main
and/or interaction effects of treatment and either strain or haplotype, where applicable.
For HMDP experiments, Pearson’s product moment correlations were performed and
using the psych package (Revelle, 2012) in R, principal components analysis (PCA)
was performed on varimax-rotated correlation matrices. The number of principal
components was determined by examining scree and parallel analysis plots as well as
performing chi square analyses.
!

Experiment 1. To validate the anxiolytic-like responses of acute ethanol in the

EPM, we performed experiments with and without restraint stress in B6 and D2 mice
following the protocol listed above.
!

Experiment 2. In order to determine whether the Etanq1 locus may modulate

acute ethanol phenotypes observed in another preclinical model of “anxiety”, the EPM,
we selected BXD strains with either high or low ethanol-induced PTS/PDT in the LDB
whose haplotypes were either B6 or D2 across the Etanq1 support interval on
chromosome 12, 69.1-72.6Mb (Wolen, 2012). We hypothesized that if the Etanq1 locus
modulated PTS/PDT in the open arms of the EPM following acute ethanol, then when
collapsed by the Etanq1 haplotype, strains having the B6 haplotype would show a
higher PTS/PDT than those having the D2 haplotype, without a significant difference
between saline groups. In other words, we predicted a significant haplotype x treatment
interaction, in which having the B6 haplotype would increase the ethanol-responsive
phenotype. To avoid possible interaction effects of a separate suggestive QTL locus for
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Etanq1, genotypes were clamped (all D2) at the peak marker on distal chromosome 1,
located at 165.32Mb.
!

Experiment 3. Next, we selected eight inbred strains from the hybrid mouse

diversity panel (HDMP) to test in the LDB, EPM, and MB tasks in the order depicted in
Figure 4.1. Since the LDB and EPM assays are computerized, the number of
phenotypes resulting from each test is quite large. Collecting all of this data allowed us
to perform principal components analysis (PCA), which enabled the reduction of
phenotypes into principal components. We hypothesized that the genetic architecture
underlying ethanol’s anxiolytic-like effects across preclinical models of anxiety may be
detectable through correlation analysis of these principal components across assays.

Results
Eight strains selected for their Etanq1 haplotype provide sufficient power to detect
haplotype x treatment interactions for LDB phenotypes.
!

After selecting BXD strains differing by Etanq1 haplotype (BXD11, 32, 66, 67, 90,

and 98), we performed twoway ANOVAs on this same subset of BXDs previously tested
in the LDB by Dr. Putman in the Miles Laboratory to ensure that we had sufficient power
with eight BXD strains to detect haplotype x treatment interactions with the EPM
experiments. His studies were able to detect a significant haplotype x treatment
interaction across the original panel of 27 BXD strains (Putman, 2008), thus, we
hypothesized that selecting a subset of these strains, in which the interaction remains
significant, would allow us to interrogate the effect of the Etanq1 haplotype in the EPM.
Figure 4.2 shows that indeed, we were able to detect a significant haplotype x treatment
58

Figure 4.1 - Timeline for testing ethanol phenotypes in eight inbred strains across
three preclinical models of anxiety. Eight strains from the hybrid mouse diversity panel
(HMDP) were used for high-throughput phenotyping of ethanol-responsive behaviors in the
light dark box (LDB), elevated plus maze (EPM), and marble burying (MB) task. In between
assays, mice were given a two-week test-free period. Mice receiving ethanol in the LDB
received saline in the EPM and vice versa. For the MB assay, treatment groups were rerandomized within each strain.
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Figure 4.2 - Eight selected strains of mice provide adequate power for measuring
haplotype x treatment interactions in the LDB following acute ethanol. When
collapsed by their Etanq1 haplotype, a subset of BXD strains tested by Dr. Putman
(BXD11, 32, 66, 67, 90, and 98) (Putman, 2008) demonstrated significant effects of
treatment, haplotype, and haplotype x treatment interactions for both PTS and PDT
(p<0.01, twoway ANOVA), in the light side of the LDB following restraint stress and acute
ethanol administration, but not TLA. (Panels a-c, with the progenitor strains, B6 and D2
(n=32-25/group) and d-f, without progenitor strains (n=17-19/group). Panel f also
revealed a near significant interaction of haplotype x treatment for TLA in the BXD only
subset (p=0.09782).
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interaction for the acute ethanol phenotypes, PTS and PDT in the light, with the B6
haplotype significantly increasing PTS and PDT in the light following ethanol treatment
compared to the D2 haplotype. The interactions remained significant even following the
removal of the progenitor strains, B6 and D2, suggesting that this number of and these
particular strains are sufficient.

Restraint stress alters acute ethanol phenotypes in B6 and D2 mice using the EPM
assay.
!

As observed in the LDB, a 1.8g/kg dose of acute ethanol was effective in the

EPM for significantly increasing the PTS and PDT in the open arms in B6 mice with and
without restraint stress (Figure 4.3, a-b, f-g). However, D2 mice showed significant
increases in PTS, but not PDT, in response to ethanol only after undergoing restraint
stress (Figure 4.3, f-g). Under conditions with and without restraint stress, D2 mice
exhibited a similar locomotor activation response following a 1.8g/kg dose of ethanol
(Figure 4.3, c,d) as is routinely seen in the LDB, further validating the efficacy of ethanol
in this assay. Interestingly, restraint stress had no effect on the mean number of fine
movements (eg, grooming behaviors, Figure 4.3, d, i); there was a significant strain x
treatment interaction for this phenotype under both conditions. Finally, restraint stress
elucidated a near significant trend for the mean entries into the center compartment of
the EPM (Figure 4.3, j) that is not present without restraint stress (Figure 4.3, e). The
remaining phenotypes recorded, mean transitions between arms, mean entries into the
open arms, and mean pokes into the open arms, did not show significant strain x
treatment interactions. Overall, these data suggest that experimental parameters, here
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Figure 4.3 - Validation of ethanol anxiolytic-like responses in the EPM in B6 and D2 strains of mice. Acute
ethanol administration significantly increased the PTS (p<0.01, n=6/gp, oneway ANOVA, Tukey’s HSD) and PDT
(p<0.01, n=6/gp, oneway ANOVA, Tukey’s HSD) in the open arms of the EPM in B6 mice and significantly increased
TLA in D2 mice (p<0.05, n=8/gp, oneway ANOVA, Tukey’s HSD, Panels a-c). Panels a, b, and d exhibit significant strain
x treatment interactions for PTS, PDT, and fine movements (all p<0.05, twoway ANOVA). Panels f-g represent the same
phenotypes with restraint stress. Acute ethanol administration significantly increased PTS in both B6 (p<0.01, n=10/gp,
oneway ANOVA, Tukey’s HSD) and D2 mice(p<0.01, n=11/gp, oneway ANOVA, Tukey’s HSD), significantly increased
PDT in B6 mice (p<0.01, n=10/gp, oneway ANOVA, Tukey’s HSD), TLA in D2 mice (p<0.01, n=11/gp, oneway ANOVA,
Tukey’s HSD), and entries into the center in D2 mice (p<0.05, n=11/gp, oneway ANOVA, Tukey’s HSD). With restraint
stress, the significant strain x treatment interaction for PTS does not exist, but trends toward significance for PDT
(p=0.06245, twoway ANOVA) (Panels f-g). There is a significant strain x treatment interaction for TLA (p<0.01, twoway
ANOVA), fine movements (p<0.01, twoway ANOVA), and a trend for an interaction effect for entries into the center
(p=0.05002, twoway ANOVA).

specifically, restraint stress, are important in determining phenotypic outcomes in
preclinical behavioral assays of anxiety.

PTS and PDT phenotypes in the EPM show significant interactions between ethanol
and the Etanq1 haplotype in select BXD strains following restraint stress.
!

Testing of six BXD strains selected for having either a B6 or D2 Etanq1

haplotype, BXD11, 32, 66, 67, 90, and 98, revealed significant interactions between
haplotype and treatment for PTS, PDT, and total distance traveled (Figure 4.4, a-c)
following an brief restraint stress. Strikingly, these interactions were not detected upon
testing of the same strains without restraint stress (Figure 4.4, d-f). However, PTS, PDT,
and TLA did show significant effects of ethanol treatment when restraint stress was not
present. Together, these findings implicate the Etanq1 haplotype as a modulator of the
restraint stress-induced acute ethanol phenotypes, PTS and PDT in open arms as well
as total distance traveled in the EPM, however, these interactions provide additional
evidence to support the dramatic effect of restraint stress on ethanol responses in
preclinical behavioral assays of anxiety.
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Figure 4.4 - Testing a subset of BXDs with and without restraint in the EPM
revealed different haplotype x treatment interaction effects. When collapsed by their
Etanq1 haplotype, a subset of BXD strains (BXD11, 32, 66, 67, 90, and 98) demonstrated
a significant main effect of treatment and significant haplotype x treatment interactions for
both PTS and PDT, in the open arms of the EPM (p<0.05, twoway ANOVA), and TLA
(p<0.01, twoway ANOVA) following restraint stress and acute ethanol administration.
(Panels a-c, n=6-18/group). Conversely, acute ethanol administration without restraint
stress only reveals significant effects of treatment (all p<0.01, oneway ANOVA), but not
haplotype x treatment interactions for PTS (p=0.8679), PDT (p=0.7370), or TLA
(p=0.5639, panels d-f, n=8-9/group).
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Figure 4.5 - HMDP strain distributions for PTS, PDT, and TLA in the LDB and EPM. Nearly
all strains tested demonstrated a significant increase in PTS and PDT in the light side of the
LDB following acute ethanol (p<0.05, oneway ANOVA, Tukey’s HSD post-hoc, n=8-11/group,
panels a-b). Conversely, only B6, D2, and NOD strains demonstrated significant increases in
PTS in the open arms of the EPM (d-e). Panels c and f show TLA measures for both assays,
with D2 mice displaying a significant increase in TLA following acute ethanol, as expected.
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Acute ethanol treatment resulted in significant increases in time spent in the light side of
the light dark box in nearly all HMDP strains tested, but these phenotypes did not
translate to the elevated plus maze.
!

Following a brief restraint stress, acute ethanol significantly increased PTS and

PDT in the LDB in all strains except C3H (Figure 4.5, a-b). Additionally, A/J, AKR, Balb/
c, C3H, and D2 strains showed significant increases in TLA following ethanol (Figure
4.5, c), while 129S and B6 mice demonstrated significant decreases in TLA. There were
significant main effects of strain any of these three phenotypes. On the other hand, in
the EPM, only B6, D2, and NOD strains showed significant increases in PTS in the
open arms and only NOD mice also showed significant increases in PDT in the open
arms following acute ethanol treatment. (Figure 4.5, d-e). 129S, AKR, C3H, and D2
mice showed significant locomotor activation with acute ethanol (Figure 4.5, f). Of these
4 strains, AKR and D2 mice also had significant increases in total transitions, open arm
entries, and entries into the center. Interestingly, 129S mice showed a significant
decrease in total transitions, open arm entries and fine motor movements, even though
that strain had a significantly greater TLA following ethanol, suggesting that ethanol
activated locomotion, but not exploratory activity. 129S, AKR, B6, Balb/c, C3H, and
NOD mice all fell/jumped off of the open arms a significantly greater number of times
than their within-group saline mice.
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Ethanol significantly reduced digging behavior in the marble burying task
!

In all strains tested, acute ethanol significantly reduced or abolished digging

behavior (Figure 4.6). More recent reports in the literature indicate that this behavior is
genetically regulated, persists over multiple testings, but may be more indicative of
perseverance or repetitive behavior, rather than anxiety-related or fear or novel objects
(Thomas, 2009).

Multiple saline and ethanol endophenotypes within the LDB and EPM correlate with
each other.
Figure 4.7 depicts Spearman correlation matrices for saline (a) and ethanol (b)
phenotypes in the LDB. Regardless of saline or ethanol treatment, PTS, PDT, and
percent stereotypies in the light significantly correlate to each other, however, when
ethanol is administered, latency to enter the light also significantly correlates with these
phenotypes. Interestingly, following saline administration, TLA correlates significantly
with the number of transitions, jumps, and speed. However, following ethanol
administration, the number of transitions, jumps, and speed correlate more strongly to
each other than to TLA.
Figure 4.8 depicts Spearman correlation matrices for saline (a) and ethanol (b)
phenotypes in the EPM. As observed in the LDB, PTS and PDT are tightly significantly
correlated following both saline and ethanol. With the exception of the number falls or
jumps off of the maze, the remaining phenotypes, TLA, fine movements, center entries,
open arm entries, open arm pokes, and number of transitions largely correlate with each
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Figure 4.6 - Ethanol significantly decreases the marble burying phenotype in nearly all HMDP strains
tested. Strain distribution for the effect of acute saline or ethanol on the percent of marbles at least 50%
buried. All strains bury marbles as a result of digging behavior following acute saline, while ethanol either
abolished or significantly decreased the marble burying phenotype in all strains (p<0.05, oneway ANOVAs,
Tukey’s HSD, n=8-11/gp).

Figure 4.7 - Correlation matrices for saline and ethanol LDB phenotypes.
Correlation scattergrams (left of diagonal), univariate density plots (in white, along the
diagonal), and Spearman’s rho values (right of diagonal) are displayed for saline (a) and
ethanol (b) phenotypes for the LDB. For the correlation scattergrams, each point
represents a strain mean with linear fits plotted in red. A blue rho values denotes a
significant correlation, while grey rho values are non-significant at an alpha = 0.05.
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Figure 4.8 - Correlation matrices for saline and ethanol EPM phenotypes.
Correlation scattergrams (left of diagonal), univariate density plots (in white, along the
diagonal), and Spearman’s rho values (right of diagonal) are displayed for saline (a) and
ethanol (b) phenotypes for the EPM. For the correlation scattergrams, each point
represents a strain mean with linear fits plotted in red. A blue rho values denotes a
significant correlation, while grey rho values are non-significant at an alpha = 0.05.
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Figure 4.9 - Principal components analysis of saline phenotypes in the LDB and
EPM. Scree plots and biplots from the of principal components analysis of salineresponsive phenotypes in the LDB (a-b) and the EPM (c-d) following varimax rotation
of correlation matrices. For the LDB, scree plots, parallel analyses, and chi-square
analyses revealed that two principal components (PC) were sufficient (p<0.05, n=8,
df=8), whereas for the EPM, the chi-square analysis revealed that one PC was
sufficient (p<0.05, n=8, df=8).
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other following saline administration. However, following ethanol administration, the
number of falls significantly correlates with PTS and PDT and with the number of open
arm pokes.

Principal components analysis and correlation analysis reveal that the anxiolytic-like
components of the LDB and EPM are not being regulated by common genes.
Principal components analysis (PCA) of saline phenotypes revealed two principal
components in the LDB (Figure 4.9, a-b), contributing to 84% of the total variance, but
only one principal component in the EPM (Figure 4.9, c-d), contributing to 47% of the
overall variance. Previous BXD studies in our laboratory showed that PTS and PDT are
tightly genetically correlated (Putman, 2008) and since an n=8 strains were used for
PCA, only 7 phenotypes could be assessed, thus, PDT was not used in the LDB PCAs.
Factor loadings for the saline LDB phenotypes, Table 4.1, revealed that PTS, percent
rears in the light, and percent stereotypies in the light are most strongly correlated with
PC1, while TLA and total transitions are most strongly correlated with PC2. For the
EPM, saline phenotypes did not separate into multiple components. These results may
indicate that in general, the LDB may be a better assay for interrogating anxiolytic drugs
in mice, as locomotor-related and exploratory behaviors may be parsed.
Principal components analysis of ethanol phenotypes revealed two principal
components for the LDB (Figure 4.10, a-c), contributing to 84% of the total variance,
and two principal components in the EPM (Figure 4.10, d-f), contributing to 87% of the
overall variance. Factor loadings for the ethanol LDB phenotypes, Table 4.2, revealed
that PTS, percent rears in the light, and percent stereotypies in the light are most
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0.1326
-0.6150
0.8082

PC2 (41%)
0.1751
0.9266
0.9510

Saline-Induced
Endophenotype (EPM)
PTS in Open Arms
PDT in Open Arms
Total Distance Traveled
Total Transitions
Fine Movements
Open Arm Pokes
Number of Falls/Jumps

PC1 (47%)
-0.3164
-0.3444
0.9408
0.8489
0.9629
0.6406
-0.3934

Table 4.1 - Principal component loading for saline LDB and EPM phenotypes. Factor loadings, overall variance for
each component, and each saline-responsive endophenotype from the LDB or EPM and its correlation to each PC are
shown. Values < |0.05| were removed for clarity.

Saline-Induced
Endophenotype (LDB)
PC1 (43%)
PTS in the Light
0.9619
Total Distance Traveled
0.2818
Total Transitions
Percent Rearing in Light
0.8611
Percent Stereotypies in Light
0.9659
0.2544
Latency to Enter Light
Jumps
0.4984

Figure 4.10 - Principal components analysis of ethanol phenotypes in the LDB and
EPM. Scree plots and biplots from the of principal components analysis of ethanolresponsive phenotypes in the LDB (a-c) and the EPM (d-f) following varimax rotation of
correlation matrices. For both assays, scree plots, parallel analyses, and chi-square
analyses (p<0.05, n=8, df=8) revealed that two principal components (PC) were sufficient.
For each assay, PC1 contains locomotor endophenotypes, while PC2 represents the
anxiolytic-like endophenotypes. Interestingly, latency to enter the light loads onto both
PC1 and PC2 in the LDB, revealing a possible additional endophenotype of Etanq1. In the
EPM, the number of falls loaded with the anxiolytic-like component, PC2, while pokes into
the open arms loaded onto both PCs. (PCA was not performed on the MB assay since
only one phenotype was measured).
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0.9871
-0.5823
0.2236

PC2 (34%)
0.9859

Ethanol-Induced
Endophenotype (EPM)
PTS in Open Arms
PDT in Open Arms
Total Distance Traveled
Total Transitions
Fine Movements
Open Arm Pokes
Number of Falls/Jumps
0.9754
0.9735
0.9547
0.5738
0.3052

PC1 (46%)

-0.5718
0.8471

PC2 (41%)
0.9123
0.9704
0.1101
0.1664

Table 4.2 - Principal component loading for ethanol LDB and EPM phenotypes. Factor loadings, overall variance
for each component, and each ethanol-responsive endophenotype from the LDB or EPM and its correlation to each PC
are shown. Values < |0.05| were removed for clarity.

Ethanol-Induced
Endophenotype (LDB)
PC1 (50%)
PTS in the Light
Total Distance Traveled
0.7482
Total Transitions
0.9861
Percent Rearing in Light
0.8450
Percent Stereotypies in Light
0.1182
-0.7021
Latency to Enter Light
Jumps
0.8466

strongly correlated with PC1, while TLA and total transitions are most strongly correlated
with PC2.
In order to determine whether the genes underlying ethanol’s anxiolytic-like
responses can be generalized across preclinical anxiety assays, PC1 and PC2 resulting
from the LDB ethanol phenotypes were correlated with all of ethanol phenotypes from
the EPM as well as ethanol’s marble burying phenotype (Figure 4.11). As expected, the
largely locomotor-related PC1 from the LDB significantly correlated with multiple
locomotor-related phenotypes part of PC1 in the EPM, transitions, open arm entries,
entries into the center, number of falls of of the maze. Additionally, the percent of
marbles buried significantly correlated to the LDB’s PC1. Strikingly, PC2 from the LDB,
which was contained the PTS and PDT in the light phenotypes, did not correlate with
any ethanol endophenotype in the EPM, nor the marble burying task, indicating that
Etanq1 is not generalizable across these two assays.

76

77

Figure 4.11 Correlation matrix of the LDB PCs with each ethanol-responsive phenotype from the EPM and MB
task. Correlation scattergrams (left of diagonal), univariate density plots (in white, along the diagonal), and Spearman’s
rho values (right of diagonal) are displayed. For the correlation scattergrams, each point represents a strain mean with
linear fits plotted in red. A blue rho values denotes a significant correlation, while grey rho values are non-significant at
an alpha = 0.05. PTS, PDT, and NoFalls, which constitute PC2 of the EPM, do not correlate with either LDB PC.

Discussion
!

Here, we sought to determine whether genes underlying the behavioral QTL,

Etanq1, could be generalized across other preclinical models of anxiety, the EPM and
MB task. Acute ethanol significantly increased PTS and PDT in the open arms and
decreased the percent of marbles buried, two phenotypes routinely interpreted in the
literature as “anxiolytic-like”, thus we hypothesized that Etanq1 might modulate
anxiolytic-like responses across assays.
!

Upon testing BXD strains selected for Etanq1 haplotypes in the EPM with acute

ethanol, we only observed haplotype x treatment interactions when restraint stress was
used prior to ethanol administration, strongly suggesting that restraint stress is
necessary to detect significant interactions between the Etanq1 haplotype and ethanol
treatment for PTS and PDT in the open arms of the EPM. Interestingly, these
interactions were abolished when testing was done in the absence of restraint stress.
Furthermore, these BXD studies do suggest that the Etanq1 locus may be influencing
the ethanol responses, PTS and PDT, across both the LDB and EPM assays. One
limitation of these studies is that the BXDs grouped based on Etanq1 haplotypes have
additional locations across their genomes in which they group in the same manner, thus
the test for significant interactions would show the same results at each of these loci as
well. Upon searching for locations in which the six BXD strains grouped by haplotype
similarly to Etanq1 haplotype grouping (Supplemental Table S1), additional loci were
found on chromosomes 3, 7, 10, 12, and X. Within these haplotype blocks, we searched
for genes with non-synonymous exon SNPs between the B6 and D2 strains
(Supplemental Table S2) and correlated each of genes with the phenotypes driving
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Etanq1. Of the 150 genes with SNPs, only 10 showed significant correlations between
basal NAc expression, a brain region we think is important for Etanq1 (Chapter 7), and
PTS and PDT in the light side of the LDB (Supplemental Table S3), three of which, Nin,
Pygl, and Atp5s, lie within the Etanq1 support interval. The fact that the expression of
very few genes at the other loci where the BXD strains grouped by haplotype correlate
significantly to Etanq1 adds confidence in our results, which suggest that genetic
variation within a gene (or genes) in the Etanq1 support interval modulates both PTS
and PDT in the LDB and EPM.
!

Next, we used principal components analysis across the phenotypes from three

preclinical models of anxiety, LDB, EPM, and MB tasks, to determine whether the
genetic components of ethanol’s responses overlap across assays. We found that both
saline and ethanol responses in the LDB and EPM were largely locomotor-driven as
evidenced from their first principal components. This was expected, as multiple
literature studies have reported the locomotor-dependence of these assays (Clement,
2007; Henderson, 2004; Turri, 2001; Flint, 2003). Interestingly, the MB phenotype
correlated significantly with the locomotor PC from the LDB, suggesting that this
phenotype may not reflect anxiolytic-like behavior in mice. In both PCAs performed on
the ethanol phenotypes, PC2 for each assay contained the PTS and PDT phenotypes,
however, upon correlation of these phenotypes with each other, we found that they were
genetically correlated. In contrast to our BXD studies, the HMDP studies suggest that
the same genetic loci do not influence PTS and PDT across the LDB and EPM. There
may be multiple reasons for the conflicting results. First, perhaps the PCA and
correlation analyses were underpowered with an n=8. However, early PCA across
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preclinical anxiety assays have been performed using just two inbred strains of mice
(Clement, 2007). Second, the strains used are all inbred, thus a limited genetic diversity
may have masked our ability to detect the relationships between ethanol responses in
these assays if the driver loci or variants were not present. Lastly, maybe these ethanol
responses are so complex that Etanq1 does play a role in both the EPM and LDB, but
its effect is major in the LDB, but minor in the EPM.
!

Overall, these studies have provided evidence of the complexity of acute ethanol-

responsive phenotypes in unconditioned preclinical models of anxiety, thus
interpretation and interrogation of genetic loci influencing these traits is not trivial.
Future, controlled studies should be performed with an expanded panel of mice across
additional unconditioned preclinical anxiety assays, such as the elevated zero maze
and/or open field test, in order to continue to parse ethanol’s endophenotypes. Such
studies may allow us to “genetically dissect” the mechanism of ethanol-induced
anxiolysis, which has important implications in the future treatment of alcohol use
disorders.
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Chapter 5 - Ninein as a Candidate Gene for Etanq1

Introduction and Preliminary Studies
Risk for developing various aspects of alcoholism is determined by a combination
of an individual’s genetic makeup, environment, and neuroadaptations that occur
following acute and chronic exposure to alcohol. These complex interactions manifest
themselves heterogeneously among individuals, thus there remains a need to
understand the biological and genetic bases of risk for developing different stages of the
disease. Alcoholics frequently self-report anxiety and stress as motives for drinking
(Brown, 1991; Schuckit, 1990) and it has been hypothesized that alcohol’s ability to
relieve stress may contribute to initiation of drinking, development of excessive drinking,
and/or its reinforcing effects and relapse (Spanagel, 1995). Thus, one focus of my thesis
is to elucidate the genetic architecture underlying the acute anxiolytic-like response to
ethanol. Previously, Dr. Putman, of the Miles Laboratory, utilized two parental inbred
strains of mice, C57BL/6J (B6) and DBA2/J (D2) and BXD (B6 x D2) recombinant
inbred (RI) strains. Following an acute dose of saline or ethanol, mice were assayed in
the light-dark box (LDB) preclinical model of “anxiety” and genetic mapping of an acute
anxiolytic-like phenotype was performed. Those studies identified and confirmed a
behavioral quantitative trait locus (bQTL) for both PTS and PDT in the light, on
chromosome 12, deemed Etanq1 (ethanol-induced anxiolysis QTL 1), shown in Figure
5.1 (Putman, 2008). Using advanced-intercross recombinant inbred (ARI) strains
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containing additional recombination events within the Etanq1 suport interval, Dr. Wolen,
from the Miles laboratory, was able to refine the support interval from a 17.74Mb region
containing 106 genes to a 3.4Mb region containing 48 genes, spanning 69.1-72.6Mb on
distal chromosome 12 (Wolen, 2012). Four hours following behavioral testing, tissue
from the mesolimbic dopamine reward pathway, nucleus accumbens (NAc), medial
prefrontal cortex (mPFC), and ventral midbrain (VMB) of each BXD mouse was
harvested. Affymetrix M430 2.0 chips were used to conduct gene expression analysis of
39,000 transcripts across the genome captured by 45,000 probesets of over 34,000
well-characterized genes. Transcript levels at this timepoint are thought to be a
surrogate measure of signal transduction events that occurred as a result of earlier drug
administration and behavioral testing (Kerns, 2005). Following cis expression QTL (cis
eQTL) analysis across these brain regions, it was found that of the 48 genes within the
Etanq1 support interval, four (Nin, Atp5s, Sos2, and Trim9) have putative cis eQTL in
the NAc, which overlap with Etanq1, Figure 5.2. Furthermore, the basal expression of
each gene within the NAc significantly correlates to Etanq1, making Nin, Atp5s, Sos2,
and Trim9 top-priority quantitative trait genes (QTGs), Figure 5.3.
Although Sos2 and Trim9 both contain cis eQTLs overlapping with and correlated
to Etanq1, they do not contain non-synonymous exon or untranslated region (UTR)
polymorphisms differing between the B6 and D2 mouse strains, which are the most
common variants predicted to underlie cis eQTL (Schadt, 2005). The number of genes
passing each criterion are pictured in Figure 5.4. It is entirely possible that nonsynonymous intra- or intergenic SNPs may lie within regions containing enhancer
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Figure 5.2 - Significant cis eQTL overlap with the PTS bQTL, Etanq1, for
candidate genes, Nin, Atp5s, Trim9, and Sos2. Strain-mean interval mapping of
NAc saline RMA data using 1000 permutations resulted in identification of signifiant
cis eQTL on chromosome 12 for Nin (a), Atp5s (b), Trim9 (c), and Sos2 (d) for the
probesets indicated in each legend.
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Figure 5.3 - Nin, Atp5s, Trim9, and Sos2 mRNA expression in the NAc
significantly correlate with the PTS and PDT LDB phenotypes. Correlation
scattergrams (left of diagonal), univariate density plots (in white, along the diagonal),
and Pearson’s r values (right of diagonal) are displayed. For the correlation
scattergrams, each point represents a strain mean with linear fits plotted in red and
95% confidence intervals plotted in blue. Blue r value denote a significant correlation
at an alpha = 0.05.
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Figure 5.4 - Venn diagram of characteristics of quantitative trait genes for Etanq1.
Of the 48 genes within the Etanq1 support interval on chromosome 12, 69.1-72.6Mb, 29
genes contain SNPs between B6 and D2 strains, 4 of which are missense SNPs. 14
genes have either cis or trans eQTL which overlap with Etanq1, and 24 genes show
significant correlations to PTS and PDT (p(Pearson’s r) <0.01) across the NAc, mPFC,
and/or VMB. Of note, only 4 genes possess cis eQTL, all of which are in the NAc, and
only two of these contain missense coding SNPs, Nin and Atp5s.
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binding-sites, which in turn, may cause cis-regulated expression, however, enhancer
regions within the mouse genome are poorly mapped at present. With the advent of
next-generation sequencing, regulatory regions such as these are currently being
identified in human cells using chromatin profiling (Ernst, 2011). Thus, without the
availability of this information in the mouse, we further narrowed down our candidate
gene list to Nin and Atp5s on the basis of possessing non-synonymous exon SNPs.
Quantitative, real-time PCR (qRT-PCR) performed from B6 and D2 NAc tissue for
all four genes containing cis eQTL and allele-specific sequencing of Nin from B6D2F1/J
tissue confirmed cis regulation of basal Nin transcript levels in the NAc, resulting in
significantly higher Nin expression in D2 mice compared to B6 mice. Next, analysis of
putative splice sites has revealed that two of the missense coding SNPs within the Nin
gene, but not Atp5s are predicted to enhance alternative splicing at those locations in
D2 mice. Finally, we have shown that in the NAc, D2 mice have significantly higher
levels of two protein isoforms likely resulting from increased alternative splicing
compared to B6 mice. Taken together, this aim has largely focused on interrogating the
role of Nin in modulating phenotypic responses to ethanol in LDB and EPM. Through
behavioral testing of hybrid mouse diversity panel (HMDP) strains selected for
possessing either B6 or D2 missense exon SNPs as well as D2 mice in which Nin was
knocked down via lentiviral delivery into the NAc, we have discovered that Nin may
modulate one endophenotype of the LDB’s PC2, latency to enter the light side of the
LDB. Overall, these studies provide evidence for basal Nin levels in modulating one
component of acute ethanol anxiolytic-like behavior, perhaps through a novel
mechanism. Confirmation of candidate genes involved in acute responses to ethanol in
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rodents, such as Nin, may lead to discovery of new and important molecules to further
research or target pharmcotherapies which may ultimately aid in the treatment of
alcohol addiction disorders in relevant populations.

Materials and Methods
!

Mice and husbandry conditions. Male C57BL/6J, DBA/2J, B6D2F1/J, AKR/J,

NOD/ShiLtJ, 129S1/SvImJ, C3H/HeJ, and Balb/cByJ mice were obtained at 7-8 weeks
of age from the Jackson Laboratories (Bar Harbor, ME). Mice were housed 4/cage and
allowed to habituate to the animal vivarium for two weeks following shipment to Virginia
Commonwealth University (VCU). Mice were maintained on a 12-hour light/dark cycle
with ad libitum access to standard rodent chow (Harlan, 7012) and tap water. All mice
were 8-12 weeks old at time of behavioral testing. All behaviors were assayed during
the light cycle between the hours of 0800 and 1300. Mice used only for molecular
studies were housed with Teklad aspen sani-chip (Harlan, 7090A) and mice undergoing
behaviors were housed on Teklad corn cob (Harlan, 7092) bedding.
!

Drugs. For all behavioral studies, a 1.8g/kg of ethanol dose was administered

intraperitoneally (i.p.) using a 10% ethanol (w/v) stock solution dissolved in a 0.9%
physiological saline vehicle. This dose was chosen based on previous LDB studies in
our laboratory (Putman, 2008). For stereotaxic surgeries, mice received ad libitum
access to 0.188mg/mL cherry-flavored children’s ibuprofen in their drinking water from
day prior to surgery until 48 hours after surgery. Mice were anesthetized with 5%
isoflurane and 7L O2 per minute and maintained sedated with 2-3% isoflurane/7L O2 per
minute. For local anesthesia, 0.1mL of 0.25% bupivacaine, was administered at the
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incision site. Lentivirus at a titer of 1.0x107 pg p24 per mL was used for in vivo infection.
This titer was chosen based on previous studies showing behavioral alterations using
shRNA lentiviruses (Lasek, 2007; Lasek, 2008; Lasek, 2010).
!

Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR). For

molecular studies using mouse tissue, single nucleus accumbens (NAc) samples from
9-week old, untreated B6 and D2 mice were micro-dissected on ice and immediately
flash-frozen in liquid nitrogen using a protocol described previously (Kerns, 2005).
Samples were homogenized with a Polytron® (Kinematica AG) and RNA extracted
using a guanidine/phenol/chloroform method (STAT-60, Tel-Test, Inc.). Each RNA liquid
layer was added to an RNeasy Mini Column (Qiagen) for cleanup and elution of total
RNA. For studies using cell lysates, cells were pelleted and washed three times with 1X
sterile PBS. Cells were lysed using Buffer RLT and RNA was extracted following the cell
culture protocol from the RNeasy Mini kit (Qiagen). RNA quality and purity was
determined using an Experion Automated Electrophoresis Station (Bio-Rad) and a
Nanodrop 2000 (Thermo Scientific). 1µg of RNA was converted to cDNA using BioRad’s iScript cDNA synthesis kit containing random hexamers according to
manufacturer’s instructions. For qPCR, primer efficiencies were between 90-110% and
each primer set resulted in only one PCR product. Primer sequences, Tm’s, amplicon
sizes, and cDNA dilutions used for each gene are listed in Table 7.1. Data analysis was
performed using the 2-[∆∆CT] method (Heid, 1996). Statistical analysis of qRT-PCR data
was performed using a Student’s t-test between the two strains tested.
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FWD Primer (5' to 3')
CAGGGAAACCAGGAACACC
ATCTCTCACCCTTGCCCTTT
ATCTCTCACCCTTGCCCTTT
ACCATCTTTGCTCCAGTCCT
TCGTCAACAATGAACAGCAAG
GCTGTATTCCCCTCCATCGT

REV Primer (5' to 3')
ACCACGGCATCTGTTTTTGT
CCCATTTTGTGTGCTTTCGT
TTTAGTTCCAGAGAAGGCAGTG
GTGGAATAGCAGGAGGGTCA
CTCGGCTGGAGTAGAAGTCG
CATGTCGTCCCAGTTGGTAA

Amplicon
Tm (°C) Size (bp)
61
149
79
61
61
120
61
184
61
138
61
162

cDNA
dilution
1:25
1:25
1:25
1:25
1:25
1:25

Table 5.1 - Primer sequences used for quantitative, real-time PCR. Table containing all primer sequences, Tms, and
amplicon sizes from the qRT-PCR experiments.

Target
Gene
Nin
Ppp2r2a
Atp5s
Sos2
Trim9
Actb

Cis-trans test via pyrosequencing. Single nucleus accumbens (NAc) samples
from 9-week old, untreated B6D2F1/J hybrid mice were micro-dissected on ice and
immediately flash-frozen in liquid nitrogen using a protocol described previously (Kerns,
2005ks). Samples were homogenized with a Polytron® (Kinematica AG) and RNA
extracted using a guanidine/phenol/chloroform method (STAT-60, Tel-Test, Inc.). Each
RNA liquid layer was added to an RNeasy Mini Column (Qiagen) for cleanup and elution
of total RNA. RNA quality and purity was determined using an Experion Automated
Electrophoresis Station (Bio-Rad) and a Nanodrop 2000 (Thermo Scientific). 1µg of
RNA was converted to cDNA using Bio-Rad’s iScript cDNA synthesis kit containing oligo
dT’s according to manufacturer’s instructions. End-point PCR was performed using the
primers listed in Table 5.2, which were designed around two of the four nonsynonymous coding SNPs present between B6 and D2 mice, dbSNPs rs29192398 and
rs29159683, creating a 413bp amplicon for sequencing. These primer sequences were
also extended with a unique identifier (MID) sequence such that all samples could be
multiplexed during pyrosequencing. PCR products were sequenced on the Roche 454
instrument and then analyzed for SNP allele frequency.
!

Immunoblotting. Single nucleus accumbens from untreated B6 and D2 mice were

microdissected and flash-frozen in liquid nitrogen as described above. Samples were
triturated in 100uL of cold 1X LDS (Life Technologies, Grand Island, NY) containing 2X
Halt protease and phosphatase inhibitor cocktail and 10mM EDTA (Thermo Fisher
Scientific). Each sample was passed through a 28g syringe until brain tissue was no
longer visible upon quick spin centrifugation. Protein concentrations on the whole
sample homogenates were determined using the bicinchoninic acid assay (Thermo
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MID sequence
+ ATAGATAGAC
+
+ TCACGCGAGA +

Reaction
REV primer B (5' to 3')
2 (MID86) CTATGCGCCTTGCCAGCCCGCTCAG
3 (MID66) CTATGCGCCTTGCCAGCCCGCTCAG

REV Nin Primer (5' to 3')
ACTCGGTCCTGGTGTCTTCA
ACTCGGTCCTGGTGTCTTCA

FWD Nin Primer (5' to 3')
AGCCATGTCCCTGCTTCA

Amplicon
REV Nin Primer (5' to 3')
Tm (°C) Size (bp)
ACTCGGTCCTGGTGTCTTCA
60
413
Amplicon
FWD Nin Primer (5' to 3')
Tm (°C) Size (bp)
AGCCATGTCCCTGCTTCA
60
413
AGCCATGTCCCTGCTTCA
60
413

Table 5.2 - Pyrosequencing primers used for the cis-trans test to determine regulation of Nin in the NAc of B6 and
D2 mice. Three PCR reactions were performed using two pooled NAc tissues from B6D2F1/J mice using the primers
listed above. For each reaction with a unique MID (Molecular Identifier), primers are listed. Plusses indicate that the
sequences were joined together. For example, for MID 36, the entire forward primer consisted of FWD primer A
+MID36+FWD Nin primer and the reverse primer was the Nin-specific primer.

MID sequence
+ CGACGTGACT +

Reaction
FWD primer A (5' to 3')
1 (MID36) CGTATCGCCTCCCTCGCGCCATCAG

Fisher Scientific). Samples were balanced with 1X LDS, reduced with 50mM
dithiothreitol and boiled for 10 minutes. For each antibody used herein, it was
determined that 17.5µg of protein lie within the linear range of detection, thus 17.5µg of
protein were loaded per lane on a 3-8% Tris-acetate gel (Life Technologies). Using a 1X
tris-acetate running buffer, electrophoresis was performed at 150V. The gel was
transferred to a 45µm PVDF membrane at 10V for 24 hours using a freshly prepared
transfer buffer containing 10% methanol. Coomassie staining of the gel and Ponceau
staining of the membrane indicated efficient and even transfer. Prior to each primary
antibody incubation, the membrane was blocked with 5% nonfat milk in 1X wash buffer
(TBS-T containing 0.2% Tween 20 and 1M NaCl) for 30 minutes at room temperature.
For ACTB, Primary and secondary antibody catalog numbers, dilutions, and incubation
times are provided in Table 3.2. For NIN, 1, 1000 of rabbit primary (Bethyl Laboratories,
Montgomery, TX, Cat# A301-504) and 1, 2000 of donkey anti-rabbit (Table 6.2) were
used. Immunoblots were imaged on Kodak film using the chemiluminescent ECL prime
reagent (GE Healthcare Life Sciences) and quantitated using ImageJ processing and
analysis software (National Institutes of Health). All proteins were normalized to the
loading control, β-actin (ACTB).
!

Plasmids. Bacterial glycerol stocks for five Ninein (Nin) and one b-actin (Actb)

shRNA-containing plasmids and DNA for a plasmid containing a non-mammalian target
scrambled shRNA sequence (denoted sh-scram) were obtained from Sigma Aldrich
(Table 5.3). The shRNAs were previously cloned into the pLKO.1-puromycin plasmid
backbone immediately downstream of the U6 promoter. Bacterial slabs of second
generation lentiviral plasmids, psPAX2 (Plasmid 12260) and pMD2.G (Plasmid 12259),
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Clone ID
non-mammalian target
NM_007393.1-704s1c1
NM_008697.1-1274s1c1
NM_008697.1-5927s1c1
NM_008697.1-964s1c1
NM_008697.1-1763s1c1
NM_008697.1-5335s1c1

Denoted Name
sh-scram (03)
sh-Actb (24)
sh-Nin (1274)
sh-Nin (5927)
sh-Nin (964)
sh-Nin (1763)
sh-Nin (5335)

Sequence (sense, loop, antisense, terminator - 5' to 3')
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT
CCGGCGTGCGTGACATCAAAGAGAACTCGAGTTCTCTTTGATGTCACGCACGTTTTTG
CCGGCGGCACTTGTTAGAACGAGTTCTCGAGAACTCGTTCTAACAAGTGCCGTTTTTG
CCGGCGAGGATTAGAAACAATCCATCTCGAGATGGATTGTTTCTAATCCTCGTTTTTG
CCGGGCATCTCTCTATGCAGTCTTTCTCGAGAAAGACTGCATAGAGAGATGCTTTTTG
CCGGGCGCAGATGAGAAATGAATATCTCGAGATATTCATTTCTCATCTGCGCTTTTTG
CCGGGCACAGAATTGCTACAATGAACTCGAGTTCATTGTAGCAATTCTGTGCTTTTTG

Table 5.3 - shRNA sequences used for knockdown studies. pLKO.1-U6-sh-CMV-eGFP plasmids (Sigma Aldrich) were
used for all knockdown studies. Catalog numbers and designations used herein are listed. Sequences contain sense,
loop (CTCGAG), antisense, and terminator (TTTTT) motifs. sh-scram was designed against the luciferase genome and
therefore, does not target any known mammalian genes. Each of the Nin shRNAs targets both transcript variants for Nin.

Catalog Number
SCH002
TRCN0000090901
TRCN0000114701
TRCN0000114702
TRCN0000114704
TRCN0000114705
TRCN0000114703

were obtained from Addgene (Cambridge, MA). For positive control studies requiring the
GFP reporter protein, the pLL3.7 plasmid (Rubinson, 2003) (Plasmid 11795) was
obtained. All plasmid maps are pictured in the appendix (A4). Bacterial glycerol
stocks were streaked onto sterile 1.5% luria agar plates infused with 100µg/mL
ampicillin. 0.01ng of the sh-scram plasmid were transformed into Stabl (Invitrogen) E.
coli using the manufacturer’s protocol. 10, 20, and 100µL of the transformation solution
was spread onto sterile 1.5% luria agar plates infused with 100µg/mL ampicillin. All
plates were incubated at 37°C overnight. No more than 16 hours later, single colonies
were picked into 3mL of either sterile Luria Broth (LB) containing with 10g NaCl or
Terrific Broth (TB) containing 100µg/mL ampicillin in 15mL cell culture tubes. Tubes
were shaken at 2000rpm and 37°C for 8h, after which the 3mL was poured into 500mL
of sterile broth containing 100µg/mL ampicillin in a 1L erlenmeyer flask. The flasks were
shaken under the same conditions overnight for no more than 16h. Following the
incubation, bacterial glycerol stocks were made using 500µL of bacteria and 500µL of
50% sterile glycerol. Stocks were frozen at -80°C. Bacteria were pelleted by
centrifugation at 6000 rpm at 4°C for 10 minutes. Pellets were either frozen at -80°C
until harvesting or immediately lysed. Lysis, cleanup, and DNA precipitation were
performed using the endotoxin-free Qiagen MegaPrep kit according to the
manufacturer’s instructions. The purity and integrity of plasmid DNA were determined by
NanoDrop 2000 (ThermoScientific) analysis, restriction enzyme digestion, and agarose
gel electrophoresis (Figure A5).
In vitro transfection. Mouse fibroblast cells, NIH3T3, maintained in high-glucose
DMEM containing 10% FBS, 2mM L-glutamine, and 50U/mL penicillin/streptomycin,
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(complete media) were used for all transfection experiments. Prior to transfection, a
puromycin kill curve was performed in NIH3T3 cells, which determined that 2µg/mL was
the optimal concentration of puromycin required to kill 100% of this cell type within 48
hours. The afternoon prior to transfection, 0.25x106 cells were plated in 6 -well dishes.
The morning of transfections, media was removed and replaced with 400µL Opti-MEM.
3µL of X-tremeGENE 9 transfection reagent was diluted into 96µL Opti-MEM and 1µL of
1µg/µL plasmid DNA was added to the solution, mixed, and incubated at room
temperature for 20 minutes. DNA-lipid complexes were added drop-wise to each dish,
dishes were swirled, and placed into a humidified 37°C/5% CO2 incubator overnight. 24
hours later, media was replaced with complete media containing 2 µg/mL puromycin.
(Prior studies testing multiple ratios and seeding densities determined that the optimal
transfection reagent to DNA ratio was 3µL, 1 µg using 0.25x106 cells seeded the
afternoon prior to transfection). Cells were harvested at 48 and 72 hours posttransfection.
!

Lentivirus Production and Titering (adapted from Dr. Amy Lasek, University of

Illinois - Chicago). HEK293FT cells were obtained from Invitrogen and maintained
according to the manufacturer’s instructions. Upon thawing, cells were passaged at
least three times before use in viral production. On the afternoon prior to transfection,
for each construct, 3-15cm dishes 16x106 HEK293FT cells were seeded in 20mL of
room-temperature media without Geneticin (G418), such that cells were 80-90%
confluent for transfection. 16 hours following cell seeding, media was removed and
replaced with 13mL of fresh, room-temperature media without G418. For each dish,
12µg of psPAX2, 5µg of pMD2.G, and 15µg of either the sh-Nin or sh-scram plasmid
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were combined in 3.5mL of Opti-MEM and incubated at room temperature for 5 minutes.
In a separate 3.5mL of Opti-MEM, 80µl of Lipofectamine 2000 (Invitrogen) was added
and placed at room temperature for 5 minutes. Next, the 3.5mL of media containing the
DNA was added to the 3.5mL of media containing Lipofectamine and incubated for 20
minutes at room temperature. The 7mL mixture was then added drop-wise a 15cm dish,
swirled, and placed into a humidified 37°C/5% CO2 incubator overnight. The following
morning, the media was removed and replaced with 22mL of fresh, room-temperature
Opti-MEM. 48 hours following transfection, media was removed from the cells,
transferred into a 50mL conical tube, and spun at 1200rpm for 5 minutes at 4°C. Media
was poured into a 45µm Steriflip filter unit (Millipore), transferred into ultraclear 38.5mL
tubes (Beckman), and qs’d to 30mL with cold Opti-MEM. Tubes were massed and
balanced prior to centrifugation. Using an SW 32 Ti rotor, tubes were spun at 26,000rpm
for 90 min. at 4°C. After centrifugation, the supernatant was discarded and 20µL of
sterile, 1X PBS was added to the bottom of the tube without disturbing the pellet. The
pellet was resuspended by gentle pipetting 10 times and the virus from 3 tubes (3
transfection dishes) was combined, mixed, and then distributed into 10µL aliquots.
Aliquots were frozen on dry ice and stored at -80°C until titering. Viral titers were
determined using the HIV-1 p24 ELISA (ZeptoMetrix Corporation, Buffalo, NY).
In vitro viral transduction (adapted from Sigma Aldrich). Mouse fibroblast cells,
NIH3T3, maintained in high-glucose DMEM containing 10% FBS, 2mM L-glutamine,
and 50U/mL penicillin/streptomycin, were used for all transduction experiments. The
afternoon prior to transduction, 0.1x105 cells were plated in 96-well dishes. The morning
of transduction, media was removed and replaced with 100µL of media containing 8µg/
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mL hexadimethrine bromide (polybrene) and viruses at a concentration sufficient for a
multiplicity of infection (MOI) of either 0.5, 1.0, 2.0, or 5.0 were added drop-wise to each
well. Plates were swirled and placed into a humidified 37°C/5% CO2 incubator
overnight. 24 hours later, cells were transferred to 6-well plates and at 48 hours,
lentivrus-containing media was replaced with media containing 2µg/mL puromycin. At
96 hours, puromycin-containing media was replaced to continue selection. At 140-144
hours post-transduction, cells were harvested.
In vivo viral infection via stereotaxic delivery. 8-week old D2 mice received ad
libitum access to 0.188mg/mL cherry-flavored children’s ibuprofen in their drinking water
from day prior to surgery until 48 hours after surgery. Prior to surgery, mice were
anesthetized with 5% isoflurane and 7L O2 per minute and maintained sedated with
2-3% isoflurane/7L O2 per minute. Scalps were shaved, wiped with isopropanol to
remove hair, mice were placed in the stereotaxic rig, earbars were inserted to
immobilize the head, and the head was adjusted to be level. Ophthalmic ointment
(Henry Schein) was applied generously to each eye, the incision site was cleaned with
ethanol, betadine, ethanol, and then a 0.1mL of 0.25% bupivacaine, was injected at the
incision site. An anterioposterior (AP) incision was made to expose the skull and
needles were centered at bregma. If necessary, the animal’s head was adjusted to be
within the same AP and mediolateral (ML) planes as bregma. AP and ML coordinates
from bregma were recorded. NAc coordinates (A, +1.7mm, L, +1.4mm, V, -4.1mm)
were added/subtracted from those recorded at bregma and A and L coordinates
adjusted. Needles were lowered to the surface of the skull , where marks were made for
drilling. Holes were drilled through the skull and needles were rinsed with water,
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ethanol, and water before loading them with virus. Needles were placed at the edge of
the skull and dorsal readings were taken. Ventral coordinates were subtracted and
needles were lowered to the NAc. 0.1 µL of virus was injected every minute for a total of
1µL of virus injected bilaterally. Needles were allowed to sit at the injection site for 10
minutes and then slowly removed and cleaned. Incisions were sealed with Vetbond
(3M) and mice were placed into a clean cage on a heating pad until coming out from
under anesthesia. Sterile technique was maintained throughout the surgery and the
absence of a toe pinch reflex was recorded at 15 minute intervals. Behavioral studies
were performed three weeks following viral injections, as previous studies have
demonstrated maximal lentiviral expression occurs at two weeks following injection and
is maintained for at least one year following infection (Baekelandt, 2002).
Light Dark Box. The LDB (Med-Associates, St. Albans, VT) consists transparent
square box of dimensions 10.75" L x 10.75" W x 8" H with a black insert which divides
the chamber into two equally sized chambers. The entire apparatus is contained within
a sound-attenuating chamber. Mice were placed into a 50mL conical tube on top of a full
cage of bedding for 15 minutes. Immediately following a 15-minute restraint stress, mice
were injected i.p. with either ethanol or saline, returned to their home cage for 5
minutes, and then placed into center of the LDB, facing the dark side, and behaviors
were recorded for 10 minutes. Studies used house lights (100mA) within the light-dark
box.
!

Elevated Plus Maze. The EPM (Hamilton Kinder, San Diego, CA) consists of four

black arms in a cross shape raised 30.5” from the ground. Each arm is 15” L x 2” W and
the apparatus contains with center section measuring 2” L x 2” W. The closed arms
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have 6” black walls and the open arms do not have walls. Mice were placed into a 50mL
conical tube on top of a full cage of bedding for 15 minutes. Immediately following the
restraint stress, mice were injected i.p. with either ethanol or saline, returned to their
home cage for 5 minutes, and then placed into center of an EPM, facing one of the
open arms, and allowed to roam for 5 minutes. The open arm that each mouse faced to
begin the assay was randomized and balanced within treatment groups. If mice did not
receive restraint stress, they were administered either ethanol or saline i.p., placed into
their home cage for 5 minutes, and then placed into the center of the EPM and allowed
to roam for 5 minutes. If a mouse fell or jumped off of the maze, it was placed back into
the center facing the opposite open arm from which it fell. The number of falls was
counted as a separate phenotype.
Statistics. Using JMP and/or R, appropriate Student’s t-tests or oneway ANOVAs,
followed by Tukey’s HSD post-hocs were performed for all cellular and molecular
studies, as noted where applicable. A twoway ANOVA, followed by a Tukey’s HSD posthoc was performed for all behavioral studies to determine the presence of main and/or
interaction effects of treatment and genotype. Pearson’s or Spearman’s correlations,
where appropriate, were performed using the psych package in R (Revelle, 2012).

Results
!

Functional analysis of non-synonymous exonic SNPs within Nin and Atp5s

revealed that two of the four SNPs within the Nin gene overlap with exonic splicing
enhancer (ESE) sequences, while the single missense coding SNP within the Atp5s
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Figure 5.5 - Two of Nin’s missense SNP alleles in the D2 strain result in alteration of or creation of exon splice
enhancer sequences. Exonic splicing enhancer (ESE) analysis of B6D2 SNPs within the Nin and Atp5s genes revealed
that the D2 allele for rs29192398 (b, position 101 on the diagram) is predicted to cause an ESE hexamer binding site,
whereas the B6 allele does not. Additionally, Nin SNP rs29159683 alters the ESE between B6 and D2 strains (c). Nin
SNPs rs32225358 (a) and rs29149025 (d) were not predicted to create ESE sites. For Atp5s, the missense SNP,
MRS3453016 (position 114 on the diagram), is not predicted to create an ESE site (e). Arrows denote SNP alleles.
(Screenshots adapted from the RESCUE-ESE online tool (Yeo, 2004)).
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gene does not (Fairbrother, 2002; Yeo, 2004), Figure 5.5. Furthermore, the Nin SNP,
rs29192398, was predicted to create an ESE site in the presence of the D2 T allele,
which is not present with the B6 C allele in the same position, suggesting that D2 mice
might have increased splicing of Nin transcripts at this location, which may lead to
different pools of NIN protein isoforms, and consequently, NIN function between the two
strains. In fact, two alternatively-spliced variants which are translated into two protein
isoforms of NIN have been discovered in the mouse genome (Figure 5.6).

Basal transcript levels of Ninein in the NAc are cis-regulated.
!

qRT-PCR analysis of NAc samples from untreated B6 and D2 mice only

confirmed differential mRNA expression of Nin, but not Atp5s, Sos2, nor Trim9 (Figure
5.7, a), the four candidate QTGs possessing cis eQTL in the NAc. The expression of
Nin was significantly greater in the NAc of D2 mice compared to B6 mice. Thus,
pyrosequencing was performed on only Nin. In the NAc of untreated B6D2F1/J mice,
allele-specific pyrosequencing of missense SNPs within the Nin gene revealed a
significantly greater frequency of the D2 SNP alleles compared to B6 alleles, confirming
cis regulation of Nin in the NAc (Figure 5.7, b).

Basal NINEIN protein isoforms in the NAc are differentially regulated between B6 and
D2 mice.
!

Immunoblotting confirmed significantly higher basal levels of two protein isoforms

in the NAc of D2 mice compared to B6 mice (Figure 5.8). If either one or both SNPs,
rs29192398 and rs29159683, result increased splicing out of exon 16 in D2 mice, the
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Figure 5.6 - Diagram of the Ninein transcripts and protein isoforms. The Ninein gene produces two alternativelyspliced transcripts, denoted transcript variant (TV) 1 and 2, depicted above. TV1 contains 29 exons of 9654bp and TV2
contains 28 exons of 6590 bp. The four missense coding SNPs between B6 and D2 lie within exon 16 (2121bp) and are
denoted with a red star. Each TV is translated to its full-length protein, shown in red. The NIN protein isoform 1 is 2113
amino acids in length with a calculated mass of 244 KDa and isoform 2 is 2035 amino acids in length with a calculated
mass of 235 KDa. If exon 16 were spliced out of each full-length transcript, protein isoforms of ~160KDa and ~150KDa
would result (blue). Adapted from the Vega genome browser (Ashurst, 2005).

2113 aa ~ 244 KDa

6590 bp

9654 bp

Mouse genome build GRCm38

b

3.0

0.8

*

2.5

SNP Allele Frequency

Normalized Expression Ratio

a

*

0.6

2.0
1.5

Strain
B6
D2

0.4

1.0

a b

0.5
0.0

0.2
0.0

atp5s

nin

sos2

Gene

trim9

B6

D2

Progenitor Allele

Figure 5.7 - Confirmation of cis regulation of Ninein. (a) Basal mRNA levels
of Nin in NAc of D2 mice were found to be significantly greater than levels in B6
mice (*p<0.01, n=8 per group) as confirmed by qRT-PCR. However, basal
mRNA levels of Sos2, Atp5s, and Trim9 were not found to be different between
B6 and D2 mice in NAc as measured by qRT-PCR. (b) Pyrosequencing of
B6D2F1/J hybrid mice for an amplicon of Nin containing two SNPs between B6
and D2 mice (rs29192398 and rs29159683 at 71.144373 and 71.144376 Mb of
mouse build mm9, respectively) confirmed a higher D2 allele frequency in NAc
compared to B6 allele frequency (*p<0.01, n=2 pooled per sample, n=3 per
group, n>4000 reads per group) for those SNPs.
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An example of 10 l HiMark™ Pre-Stained HMW Protein
Standard analyzed on a NuPAGE® Novex 3-8% Tris-Acetate
Gel is shown below.
a
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Figure 5.8 - Immunoblotting confirms differential regulation of NIN protein
isoforms in the NAc between B6 and D2 mice. Immunoblotting of single NAc tissue
from untreated B6 and D2 mice revealed significantly higher levels of the provisional
NIN4 and NIN5 isoforms in D2 compared to B6 mice (*p<0.05, Student’s t-test, n=5/gp).
Page
Panel a, blot images and panel b, quantitation of 10 NIN isoforms. D2 mice also show a
trend for higher levels of NIN6, NIN8, and NIN10 isoforms (p=0.1703, p=0.0589, and
p=0.1516, respectively, Student’s t-test). NIN levels were normalized to ACTB protein
levels.
The apparent molecular weight of protein bands in the

Example

HiMark™ Pre-Stained HMW Protein Standard in several buffer
105
systems is shown below. The protein bands have different
mobilities in various SDS-PAGE buffer systems.

3

resulting protein isoforms would be predicted to be ~150 and ~160KDa (Figure 5.6). In
fact, compared to B6 mice, the two provisional isoforms significantly increased in D2
NAc are NIN4 and NIN5, with predicted molecular weights between 117-171KDa. These
data support the hypothesis of enhanced splicing activity in D2 mice as a result of an
additional and/or altered ESE sequence in exon 16, resulting in a greater pool of these
smaller isoforms in D2 mice. These differences in protein isoforms may suggest
functional differences in NIN between B6 and D2 mice.

HMDP strains selected for Nin SNPs show multiple genotype x treatment interactions in
the LDB and EPM, but not the marble burying task.
!

In order to determine whether Nin is influencing ethanol-responsive phenotypes

in the LDB and EPM, strains from the mouse hybrid diversity panel (HMDP) were
selected on the basis of possessing either the B6 or D2 alleles for the four nonsynonymous coding SNPs within the Nin gene. Table 5.4 lists the HMDP strains
selected. We hypothesized that if Nin is modulating Etanq1 through differences in one
or more of these missense SNPs, and its effect is large, then we may be able to detect
significant genotype x treatment interactions for the anxiolytic-like phenotypes
measured in the LDB and/or EPM. To avoid possible interaction effects of a separate
suggestive QTL locus for Etanq1, genotypes were clamped (all B6) at the peak marker
on distal chromosome 1, located at 165.32Mb.
!

In the LDB, Figure 5.9, MDP strains show significant genotype x treatment

interaction effects for TLA, total transitions, percent rearing in the light, jumps, and a
trend for stereotypic counts (p=0.0533) in the LDB, but not PTS, nor PDT in the light.
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AKR/J

NOD/ShiLtJ

C57BL/6J

DBA/2J

A/J

Balb/cByJ

C3H/HeJ

129S1/SvImJ

Chr
12
12
12
12

Location+(Mbp)+
mouse+build+37
71.144164 C
71.144373 C
71.144376 G
71.144902 T

C
C
G
T

C
C
G
T

C
C
G
T

T
T
T
C

T
T
T
C

T
T
T
C

T
T
T
C

+dbSNP+rs
rs32225358
rs29192398
rs29159683
rs29149025

Table 5.4 - Hybrid Mouse Diversity Panel strains of mice chosen based on Nin
missense exon SNPs. Nin contains 4 non-synonymous coding SNPs between B6
and D2 mice, two of which are predicted to alter protein function. 129S1/SvImJ, AKR/
J, and NOD/ShiLtJ strains possess B6 SNP alleles and A/J, Balb/cByJ, and C3H/HeJ
strains possess D2 SNP alleles. Mice were obtained from the Jackson Laboratory.
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Figure 5.9 - Interaction effects between the Nin genotype and ethanol treatment across eight inbred strains tested
in the LDB. MDP strains selected for either B6 or D2 SNP alleles in Nin show significant interaction effects (p<0.05,
twoway ANOVAs) between the Nin genotype and ethanol treatment for TLA, total transitions, percent rearing in the light,
jumps, and a trend for stereotypic counts (p=0.0533) in the LDB. There were significant effects of Nin genotype for
transitions and a near significant effect of genotype for latency to enter the light (p=0.0721, n=36-40/genotype).
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Additionally, there was a significant main effect of the Nin genotype for transitions and a
near significant effect of genotype for latency to enter the light (p=0.0721).
In the EPM, Figure 5.10, MDP strains show significant genotype x treatment
interaction effects for PDT, total transitions, fine movements, entries into the center, and
near significant trends for TLA (p=0.0533) and number of falls (p=0.0750) off of the
maze.
!

There was no significant interaction between the Nin genotype and ethanol

treatment in the marble burying assay across the MDP strains tested. However, there
are significant main effects of genotype, treatment, and a significant genotype x saline
treatment interaction only, Figure 5.11.

The NAc expression of Nin is significantly correlated with PDT in the open arms of the
EPM, shows a near significant correlation with the number of falls and trends toward a
significant correlation with latency to enter the light.
!

A separate cohort of the same HMDP strains were used for qRT-PCR analysis of

basal Nin levels in the NAc. Figure 5.12 depicts correlations with basal Nin expression
and several ethanol-responsive phenotypes from the LDB and EPM. As the interaction
effect plots failed to show genotype x treatment interaction for PDT in the light (Figure
5.9, b), we also failed to observe a significant correlation between Nin expression and
PDT in the light following ethanol (Figure 5.12, a). However, in support of the significant
interaction effect observed for PDT in the open arms (Figure 5.10, b), we observed a
significant inverse correlation between Nin expression in the NAc and PDT in the open
arms of the EPM (Figure 5.12, b). Additionally, we observed a near significant
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Figure 5.10 Interaction effects between the Nin genotype and ethanol treatment across eight inbred strains tested
in the EPM. MDP strains show significant interaction effects (p<0.05, twoway ANOVAs) between the Nin genotype and
ethanol treatment for PDT, total transitions, fine movements, entries into the center, and trends for TLA (p=0.0533) and
NoFalls (p=0.0750) in the EPM (n=37-40/genotype).
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Figure 5.11 - Interaction effect plot for the Nin genotype and treatment across
eight inbred strains tested in the marble burying assay. When collapsed by Nin
genotype, there are significant main effects of genotype, 1.8g/kg ethanol treatment, and
a significant genotype x saline treatment interaction (all p<0.01, twoway ANOVA,
n=36-40/genotype).
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Figure 5.12 Correlations between the Nin mRNA levels in the NAc and ethanol
responses in the LDB and EPM across eight HMDP strains. Correlation of basal
NAc Nin levels measured by qRT-PCR with ethanol responses in the LDB and EPM
revealed a lack of correlation for PDT in light side of the LDB (a), but a significant
correlation for PDT in the open arms of the EPM (b). Additionally, there were near
significant correlations between Nin transcript levels and the number of falls (c) off of
the EPM and the latency to enter the light side of the LDB (d). Spearman’s rho with their
p-values are noted (n=8 strains, n=8 per strain). Actual values are plotted in the
correlation matrices. Nin was normalized to the housekeeping gene, Ppp2r2a.
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correlation with the number of falls off of the maze (Figure 5.12, c), consistent with the
near significant interaction in Figure 5.10, h). Finally, we observed a trend for a
correlation between basal Nin levels and the latency to enter the light side of the LDB,
another phenotype that loaded onto PC2 of the LDB, along with PTS and PDT. We did
not observe significant correlations between Nin expression and the marble burying
phenotype following ethanol administration (data not shown).

Lentiviral plasmids containing Actb or Nin shRNAs were able to significantly decrease
Actb or Nin mRNA levels in mouse NIH3T3 cells following transfection.
!

In order to more directly interrogate the role of Nin in the NAc of mice, a

approach was taken to knock down Nin levels using short-hairpin RNAs (shRNAs).
Lentiviral plasmids containing the shRNA sequences for the positive control, sh-Actb,
the negative control scrambled RNA sequence, sh-scram, or sh-Nin were obtained and
transfected into the mouse embryonic fibroblast cell line, NIH3T3.
!

Figure 5.13 depicts two positive controls used to test transfection efficiency and

shRNA plasmid mRNA knockdown efficiency. Transfection of an shRNA plasmid
containing an eGFP reporter, pAAV-U6-sh-scram-CMV-eGFP, demonstrated that 48
hours following transfection, roughly 40-50% of cells contained the plasmid (Figure
5.13, a). The positive shRNA plasmid control for Actb, pLKO.1-U6-sh-Actb-CMV-puro,
was able to significantly decrease Actb mRNA levels in NIH3T3 cells at 48 hours posttransfection (Figure 5.13, b).
!

Next, five pLKO.1-U6-shRNA-CMV-puro plasmids containing different Nin

shRNA sequences were transfected into NIH3T3 cells, but only two, sequences 1763
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Figure 5.13 - Positive controls confirm both transfection and shRNA efficiency.
The pAAV-U6-sh-scram-CMV-eGFP plasmid (Vector Biolabs) transfected into NIH3T3
cells shows roughly 40-50% of cells containing the plasmid by 48 hours. Transfection of
the pLKO.1-U6-sh-Actb-CMV-puro plasmid (Sigma Aldrich) into NIH3T3 cells was able
to significantly decrease Actb mRNA levels compared to a scrambled control at 48
hours post-transfection (*p<0.01, F[2,6]=35.2814, oneway ANOVA, Tukey’s HSD posthoc, n=3 biological replicates, n=technical replicates). Actb expression levels were
normalized to Ppp2r2a.
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and 924, showed significant knockdown of Nin mRNA levels at both 48 and 72 hours
post-transfection, Figure 5.14.

In vitro transduction of pLL3.7 lentivirus confirms viable lentivirus production using
second generation plasmids.
!

Using second generation packaging plasmids in the protocol described to make

lentivirus, subsequent transduction of the pLL3.7-U6-sh-CMV-eGFP virus into NIH3T3
cells confirmed that the lentivirus produced was indeed viable, Figure 5.15.

In vitro transduction of lentivirus containing Nin shRNA was able to knock down mRNA
levels of Nin in NIH3T3 cells.
!

Using second generation packaging plasmids in the protocol described to make

lentivirus, subsequent transduction of the pLKO.1-U6-shNin-CMV-puro virus into
NIH3T3 cells at MOIs of 2.0 and 5.0 was able to knock down Nin mRNA levels
compared to the plasmid containing the scrambled shRNA control (Figure 5.16).

Site-specific delivery of Nin shRNA lentivirus in the NAc of D2 mice significantly altered
the latency to enter the light side of the LDB.
!

Three weeks following viral injection of lentiviruses expressing either Nin or

scrambled shRNA into the NAc (Figure 5.17), D2 mice, the strain with higher basal NIN
levels in the NAc, were tested for ethanol-responsive behaviors in the LDB and EPM. Of
all of the phenotypes tested in the LDB, only one, latency to enter the light, was altered
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Figure 5.14 - mRNA knockdown of Ninein via transfection. Transfection of two
pLKO.1-U6-sh-Nin-CMV-puro plasmids, 1763 and 924, into NIH3T3 cells was able to
significantly decrease Nin mRNA levels at 48 hours post-transfection (*p<0.01,
F[4,8]=13.2761, oneway ANOVA, Tukey’s HSD post-hoc, n=3 biological replicates, n=3
technical replicates) and transfection of three of the plasmids, 1763, 5335, and 924,
significantly decreased Nin mRNA expression at 72 hours (*p<0.05, F[6,12]=6.1310,
oneway ANOVA, Tukey’s HSD post-hoc, n=3 biological replicates, n=3 technical
replicates) compared to the scrambled shRNA control plasmid. Nin expression levels
were normalized to the housekeeping gene, Ppp2r2a.
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a

b

Figure 7.15 - Transduction of pLL3.7 lentivirus into NIH3T3 cells confirms
successful lentiviral production. Bright field (a) and 488nm field (b) views of NIH3T3
cells 48 hours following transduction with pLL3.7 lentivirus made with the second
generation plasmids, psPAX2 and pMD2.G.
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Figure 5.16 - Successful knockdown of Nin mRNA with pLKO.1-U6-sh-Nin-CMVpuro lentivirus. Viral transduction of pLKO.1-U6-sh-Nin-CMV-puro plasmids, 924, into
NIH3T3 cells was able to significantly decrease Nin mRNA levels at 144 hours postinfection (*p<0.05, F[4,10]=23.9992, oneway ANOVA, Tukey’s HSD post-hoc, n=3
biological replicates, n=3 technical replicates) compared to the scrambled shRNA
control plasmid. Nin expression levels were normalized to the housekeeping gene,
Ppp2r2a. Multiplicities of infection used were either 2.0 or 5.0, as noted.
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Veriﬁca(on+of+len(viral+injec(on+into+the+NAc
Photo credit: Yun Kyung Hahn

A: +1.7mm
L: +1.4mm
V: -4.1mm

Mouse Brain Library, DBA/2J mouse, Section 13.

Figure 5.17 - Verification of stereotaxic injection into the NAc. Three weeks following
injection of pLL3.7-CMV-eGFP lentivirus into the NAc of an 8-week old DBA/2J mouse,
brains were perfused in 4% paraformaldehyde, sliced at 20µm thickness, and imaged
using confocal microscopy. Brain slice image of DBA/2J mouse, section 13, A: + 1.7mm
from bregma, from the Mouse Brain Library Database (Rosen, 2000). The blue arrow
denotes the approximate injection site. Coordinates are listed to the right. Inset, confocal
image of a slice showing eGFP-positive cells, confirming viral infection. (Mouse injected
by Julie (So Hyun) Park and confocal image taken by Dr. Yun Kyung Hahn).
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Figure 5.18 - LDB interaction effects between the Nin genotype and ethanol treatment across D2 mice infected
with lentivirus expressing Nin shRNA. D2 mice demonstrated a significant interaction between Nin genotype and
treatment for only latency to enter the light (p<0.05, twoway ANOVA, n=12-14/group).
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by knockdown of Nin, shown in Figure 5.18. None of the EPM phenotypes
demonstrated significant genotype x treatment interactions (Figure 5.19), suggesting
that Nin modulates one endophenotype of the LDB PC2, latency to enter the light, and
this regulation by Nin is not generalizable to ethanol anxiolytic-like responses in the
EPM.
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Figure 5.19 - EPM interaction effects between the Nin genotype and ethanol treatment across D2 mice infected
with lentivirus expressing Nin shRNA. D2 mice did not show any significant interactions between Nin genotype and
treatment across the phenotypes recorded in the EPM (n=12-14/group).
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Discussion
!

In this chapter, we sought to determine whether the QTG, Ninein, plays a role in

Etanq1’s behavioral responses to ethanol. Although the literature on the function of Nin
is limited, it has been shown to play a role in anchoring microtubules in the centrosome
(Bouckson-Castaing, 1996; Mogensen, 2000). In mice, the Nin gene produces two
known transcript variants (TV1, 9.7Kb and TV2, 7.6kb) and two major protein isoforms
(244 KDa and 235 KDa). These protein isoforms share an overall ~78% sequence
similarity to the human NIN protein and similarity at most protein domains is largely
homologous. The GTP-binding domains share 90% homology, the four leucine zippers
share 69%, the C-terminal domains share 54%, while very little homology is shared at
the N-terminal domains, 20% (Hong, 2000). Interestingly, a phosphorylation binding site
for Gsk3b (Glycogen synthase kinase 3 beta), an ethanol-responsive gene (Wolen,
2012; French, 2009), was found within an 81 amino acid portion of the C-terminal
domain of human Nin (2010-2090) (Howng, 2004). Furthermore, this 81 amino acid
sequence is 94% identical to the homologous region in the mouse NIN protein
sequence (Appendix A6, adapted from the NCBI blast resource (Boratyn, 2013)),
suggesting conserved regulation of Nin by Gsk3b in mice, which may be important for
ethanol-responsive behaviors.
!

Here, we provide evidence of cis-regulation of Nin transcript levels in the NAc,

leading to differential protein abundance between B6 and D2 mouse strains. This data
supports an early finding suggesting transcriptional regulation of Nin, in which
correlations between Nin mRNA levels and immunohistochemical labeling were found in
cell culture and across tissues (Bouckson-Castaing, 1996).
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!

Previous studies conducted by Dr. Putman in our laboratory have mapped

Etanq1 on chromosome 12 as being comprised of the PTS and PDT in the light
phenotypes (Putman, 2008), thus we hypothesized that Nin may modulate these
phenotypic responses to ethanol. However, upon testing HMDP strains in the LDB, we
did not observe significant Nin genotype x ethanol treatment interactions, perhaps for a
number of reasons. First, the number or strains tested was only eight, and although this
number gave us enough power to detect significant interactions in the BXD experiments
in Chapter 6, we have introduced additional genetic variance by using the HMDP
strains, thus increased the likelihood of epistatic, or gene-gene, interactions. In fact, our
laboratory has recently elucidated an epistatic interaction across the BXD panel
between a chromosome 12 marker which lies within Etanq1, rs3716547 (68.67Mb), and
a chromosome 1 marker, rs13474399 (182.53Mb) (Putman, et al, in preparation). This
epistatic interaction masks an Etanq1 haplotype x ethanol treatment interaction when
the genotype at the chromosome 1 marker is B6. Incidentally, contrasted to the BXD
strains chosen in chapter 6 having a D2 genotype at rs13474399, the HMDP strains
chosen for the studies herein were all the B6 genotype at rs13474399, thus it likely that
epistasis between loci on chromosome 12 and 1 may have masked our ability to detect
significant interactions between the chromosome 12 locus and ethanol treatment for
PTS and PDT in the light dark box.
!

Behavioral studies for ethanol-responsive behaviors across the HMDP strains in

the EPM elucidated a number of significant interaction effects which were not present
upon testing of BXD strains selected based on Etanq1 haplotypes (Chapter 4).
Interactions between the Nin genotype and ethanol treatment were present for PDT in
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the open arms, total transitions, fine movements, entries into the center compartment
and near significant trend for total distance traveled and the number of falls off of the
maze. Observation of significant Nin genotype x treatment interaction effects for
endophenotypes of both principal components of the ethanol responses in the EPM
contradicts the principal components analysis data in Chapter 4, suggesting that PC2
from the LDB does not correlate with any ethanol-responsive EPM phenotype. However,
the significant interaction effect for PDT in the open arms and near significant interaction
effect of the number of falls, together with correlations to Nin mRNA levels do suggest a
common regulation across assays. There are at least two explanations for these data.
First, the genetic correlations performed in Chapter 4 may have been underpowered
without representative D2 genotypes at the chromosome 1 marker, rs13474399, leading
to a lack of correlation between anxiolytic-like phenotypes in the LDB and EPM since
the chromosome 1 locus is important for the LDB phenotypes, PTS and PDT. If this is
true, the significant interactions observed in the EPM suggest that the chromosome 1
locus is not important for detection of a significant genotype x treatment interaction on
chromosome 12. Perhaps Nin commonly regulates these two phenotypes, but another
gene is also contributing to the PTS/PDT LDB phenotypes and not the PTS/PDT EPM
phenotypes, as evidenced by the additional QTL peak on chromosome 1. Second, due
to the genetic variation across the HMDP strains not present between B6 and D2 mice,
it is entirely possible that additional epistatic interactions are present in this panel of
mice which may be responsible for the genotype x treatment interactions we have
observed in the EPM. Additionally, the strain groupings are not unique for only the Nin
genotype. In fact, mining multiple available whole genome sequence datasets for
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missense SNPs within the exons of other genes revealed that these groups also have at
least 729 missense SNPs common to their genotype groupings (See Supplemental
Table S1). Of particular interest, these strains group based on missense SNPs for the
cannabinoid receptor 1 (Cnr1) and the corticotropin releasing hormone receptor 2
(Crhr2), both of which have also been implicated in playing a role in anxiety-related
behaviors (Rubio, 2008; Kishimoto, 2000; Thiemann, 2009; Uriguen, 2004). Thus, there
remains the possibility that one or more of the significant interactions observed across
the HMDP panel may be mediated through one of these genes, rather than Nin.
!

In order to directly interrogate the role of NAc Nin in ethanol’s anxiolytic-like

phenotypes, we have produced and delivered a lentivirus expressing a Nin shRNA into
the NAc of DBA/2J mice. We hypothesized that if Nin is regulating Etanq1, we would
observe significantly greater PTS and PDT in the light side of the LDB compared to D2
mice injected with a virus expressing a scrambled shRNA. Interestingly, we did not
observe differences in PTS, nor PDT. However, we observed a significant genotype x
treatment interaction for latency to enter the light side of the LDB. The principal
components analysis across the HMDP strains reported in Chapter 6 allowed
elucidation of additional endophenotypes of Etanq1’s PC2, which contained PTS and
PDT. Of note, PC2 contained the latency to enter the light phenotype, which was not
previously measured in the original QTL mapping study. These studies suggest that
basal NAc levels of Nin may play a role in modulating Etanq1, through the latency to
enter the light phenotype. As such, low basal levels of Nin in the NAc may be a risk
factor for acute responses to ethanol by a novel mechanism possibly involving
microtubule dynamics at or near the synapse. Alternatively, higher levels of a splice
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variant which does not include exon 16 of the Nin gene may be protective. Furthermore,
recent studies have reported an association between genetic variation within the Nin
gene or altered expression patterns of Nin with a number of diseases and genetic
disorders, including breast cancer (Olson, 2011), a type of skeletal dysplasia (Grosch,
2013), microencephalic primordial dwarfism (Dauber, 2012), polycystic ovary syndrome
(Baranova, 2013), and non-alcoholic fatty liver disease (Baranova, 2013), suggesting
that certain genetic variants of Nin might be a risk factor for multiple disease
phenotypes. Overall, these studies have uncovered the first role for Nin in an acute
response to ethanol in mice and future studies investigating its neuronal mechanism
may lead to a better understanding of the genetic targets of acute ethanol in the central
nervous system, and ultimately allow for the design of new pharmacotherapies for
alcohol addiction in those with susceptible genotypes.
!
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Chapter 6 - Acute Nicotine Behavioral QTL
Introduction
Nicotine dependence as a result of tobacco use is the leading cause of
preventable death in the world, contributing to 90% of lung cancer cases in the United
States and 49,400 deaths from second-hand smoke per year (National Institutes of
Health, 2012). Several studies have demonstrated that genetic influences on nicotine
addiction and dependence exist, with trait heritabilities between 46-84% (Swan, 1997;
Kendler, 1999; Heath, 1993; True, 1999). Although roughly 70% of adult smokers aspire
to quit smoking, only 4-7% are successful without medication and only 25% of those
using current cessation therapies are able to abstain from smoking for six months
(American Cancer Society, 2013). The inability to quit smoking is thought to be due to
high rates of relapse from difficulty in managing cravings and withdrawal symptoms
(National Institutes of Health, 2008), thus, more effective treatments are needed.
It has been hypothesized that associative cues in smokers can maintain drugseeking behavior and reinforcement, even in the absence of nicotine (Rose, 1997t;
Caggiula, 2001). A conditioned stimulus choice test, conditioned place preference
(CPP), has been used in animals since the early 1940s to model appetitive reward-like
properties of drugs of abuse (Spragg, 1940; Rossi, 1976). Thus, using CPP to test an
animal’s drug-free response to contextual cues associated with nicotine may lead to
discovery of neural pathways that play a role in nicotine reward and reinforcement
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(Bardo, 2000).
Behavioral genetics studies in animal models have been widely used to study the
role of specific nicotinic subunits or other genes in nicotine’s reward-like properties or
other behaviors (Changeux, 2010). Additionally, several human studies have associated
the genetic variation within multiple nicotinic acetylcholine receptor (nAChr) genes with
different nicotine dependence phenotypes (Ehringer, 2007; Bierut, 2007; Saccone,
2007; Zeiger, 2008; Amos, 2008; Berrettini, 2008; Hung, 2008; Saccone, 2010).
However, few forward genetics approaches have been used to identify novel targets for
intervention in nicotine behaviors. Modern genetic panels, together with high-density
genotyping and use of expression genetics, have improved the prospects for using
forward genetics to identify gene networks modulating complex traits such as nicotine
dependence (Hitzemann, 2004; Carlborg, 2005).
To identify gene networks involved in nicotine dependence, we used a
combination of behavioral genetics and pharmacological studies in mice, together with
genetic analysis of gene expression. Our results implicate genetic variation in Chrna7
mRNA expression and its potential regulation of insulin signaling as modulators of
nicotine conditioned place preference. These studies may have important implications
for understanding and treating nicotine dependence in humans.

Materials and Methods
Mice. For all studies, male mice were housed 3-5 per cage and allowed at least a
one-week acclimation period to the vivarium following shipment to Virginia
Commonwealth University (VCU). Mice were maintained on a 12-hour light/dark cycle
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with ad libitum access to food and water. Adult mice were tested or had tissues
harvested between 7-12 weeks of age. C57BL/6J (B6, Stock No. 000664), DBA/2J (D2,
Stock No. 000671), and BXD mice were obtained from Jackson Laboratories (Bar
Harbor, ME). Chrna7 knock-in, gain-of-function (α7 KI) mice (Chrna7 L250T +/-) were
obtained from Baylor College of Medicine (Houston, TX) (Broide, 2002). Chrna7
homozygous knock-out (α7 KO) mice (B6.129S7-Chrna7tm1Bay/J, Stock No. 003232)
were either obtained from Jackson Laboratories or breeding pairs were obtained and
KO mice were bred and genotyped at VCU. Both α7 KI and α7 KO mice were
backcrossed to the background strain, C57BL/6J, for an additional 8-10 generations and
wild-type littermates (α7 WT) were used as controls. The animal facility was approved
by the Association for Assessment and Accreditation of Laboratory Animal Care.
Experiments were performed during the light cycle and approved by the Institutional
Animal Care and Use Committee of VCU.
Drugs and Chemicals. (-)-Nicotine hydrogen tartrate salt and methyllycaconitine
citrate (MLA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). PHA-543613
[N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide] and cocaine
hydrochloride were obtained from the Drug Supply Program of the National Institute on
Drug Abuse (Rockville, MD). All drugs were dissolved in a vehicle of physiological saline
(0.9% sodium chloride), filter sterilized, and administered at a volume of 0.1mL per 10g
of mouse mass. Nicotine, PHA-543613, and MLA were administered subcutaneously
(s.c.), while cocaine was given intraperitoneally (i.p.). All doses are expressed as the
free base of the drug.
Conditioned Place Preference (CPP) Experiments. For all CPP experiments with
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BXD strains, α7 KO, KI, and WT mice, a five-day paradigm was performed as described
previously (Kota, 2007), Figure 6.1. Each animal received cage enrichment and on
Wednesday, Thursday, and Friday of the week prior to CPP testing, each mouse was
handled by the experimenter for approximately two minutes. The CPP apparatus (MedAssociates, St. Albans, ENV3013) consisted of white and black chambers (20 x 20 x 20
cm each), which differed in floor texture (white mesh and black rod). The chambers
were separated by a smaller grey chamber with a smooth PVC floor and partitions that
allowed access to the black and white chambers. Briefly, on Day 1 (pre-conditioning
day), mice were placed in the center chamber for 5 minutes, partitions were lifted, and
mice were allowed to roam freely for 15 minutes. The times spent in the white and black
chambers were used to establish baseline chamber preferences, if any. Mice were
separated into vehicle and drug groups such that initial chamber biases were
approximately balanced. On days 2-4 (conditioning days), twice per day, mice were
injected with vehicle or drug and subsequently paired with either the white or black
chamber, where they were allowed to roam for 15 minutes. Vehicle-treated animals
were paired with saline in both chambers and drug-treated animals received saline in
one chamber and nicotine in the opposite chamber. Pairing of the drug with either the
black or white chamber was randomized within the drug-treated group of mice. On day
5 (test day), mice did not receive an injection. They were placed into the center
chamber for 5 minutes, the partitions were lifted, and they were allowed to roam freely
for 15 minutes. Time spent in each chamber was recorded.
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Figure 6.1 Experimental timeline for BXD phenotyping of nicotine CPP. Using the
5-day paradigm illustrated above, 27 BXD strains were assayed for an acute reward-like
phenotype, conditioned place preference for 0.5mg/kg nicotine or saline.
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Several studies evaluating the role of α7 nAChRs in nicotine CPP were
conducted. We tested nicotine CPP (0.1 and 0.5 mg/kg) in α7 KO, KI, and WT mice
using the procedure described above. In separate studies, C57BL/6J mice were
pretreated with either saline or PHA-543613 (4.0, 8.0 and 12.0 mg/kg) 15 min before
nicotine administration (0.1 or 0.5 mg/kg). Finally, C57BL/6J mice were pretreated with
either saline or MLA (10 mg/kg), 15 min later, treated with PHA-543613 (12 mg/kg), and
another 15 min later, treated with nicotine (0.5 mg/kg).
A similar procedure was used for cocaine CPP as our positive control. We tested
cocaine CPP (10 mg/kg) in α7 KO, KI and WT mice. Finally, C57BL/6J mice were
pretreated with either saline or PHA-543613 (12 mg/kg), and 15 min later, received
cocaine (10 mg/kg). Doses were chosen based on those previously shown to produce
reliable CPP for nicotine (Walters, 2006; Grabus, 2006) and cocaine (Sora, 2001).
Behavioral Data Analysis and Statistics. For nicotine-treated mice, preference
scores were calculated as time spent in the drug-paired side on test day minus time
spent in the drug-paired side during baseline. For saline-treated mice, preference
scores were calculated as the average of the white side on test day minus the white
side during baseline and the black side on test day minus the black side during
baseline. None of the drugs used caused locomotor suppression in the mice at the
doses used for these studies, therefore, time spent in either chamber was not
confounded by this behavior. Statistical analysis of all behavioral studies was performed
using one- or two-way analysis of variance (ANOVA), where appropriate. If a one-way
ANOVA was significant, an appropriate post-hoc test was performed (Dunnett’s for
comparisons vs. control and Tukey’s HSD for between-group comparisons when more
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than two groups existed). Post-hoc p-values of <0.05 were considered to be statistically
significant.
QTL Mapping, Correlations, and Heritability Calculations. QTL mapping and
correlations were performed using BXD strain means in GeneNetwork (Chesler, 2004)
and R/qtl (Arends, 2010). Heritabilities for nicotine and saline CPP phenotypes were
estimated using the intraclass correlation coefficient method at α=0.05 (Smith, 1957;
Lynch, 1998) using the ICC package in R.
Quantitative Reverse-Transcriptase PCR, Microarrays, Data Analysis, and
Network Generation. For qRT-PCR experiments, single nucleus accumbens (NAc)
samples from 9-week old, untreated C57BL/6J, DBA/2J, α7 KO, and WT mice were
micro-dissected on ice and immediately flash-frozen in liquid nitrogen using a protocol
described previously (Kerns, 2005). Samples were homogenized with a Polytron®
(Kinematica AG) and RNA extracted using a guanidine/phenol/chloroform method
(STAT-60, Tel-Test, Inc.). Each RNA liquid layer was added to an RNeasy Mini Column
(Qiagen) for cleanup and elution of total RNA. RNA quality and purity was determined
using an Experion Automated Electrophoresis Station (Bio-Rad) and a Nanodrop 2000
(Thermo Scientific). 1µg of RNA was converted to cDNA using the iScript cDNA
synthesis kit containing random hexamers (Bio-Rad) according to manufacturer’s
instructions.

Primer sequences, Tm’s, amplicon sizes, and cDNA dilutions used for

each gene are listed in Table 6.1. Primer efficiencies were between 90-110% and each
primer set resulted in only one PCR product. Data analysis was performed using the 2[∆∆CT]

method (Heid, 1996). Statistical analysis of qRT-PCR data was performed using a

Student’s t-test between the two strains tested.
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TCATCTAATTGGGCACGAAG
CCCCTGGAACATCTCTACTCC
AACCCCGAGAGAACGAAGA
TGTAAGGGTGGGGTTGAGTC

TTCCAGTATGACTCCACTCACGG

FWD Primer (5' to 3')
TTTGATGCCACATTCCACAC
ATCTCTCACCCTTGCCCTTT

REV Primer (5' to 3')
AGGACCACCCTCCATAGGAC
CCCATTTTGTGTGCTTTCGT
TGAAGACACCAGTAGACTCCACGAC
CATAAAACCTCGGGCTCCT
GTTCACACACCAGCACTCC
CTCTGTGGTTTGTGTCACGAG
GCACGAAAGCACAAAAGTGA

cDNA
dilution
1:25
1:25
1:25
1:25
1:25
1:25
1:25

Table 6.1. Primer sequences used for quantitative, real-time PCR. Table containing all primer sequences, Tms, and
amplicon sizes from the qRT-PCR experiments.

Target Gene
Chrna7
PPP2r2a
Gapdh
Ide
Igfbp2
Igfbp6
Ndn

Amplicon
Tm (°C) Size (bp)
61
169
61
79
60
169
60
109
60
117
60
147
60
186

Affymetrix Mouse 430A 2.0 microarrays were performed on α7 KO and WT single
NAc samples from individual animals, n=5/genotype (sample collection and RNA
extraction were performed as described above). All RQI values were >9.0, 260/280
ratios were between 1.9-2.1 and 260/230 ratios were >2.0. Samples were randomized
at all possible steps and 100ng of RNA input were used for each 16-hour I reaction.
Remaining steps were performed according to the manufacturer’s protocol. All
microarrays passed each quality control measure and Pearson correlations of robust
multi-array average (RMA) signals between single chips were ≥ 0.996. Pairwise
significance-scores (S-scores) between KO and WT chips were generated using the sscore package in R (Kerns, 2003). A one-class statistical analysis of microarrays against
a mean=0 and 100 permutations, was performed in the MultiExperiment Viewer (MeV,
Boston, MA). A delta of 0.314, a false-discovery rate of 9.8%, and s-scores ≥ |1.5| were
used to identify significantly differentially regulated genes. Gene network construction
was performed using Ingenuity Pathway Analysis (Ingenuity, Redwood City, CA), which
uses Fisher’s exact test to determine the probability of input genes belonging to the
network by chance (Ingenuity Pathway Analysis, 2005).
Immunoblotting. Single nucleus accumbens (NAc) from untreated α7 KO and WT
mice were microdissected and flash-frozen in liquid nitrogen as described above.
Samples were triturated in 100uL of cold 1X LDS (Life Technologies, Grand Island, NY)
containing 2X Halt protease and phosphatase inhibitor cocktail and 10mM EDTA
(Thermo Fisher Scientific). Each sample was passed through a 28g syringe until brain
tissue was no longer visible upon quick spin centrifugation. Protein concentrations on
the whole sample homogenates were determined using the bicinchoninic acid assay
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(Thermo Fisher Scientific). Samples were balanced with 1X LDS, reduced with 50mM
dithiothreitol and boiled for 10 minutes. For each antibody used herein, it was
determined that 20µg of protein lie within the linear range of detection, thus 20µg of
protein were loaded per lane on a 4-12% NuPage bis-tris gel (Life Technologies). Using
a 1X MOPS running buffer, electrophoresis was performed at 150V. The gel was
transferred to a 45µm PVDF membrane at 10V for 24 hours using a freshly prepared
transfer buffer containing 10% methanol. Coomassie staining of the gel and Ponceau
staining of the membrane indicated efficient and even transfer. Prior to each primary
antibody incubation, the membrane was blocked with 5% BSA in 1X wash buffer (TBST containing 0.3% Tween 20 and 1.5M NaCl) for 1 hour at room temperature. Primary
and secondary antibody catalog numbers, dilutions, and incubation times are provided
in Table 6.2. Immunoblots were imaged on Kodak film using the chemiluminescent ECL
prime reagent (GE Healthcare Life Sciences) and quantitated using ImageJ processing
and analysis software (National Institutes of Health). All proteins were normalized to the
loading control, β-actin (ACTB).

Results
Genetic correlation analysis of nicotine CPP phenotypes in BXD mice.
Following conditioning with either saline-saline (0.9%) or saline-nicotine (0.5mg/
kg) twice daily for 3 days, nicotine place preference scores (Figure 6.2, a) on test day
(no drug present) for BXD strains follow a continuous distribution for these behaviors,
indicative of a polygenic trait. Strains with negative scores are interpreted as having an
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KDa
97
118
>100
>100
42
NA

Manufacturer
Cat#
Millipore
07-724
Abcam
ab32216
Millipore
07-838
Millipore
07-841
Sigma
A2228
GE Healthcare Life Sciences NA934-1ML

2° Dilution (1h at
Room Temp)
1 to 1000
1 to 5000
1 to 10,000
1 to 10,000
1 to 10,000
see above

Table 6.2. Antibodies used for immunoblotting. Table containing all primer antibody catalog numbers, molecular
weights, dilutions, and incubation times used for immunoblotting.

Antibody
INSR
IDE
p-INSR (Y972)
p-INSR (Y1158,Y1162,Y1163)
ACTB
Donkey anti-Rabbit-HRP

1° Dilution (2h at
Room Temp)
1 to 1000
1 to 1000
1 to 1000
1 to 1000
1 to 7500
NA

Treatment

Nicotine

100
0
-100

BXD15

BXD2

BXD28

BXD33

BXD18

BXD1

BXD5

C57BL/6J

BXD12

BXD39

BXD16

BXD15

BXD39

BXD42

BXD14

BXD28

BXD1

BXD12

BXD5

C57BL/6J

BXD18

BXD16

BXD42

BXD34

BXD14

BXD21

BXD38

BXD20

BXD31

BXD11

BXD36

BXD9

BXD8

DBA/2J

-200

Strain

b
100

0

-100

BXD33

BXD38

BXD21

BXD2

BXD34

BXD36

BXD20

BXD11

BXD9

BXD8

BXD31

DBA/2J

-200

BXD32

Average [Nic-Sal] Place
Preference Score (sec)

Saline

200

BXD32

Average Place
Preference Score (sec)

a

Strain

Figure 6.2. BXD strain distribution for place preference for 0.5mg/kg nicotine. A,
Following conditioning with either saline-saline (0.9%) or saline-nicotine (0.5mg/kg),
nicotine place preference scores (black) on test day for BXD strains follow a continuous
distribution, indicative of a quantitative trait. Progenitor strains, C57BL/6J and DBA/2J,
show divergent phenotypes for this trait. Each point represents the mean ± SEM of
n=6-12 mice per group. B, Transformed distribution, nicotine minus saline BXD strain
means. (Behavioral studies performed by Tie Han and Lisa Merritt).
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aversion to nicotine and strains with positive scores showed a preference for nicotine.
Of note, some BXD strains treated with saline appear to show preferences for one side
of the CPP chamber, however, the within-strain variability is quite high. To remove
possible confounds of the saline phenotype on our nicotine phenotype, we performed a
subtraction of BXD strain means, nicotine minus saline (Figure 6.2, b) and used this
phenotype throughout the remainder of the paper. The progenitor strains, C57BL/6J and
DBA/2J, show divergent phenotypes. The mean heritability for nicotine place preference
was 18.7% (Table 6.3). Quantitative trait loci (QTL) analysis revealed suggestive
behavioral QTL (LRS>9.2) for nicotine CPP on proximal Chr X (maximum LRS 10.4;
18.79 Mb; see Table S1). Genetic correlation analysis with traits within the
GeneNetwork phenotype database (www.GeneNetwork.org) revealed that nicotine
place preference phenotypes significantly inversely correlate to the number of
cholinergic neurons in multiple dorsal and ventral striatal sections (Table 6.4),
suggesting a link between the nicotine place preference and cholinergic signaling in the
striatum. Nicotine preference scores also significantly correlated positively to
consumption of a saccharin solution (Belknap, 1992) (an appetitive reward-like
behavior), exploratory activity in an open field test following saline (Belknap, 1992),
rearing behavior following morphine (Philip, 2010), and percent time spent in the light
side of a light dark box following ethanol administration (Putman, 2008), See Table S2).
Together, these findings suggest that the genetic architecture underlying nicotine place
preference is complex and likely consists of both genes overlapping with natural food
reward and exploratory behaviors, as well as genes involved in other drug of abuse
phenotypes. A full list of significant nicotine preference phenotype correlates is provided
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ICC
0.187308
-0.01431
0.395823
0.327644
0.121614
0.221771

Lower CI
0.045651
-0.09407
0.223261
0.160089
-0.01029
0.063601

Upper CI
0.328964
0.065457
0.568385
0.4952
0.25352
0.379941

k (mean n per
strain)
8.072607
7.070621
8.072607
8.072607
7.070621
7.070621

var (within var (between
strain)
strain)
15803.49
3642.35
57808.35
815.4663
84386.02
55284.96
100784.8
49113.27
128446.2
17783.56
116119.3
33090.39

Table 6.3 - Intraclass Correlation Coefficients of BXD nicotine and saline CPP phenotypes. Intraclass correlation
coefficients (ICC) with confidence intervals for saline and nicotine phenotypes are listed as measures of heritabilities of
these traits across the BXD panel of mice. Saline place preference and post-conditioning scores ICCs were near zero,
suggesting that treatment of saline does not genetically influence these phenotypes. Nicotine place preference and postconditioning ICC estimates were 19% and 13%, respectively, with upper confidence levels reaching 33% and 25%.
Locomotor activity ICC estimates ranged from 12-40%.

Phenotype
NicPref
SalPref
NicBaseLoco
NicTestLoco
SalBaseLoco
SalTestLoco

N
(strains)
25
25
25
25
25
25

GeneNetwork
ID

Phenotype

Authors

Spearma's
rho

Central nervous system, morphology:
Striatum cholinergic neurons, section
Dains K,
10106 11 [n neurons/section]
Hitzemann -0.7356738
Central nervous system, morphology:
B, and
Striatum cholinergic neurons, section Hitzemann
10107 14 [n neurons/section]
R (1996)
-0.5443756
Central nervous system, morphology:
Striatum cholinergic neurons, section
10110 22 [n neurons/section]
-0.6417141

n Strains

p(rho)

18

0.000268

18

0.0180843

18

0.0032019

Table 6.4 BXD place preference scores correlate inversely to the number of
striatal cholinergic neurons. Within multiple sections of the striatum, the number of
cholinergic neurons (Dains et al. 1996) is significantly inversely correlated with nicotine
place preference scores of BXD mice on day 5 of the CPP paradigm. All genetic
correlations are Spearman correlations performed using GeneNetwork (GN ID =
GeneNetwork Record ID, n = number of BXD strains used for correlations).
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in Supplemental Table S2.
Basal Chrna7 mRNA expression in the NAc is genetically inversely correlated with CPP
nicotine reward-like phenotypes in the BXD panel of mice.
The lack of robustly significant QTL for nicotine place preference scores may be
due to large intra-strain variance, high environmental variance, as well as the
complexity of the behavioral assay. Furthermore, many genes or loci of small genetic
effect underlying the CPP behavior, rather than one or few loci of large effect would
likely mask detection of a significant behavioral QTL with the number of strains assayed
herein. Despite this, we reasoned that this data could still be used to identify gene
expression networks contributing to trait variation. We have previously generated basal
genomic expression profiles across the mesolimbocortical dopamine pathway (NAc,
PFC, and VTA) in many of the same BXD strains used for the studies here (Wolen,
2012). Therefore, we correlated these expression patterns to the transformed CPP
behavioral data (nicotine-saline). Correlating this trait versus gene expression in NAc,
PFC, and A resulted in 2044, 2099, and 1253 probesets, respectively, showing
provisional correlations (p<0.05) (See Supplemental Tables S3-S6). The further analysis
of these expression correlates will be reported elsewhere, but for the purposes of this
report, we simplified the data analysis by surveying the results for nicotinic receptorrelated genes that also contained putative cis expression QTL (eQTL). We proposed
that this might implicate specific nicotinic receptors not previously implicated in
modulating CPP for nicotine. Correlates were filtered for genes containing only putative
cis eQTL because cis eQTL occur most often from genetic variation within the gene
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itself, have a larger effect size, and are the primary genetic drivers of variation, while
trans eQTL have secondary or tertiary effects (Schadt, 2003; Drake, 2006). This
analysis showed that only Chrna7 in NAc contained a cis eQTL that significantly
correlated with the normalized CPP phenotype (see Table S7). Figure 6.3 depicts
correlations between the normalized CPP phenotype and Chrna7 mRNA expression
(Figure 6.3, a, probeset ID 1440681_at and 6.3, b, probeset ID 1450229_at) in each of
the three brain regions of the mesolimbic dopamine reward pathway (VCU BXD NA,
VTA and PFC, RMA saline datasets). Although preference scores correlated significantly
to Chrna7 mRNA expression in both NAc (Pearson’s r= -0.50, p=9.04E-3, probeset
1446081_at) and PFC (Pearson’s r= -0.51, p=9.07E-3, probeset 1450229_at), the cis
eQTL only existed in the NAc for probeset 1446081_at, so we focused on this probeset
for the remainder of analyses. Together, with the CPP correlation to cholinergic neurons
in the striatum, these data suggest that strains with low basal mRNA expression of
Chrna7 in the NAc may be more susceptible to the reward-like properties of nicotine
using the CPP test.
Figure 6.4a-b depicts the Chrna7 cis eQTL (probeset 1440681_at) present in the
NAc across the BXD panel of mice. Since two probes within this probeset have single
nucleotide polymorphisms (SNPs) between B6 and D2 mice that may have influenced
cRNA hybridization to the oligonucleotide microarray, causing a false cis eQTL, we
excluded those probes and re-performed interval mapping, which confirmed the putative
cis eQTL (Figure 6.4, a-b). Microarray results were validated by performing qRT-PCR
for Chrna7 from B6 and D2 NAc tissue samples (Figure 6.4, c). Genetic variation,
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Figure 6.3. The nicotine place preference phenotype is genetically correlated to Chrna7
basal mRNA expression in the nucleus accumbens, but not the prefrontal cortex, or
ventral midbrain. Preference scores (nicotine-saline) significantly correlate with basal
Chrna7 expression (Chrna7 Probeset ID = 1440681_at, panel A) in the nucleus accumbens
and prefrontal cortex (Chrna7 Probeset ID = 1450229_at, panel B), but not ventral midbrain
(denoted as VTA). Correlation scattergrams (left of diagonal), univariate density plots (in
white, along the diagonal), and Pearson’s r values (right of diagonal) are displayed. For the
correlation scattergrams, the linear fits are plotted in red with 50% confidence intervals in
blue. Each point represents the mean for a BXD strain. A blue r values denotes a significant
correlation, while grey r values are non-significant at an alpha = 0.05. All expression data are
saline RMA values from the VCU BXD NA, PFC, and VTA Datasets, with probes containing
SNPs between B6 and D2 genotypes removed.
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Figure 6.4. Genome-wide interval map for Chrna7 mRNA levels across the BXD RI
panel. A, Following 2000 permutations, a suggestive cis expression QTL (blue solid
line) exists on chromosome 7 for Chrna7 mRNA levels in the nucleus accumbens (VCU
BXD NA Dataset Saline RMA Values, Probeset ID 1440681_at). A LOD score of 3.77
(LRS of 17.38) denotes a significant QTL. The cis eQTL remained after removal of the
probes containing SNPs between B6 and D2 mice (red dotted line). The DBA/2J
genotype for Chrna7 increases its expression. B, An enlargement of Chromosome 7
reveals two possible QTL peaks driving the mRNA expression of Chrna7, of which the
proximal peak harbors Chrna7 (at 70.24Mb). C, Quantitative, reverse-transcriptase PCR
validation of microarray results. Basal mRNA expression of Chrna7 in the nucleus
accumbens is significantly greater in D2 mice compared to B6 mice (*p<0.001,
t[12]=5.068, n=7/gp, Student’s t-test). Each point represents the mean ± SEM.
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specifically, SNPs within the 3‘UTR (which may lead to increased or decreased miRNA
binding at the seed region) and/or the 5‘UTR (which may alter promoter activity) of
Chrna7 are strong candidates for differential regulation of the transcript abundance
(Schadt, 2003hp) observed between B6 and D2 strains, and thus, among the BXD
panel of mice. Alternatively, Chrna7 transcript levels in the BXD panel may be regulated
by a putative enhancer, which has been mapped to a region within intron 4 of Chrna7
(Stefan, 2005). It is possible that the enhancer contains a SNP affecting promoter
activation and subsequent transcription between B6 and D2 mice, strains which are
highly polymorphic (285 SNPs, Supplemental Table S8) within intron 4 of Chrna7.

Knock-out of the α7 nAChR increases sensitivity to, while gain-of-function or agonism of
the α7 nAChR, abolishes nicotine CPP reward-like phenotypes in mice.
We employed a series of pharmacological and genetic manipulations in mice to
confirm the involvement of the α7 nAChR in nicotine CPP as expected from the inverse
correlation between basal Chrna7 mRNA expression and nicotine CPP. First, α7 KO
mice demonstrated significant preference for 0.1mg/kg nicotine versus saline control
treatment (Figure 6.5, a). This dose of nicotine does not routinely produce place
preference in C57BL/6J mice (Walters, 2006), suggesting an increase in sensitivity to
the reward-like properties of nicotine in CPP. However, this enhancement was not
observed with 0.5 mg/kg of nicotine. In contrast, gain-of-function, α7 KI mice did not
develop preference to nicotine at either 0.1 or 0.5 mg/kg, but WT littermates developed
normal preference for 0.5 mg/kg nicotine (Figure 6.5, b). This follows the trend observed
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Figure 6.5. Deletion of the alpha7 nAChR results in increased sensitivity to nicotine place preference
and knock-in or agonism of the alpha7 nAChR prevents nicotine place preference. Panel A, on day 5 of
the CPP paradigm, a significant increase in place preference scores for 0.5mg/kg nicotine was observed in
both Alpha7 KO and WT mice (oneway ANOVA, by Dunnett’s post-hoc vs. within-genotype saline
FKO[2,20]=16.8854, *p<0.01, n=7-8/group, FWT[2,21]=24.0645, *p<0.01, n=7-8/group; 0.5mg/kg dose
previously reported by Walters, et al 2006). Alpha7 KO mice display place preference for 0.1mg/kg nicotine
(oneway ANOVA, followed by Dunnett’s post-hoc vs. saline control, F[2,20]=16.8854, #p<0.05, n=7-9/group).
This enhancement of preference for 0.1mg/kg nicotine was of significantly lower magnitude than preference
for 0.5mg/kg nicotine (oneway ANOVA, Tukey’s HSD post-hoc, F[2,20]=16.8854, ‡p<0.01, n=7-8/group). A
twoway ANOVA (F[5,41]=16.9029, n=7-9/group) revealed significant main effects of both dose (p<0.01) and
genotype (p<0.05), but no significant interaction between dose*genotype (p=0.3371). Panel B, On Day 5 of the
CPP paradigm, only wildtype (WT) mice, but not alpha7 knock-in (KI) mice, show nicotine place preference for
0.5mg/kg of nicotine. A oneway ANOVA, followed by Tukey’s HSD post-hoc, revealed a significant effect of
dose in WT mice (F[2,21]=12.1665, n=8/group, *p<0.01), but not KI mice (F[2,29]=0.0080, p=0.9920, n=8-16/
group). C, Place preference for 0.5 mg/kg nicotine was significantly higher than preference for saline in B6
mice (oneway ANOVA vs. PHA0/Nic0, Tukey’s HSD post-hoc, F[1,12]=35.8629, #p<0.01, n=6-8/group).
Pretreatment with the nAChR alpha7 selective agonist, PHA-543613 (PHA), dose-dependently blocks place
preference for 0.5mg/kg nicotine. Significant blockade was observed at 8.0 and 12.0 mg/kg PHA (oneway
ANOVA vs. PHA0/Nic0.5, Dunnett’s post-hoc, F[3,25]=10.4663, *p<0.01, n=6-8/group). D, For CPP for 0.5mg/
kg of nicotine, 12.0mg/kg PHA blocked preference and this was reversed by pretreatment with 10.0mg/kg of
methyllycacontinine (MLA) (oneway ANOVA vs. PHA12/Nic0.5 alone, Tukey’s HSD post-hoc, F[1,13]=46.5249,
*p<0.01, n=7-8/group). MLA alone did not alter nicotine preference. Each point represents the mean ± SEM.
(Behavioral studies performed by Cindy Evans).
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for low or no preference in BXD strains having high basal mRNA levels of Chrna7
(Figure 6.2). Finally, the α7-selective agonist, PHA-543613, was able to dosedependently block preference in B6 mice for 0.5mg/kg nicotine (Figure 6.5, c), a dose
that routinely produces place preference in this strain of mice (Walters, 2006). The
highest dose of PHA-543613 (12.0 mg/kg) did not significantly alter preference scores
on its own (data not shown, one-way ANOVA vs. vehicle, Tukey’s HSD post-hoc,
F[1,14]=0.5321, p=0.4778, n=8/group). Furthermore, Figure 3.5D shows that blockade
of nicotine preference by PHA-543613 can be reversed using 10.0 mg/kg of the α7selective antagonist, MLA (oneway ANOVA vs. PHA12/Nic0.5, Tukey’s HSD post-hoc,
F[1,13]=46.5249, *p<0.01, n=7-8/group). Also shown and previously reported, this dose
of MLA was unable to block preference for 0.5mg/kg nicotine in B6 mice on its own
(Walters, 2006).
To control for possible learning deficits or enhancements in the gene-targeted mice
and to determine if this effect was specific to nicotine, we tested cocaine CPP in α7 WT,
KI, and KO mice. Mice of all three genotypes developed similar place preference to
10mg/kg cocaine (Figure 5.6, a-b), suggesting that not only are these mice responsive
to pavlovian drug conditioning, but also that the α7 mechanism is nicotine-selective. As
an additional control to rule out Chrna7 involvement in place preference for cocaine, we
attempted to block preference in C57BL/6J mice with PHA-543613, but saw no
attenuation of cocaine place preference compared to control (Figure 5.6, c).
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Figure 6.6. Alpha7 knock-in and knock-out mice develop normal place preference
to a 10mg/kg dose of cocaine; pre-treatment with PHA in C57BL/6J mice does not
alter cocaine place preference. Panels A and B, On Day 5 of the CPP paradigm, a
significant increase in place preference scores for 10mg/kg cocaine compared to withingenotype saline treatment was observed for all genotypes tested (oneway ANOVA, vs.
within-genotype saline, Dunnett’s post-hoc, FKO[1,13]=83.3130, *p<0.01, n=7-8/group,
FWT-A[1,13]=47.3111, *p<0.01, n=7-8/group, FKI[1,16]=23.6439, *p<0.01, n=9/group, FWTB[1,15]=13.8604, *p<0.01, n=8-9/group). Panel C, C57BL/6J mice develop robust place
preference to 10mg/kg cocaine as previously reported (cite, year), (oneway ANOVA, vs.
saline, Dunnett’s post-hoc, F[1,8]=23.0984, *p<0.01, n=5/group). Pre-treatment with
PHA did not block cocaine place preference in C57BL/6J mice, C (oneway ANOVA, vs.
within-group PHA, Dunnett’s post-hoc, F[1,14]=4.9642, #p<0.05, n=8/group). Each point
represents the mean ± SEM. (Behavioral studies performed by Dr. Pretal Muldoon).
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Genetic interactions among Chrna7 and insulin-related genes in the NAc may contribute
to preference for nicotine.
In order to explore possible mechanisms underlying the enhanced sensitivity to
nicotine observed in α7 KO mice with the CPP test, contrasted to their WT counterparts,
we performed microarray analysis on NAc samples from only α7 KO and WT mice, but
not KI mice. Following statistical analyses and filtering, differentially regulated genes
revealed the top significant network (p=1.0E-49) as containing multiple genes involved
in insulin signaling (Figure 6.7, a). We observed differential expression between α7 KO
and WT mice in the insulin growth factor binding proteins, Igfbp2 and Igfbp6, as well as
Ide (insulin-degradation enzyme). A study in rats had reported differential mRNA
expression of Ide following nicotine treatment (Polesskaya, 2007) and furthermore, an
allele within the Ide gene had been previously significantly associated with plasma
cotinine levels in both European and African American smokers (Hamidovic, 2012),
implicating a possible role for Ide in nicotine addiction.
Furthermore, within the BXD panel of mice, we elucidated a co-expression
network of Chrna7 and insulin-related genes in the NAc, which are significantly
genetically correlated to each other as well as the normalized nicotine preference
phenotype, suggesting novel and complex gene-gene interactions underlying place
preference to nicotine (Figure 6.7, b). Finally, qPCR performed from α7 KO and WT NAc
samples confirmed significant downregulation of Ide mRNA ((p<0.05, t[7]= 2.957),
upregulation of Igfbp6 mRNA (p<0.05, t[7]=2.230), and a non-significant trend for
differential regulation of Igfbp2 (p=0.11, t[7]=1.07, see Table 3.5). qPCR for gene, Ndn,
which was upregulated in α7 KO mice likely linked to Chrna7, was performed as a
151

Figure 6.7. Knock-out of the α7 nAChR results in alterations to an insulin-related
gene network. A, Top-ranked (p=1.0E-49) biological network of genes differentially
regulated in the NAc between α7 KO and WT mice (red = upregulated, green =
downregulated, colorless = imputed gene, number below each gene = KO/WT s-score,
red arrows denote insulin-related genes). B, Genetic correlation network performed
using BXD mRNA expression data, displaying co-regulation of Chrna7 and multiple
insulin-related genes in the NAc. (All correlations drawn are significant and used
Pearson’s r, red = positive, blue = negative. bold = r ≥ |0.5|, solid = |.41| ≥ r < |0.49|).
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Gene
Ide*
Igfbp2
Igfbp6*
Ndn*

Normalized Relative
KO Expression
KO SEM
0.731
0.091
1.768
0.249
1.549
0.144
2.374
0.160

Normalized Relative WT
Expression
1.102
1.166
1.071
1.177

WT SEM
0.096
0.166
0.136
0.078

p-value
1.55E-02
1.08E-01
3.58E-02
3.09E-03

Table 6.5. Quantitative RT-PCR confirms differential insulin-related gene expression in the
NAc of α7 KO and WT mice. Basal mRNA expression of Ide is significantly down-regulated in
the NAc of KO mice compared to WT mice, while Igfbp6 is significantly up-regulated, and there is
a trend toward up-regulation of Igfbp2. Ndn, a gene likely linked to Chrna7 on chromosome 7,
was also confirmed to be up-regulated in KO mice. Each point represents the mean of ± SEM
(nKO=4 and nWT=5). All genes were normalized to the housekeeping gene, Gapdh.

153

positive control. The elucidated expression networks and qPCR data suggest an
increase in insulin signaling in both α7 KO and BXDs with low NAc levels of Chrna7
mRNA, thus perhaps these genes may be regulated by Chrna7.

Knock-out of the α7 nAChR results in basal increases in insulin signaling in the nucleus
accumbens.
To confirm functional differences in insulin signaling in the nucleus accumbens of
α7 KO and WT mice, we performed immunoblotting for proteins known to be involved in
insulin signaling. Contrasted to our microarray data in which Ide mRNA was decreased
in the NAc of α7 KO mice, we found that IDE protein was significantly upregulated
compared to WT (*p<0.01, t[6]IDE=5.18), Figure 6.8. Additionally, we found a trend for
decreased total INSR-β (insulin receptor, intracellular subunit) levels (p=0.113,
t[6]INSR=1.87) and significantly increased phosphorylation of multiple sites of the INSR in
α7 KO mice compared to WT mice (t[9]pIR(Y1158, Y1162, Y1163)/IR=4.60, t[9]pIR(Y932)/IR=4.49),
Student’s t-test, nKO=6, nWT=5.

154

Figure 6.8. Alpha7 knockout mice display differential basal expression of insulinrelated proteins in the nucleus accumbens. A, Representative immunoblots of nucleus
accumbens samples from individual mice. IDE=insulin-degrading enzyme,
pIR=phosphorylated insulin receptor (Y= tyrosine residue phosphorylated), INSR/IR=β
subunit of the insulin receptor, ACTB=β-actin). B, Quantitation and analyses of
immunoblot samples (nKO=6, nWT=5) by Student’s t-tests revealed that IDE protein levels
as well the degree of phosphorylation of the total insulin receptor were significantly
increased in alpha7 KO mice compared to WT mice (*p<0.01, t[9]IDE=5.18, t[9]pIR(Y1158,
Y1162, Y1163)/IR=4.60, t[9]pIR(Y932)/IR=4.49) while total insulin receptor levels showed a trend for
being decreased compared to WT mice (p=0.113, t[9]INSR=1.87). All proteins are
normalized to ACTB.
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Discussion
In this study, we combined behavioral and expression genetics to identify
candidate genes underlying nicotine’s reward-like behavioral response in mice. This
implicated Chrna7 as a candidate gene and we verified this assumption using genetargeted mice and pharmacological tools for Chrna7. By extending our genomic analysis
in α7 KO mice, we provide evidence that an insulin gene expression network in the NAc,
regulated by Chrna7, may contribute to reward-like effects of nicotine CPP.
Using the BXD panel of mice, we found that basal Chrna7 mRNA expression in
the NAc was significantly negatively correlated to CPP for nicotine. Studies with the α7
agonist, PHA-543613, reduced CPP for nicotine dose-dependently and MLA studies
with the α7 antagonist, MLA, were able to reverse the attenuation of nicotine CPP.
Behavioral analyses in α7 KI mice did not display nicotine CPP, but conversely, α7 KO
mice were more sensitive to a low dose of nicotine, suggesting an increased perceived
reward-like effect in these mice. Together, these behavioral data strongly implicated
Chrna7 as a candidate gene modulating nicotine reward-like phenotypes in CPP.
Previous studies using α7 KO mice or an α7 antagonist in rats have reported that
the α7 nAChR is not required for nicotine CPP (Walters, 2006) or self-administration
(Brunzell, 2012), respectively. Additionally, it was reported that reductions in α7 nAChR
activity due to antagonist administration into the NAc shell, as well as anterior cingulate
cortex, increased the motivation of rats to self-administer nicotine (Brunzell, 2012),
suggesting that low or lack of α7 nAChR activity may modulate the use of nicotine. By
surveying the BXD strains and including a lower dose of nicotine in our α7 KO studies
for nicotine CPP, our studies have unmasked the first evidence that Chrna7 transcript
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levels in the NAc are both genetically regulated and may be an important factor in
determining the magnitude of nicotine’s reward-like effects as measured by CPP.
Although CPP and self-administration were originally thought to be isomorphic models
of drug reward, that idea is no longer generally supported. Rather, it is commonly
accepted that that self-administration is a model of reinforcement, and CPP is a model
of “reward” (and is influenced by other factors such as memory), thus each measure
different components of drug-seeking behavior in animals (Bardo, 2000). Since the
CPP test measures contextual cues associated with a drug’s perceived “reward”, our
data suggests that lower levels of Chrna7 mRNA in the NAc contributed to an altered
(perhaps, enhanced) neural response to cue-related behaviors, allowing nicotineseeking behavior to persist.
Using microarray analysis, we discovered that gene-targeting of the α7 nAChR
results in up-regulation of an insulin-signaling network in the NAc. A genetic correlation
network of insulin-related genes and Chrna7 was independently elucidated in the NAc
across the BXD panel, thus validating that our microarray results are likely not due to
developmental compensation in α7 KO mice. Insulin-degrading enzyme, Ide, mRNA
was significantly decreased and previous rodent studies have demonstrated that both
knock-out of this gene (Farris, 2003), as well as a mutation decreasing its catabolic
activity (Fakhrai, 2000), results in hyperinsulinemia and glucose intolerance. Based on
these studies, we predict that in the NAc, α7 KO mice should have increased insulin
signaling compared to WT mice. Insulin and insulin growth factor 1 (IGF1) are produced
peripherally and can readily cross the blood brain barrier to elicit endocrine signaling
events. IGF1 is also secreted locally by neuronal cells (neurons, microglia, and
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astrocytes) and participates in paracrine signaling within the brain. Insulin and IGF1
signal through either of their receptors, INSR (Insulin receptor) or IGF1R (IGF1
receptor), or, through a hybrid receptor formed from dimerization of the INSR and
IGF1R receptors. Insulin binds to and activates its receptor, which stimulates
autophosphorylation of the intracellular β-subunit at tyrosine residues 1158, 1162, and
1163 promoting receptor tyrosine kinase activity. This event stimulates phosphorylation
of Y972, which creates recognition sites for insulin receptor substrates (IRS) (Draznin,
2006). Recruitment of IRS can trigger two canonical signaling pathways, PI3K-AKT and
Ras-ERK. A study performed on rat NAc slices reported that insulin potentiates the
effects of DA release in the NAc following cocaine administration and this was reversible
using a PI3K inhibitor (Schoffelmeer, 2011). Additionally, a study in rat striatal cultures
found that insulin receptor activation led to increases in DAT mRNA expression and
transporter function that resulted in higher reuptake of dopamine (Patterson, 1998) and
regulation of DAT was blocked in cell culture with a PI3K inhibitor, providing evidence for
the PI3K-AKT pathway in insulin’s modulation of dopamine uptake (Carvelli, 2002).
These studies suggest a negative feedback loop in which insulin promotes both
dopamine release and dopamine reuptake via increasing DAT transcription. In fact, α7
KO mice have been shown to have significantly higher levels of and longer persistence
of nicotine-induced DA release in the NAc compared to WT mice (Besson, 2012). This
enhancement of DA release within the brain’s reward center in α7 KO mice may be one
explanation for the increased sensitivity to low dose nicotine observed in the CPP test.
Our studies also provide evidence of feedback regulation of insulin levels, in which
Ide mRNA in α7 KO mice is lower, suggesting high insulin levels, but IDE protein levels
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are higher compared to WT mice. Protein levels may be high to compensate for
increases in insulin levels and/or due to protein-protein interactions between insulin and
IDE, thus stabilizing IDE protein. Additionally, we found significantly higher activation of
the INSR as well as a trend for decreased INSR protein levels in α7 KO mice,
suggesting possible downregulation of the receptor due to this increased activation by
insulin. Furthermore, our microarray experiment revealed higher transcript levels of
genes for two insulin growth factor binding proteins, Igfbp6 and Igfbp2, in α7 KO
compared to WT mice. The bioavailability and actions of IGF1 are tightly regulated by
insulin-like binding proteins, IGFBP1-6. Upregulation of IGF binding proteins in the NAc
of α7 KO mice may be the result of a compensatory mechanism acting to sequester free
IGF in response to the increases in insulin to prevent hyperstimulation of insulin
signaling pathways via the hybrid receptor.
Taken together, these studies provide evidence that Chrna7 modulates an
expression network of insulin-related genes and their proteins, which may alter
downstream dopamine signaling, leading to altered nicotine reward-like behaviors in
mice. These studies are the first to elucidate the genetic interplay between Chrna7 and
insulin signaling in the NAc and a role for such interactions in nicotine behavior. These
genetic and protein interactions have implications for uncovering new therapeutic
targets for nicotine cessation pharmacotherapies.
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Chapter 7 - Concluding Discussion and Future Studies

Discussion
!

Within the alcohol addiction research field, the notion that an individual’s initial

level of response to alcohol correlates inversely to his or her later susceptibility to
becoming alcoholic (Schuckit, 1994; Schuckit, 1980), has been a key driver in the study
of the neurobiological and neurogenomic mechanisms underlying acute ethanolresponsive behaviors. Together, with the extensive literature suggesting that acute and
repeated drug use lay the groundwork for rewiring the nervous system toward addiction,
the overall hypothesis of this dissertation work was that identification of genetic variants
modulating acute behavioral responses to ethanol and nicotine may allow us to better
understand the neural mechanisms contributing to these early cycles of addiction. By
using a genetical genomics approach in mice, we have identified and begun to confirm
a role for two such candidate genes, Chrna7 and Nin.
!

At this point, it is important to further discuss the relationship between the initial

level of response with later drug abuse and/or chronic drug behaviors. To reiterate, it
has been accepted that those with lower initial responses to alcohol, and thus a reduced
perception of a “high” from the same dose as others with the same blood alcohol
concentration, have a higher susceptibility of becoming alcoholic later in life (Schuckit,
1994). However, the responses tested by Schuckit were very specific (ie, body sway)
and subjective (as determined by a survey). Therefore, we must not generalize that a
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“low level” of every type of drug response will correlate with dependence susceptibility.
In fact, mouse correlation data presented in Chapter 2 (Figure 2.1) shows the exact
opposite, in which phenotypic responses in the acute paradigms tested for alcohol and
nicotine correlate positively with chronic dependence-like behaviors for these same
drugs. This discrepancy with the human literature might be due to the manner in which
the data were scored for each assay, but nonetheless, these data do show a
relationship between acute and chronic behaviors, suggesting that measuring these
type of phenotypes in mice is complex.
!

Perhaps, the data should be interpreted differently. For example, B6 mice show a

greater anxiolytic-like response in the LDB compared to D2 mice, yet they selfadminister ethanol to dependence, while D2 mice do not (Le, 1994), suggesting a
positive correlation between the acute and chronic ethanol phenotypes. The low
consumption of ethanol in D2 mice is thought to result from an aversion to the odor,
taste, and/or mucosal irritation, which B6 mice do not demonstrate (Belknap, 1977). D2
mice were reported to avoid ethanol, even when adulterated with saccharin, in a
conditioned taste aversion test (Horowitz, 1975). However, B6 mice have also been
shown to have lower blood ethanol concentrations than D2 mice administered the same
dose which persists for up to an hour following administration (Grisel, 2002). This
supports both a decreased metabolism of ethanol and higher brain concentrations of
ethanol (ethanol is a small, water-soluble molecule which readily diffuses through the
blood-brain barrier) in D2 mice, thus perhaps, higher euphoric effects of ethanol.
Unfortunately, these subjective phenotypes cannot be asked of rodents. One
interpretation of this might be that D2 mice in fact have higher initial levels of response
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to ethanol defined by Schuckit as “greater perception of a high” and in turn, this is
manifested by a lower level of response in the LDB assay and consequently, an
aversion to drinking. Following this line of thought, B6 mice might then perceive a
dampened rewarding effect of ethanol since concentrations reaching the brain would be
lower, leading to enhanced self-administration to compensate for the low brain levels.
Interestingly in support of this notion, B6 mice have been shown to turn over synaptic
dopamine (DA) in striatal nerve terminals to its metabolite, 3,4-Dihydroxyphenylacetic
acid (DOPAC), more rapidly than D2 mice under basal conditions even though total
striatal DA levels were not different between the two strains (George, 1995).
Furthermore, DA and DOPAC levels assayed immediately following a limited-access
ethanol consumption paradigm revealed that ethanol did not alter total DA levels in the
striatum, ventral midbrain, or frontal cortex, but did significantly increase the ratio of
DOPAC to DA only in the striatum compared to naive mice (George, 1995).
Pharmacological inhibition of one of dopamine’s metabolic enzymes, monoamine
oxidase B (MAO-B), with selegiline resulted in significant decreases in drinking behavior
in B6 mice, and this was reversed with co-administration of antagonists for either
dopamine receptor 1 and 2 (George, 1995). Thus, B6 mice have a genetic
predisposition resulting in dampened basal striatal DA function due to high rates of
synaptic turnover, which may cause a decreased reward-like response to ethanol and
thus, a propensity to consume high levels.
!

The acute ethanol studies performed here implicate a role for Nin in an acute

anxiolytic-like response to ethanol in mice. As mentioned earlier, the main function of
Nin is microtubule-anchoring and organization in the centrosome during mitosis,
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however, this is unlikely its function in the acute response to ethanol. Rather, Nin might
by eliciting its effects through its interaction with microtubules in synapses to contribute
to neuroplasticity. Until recently, it was thought that microtubules were not involved in
actively-forming dendritic spines, protrusions of varied shapes which receive most of the
brain’s excitatory input at the post-synaptic density (PSD) of glutamatergic neurons.
However, recent immunohistochemical labeling studies have confirmed the presence of
dynamic microtubules in dendritic spines (Hu, 2008). The shape, composition, and
microenvironment of dendritic spines are important in the synaptic transmission of and
communication between neurons (Gray, 1959). As they are mainly found on
glutamatergic neurons, the PSD of dendritic spines is largely comprised of N-methyl-Daspartate (NMDA) receptors, to which glutamate directly binds, eliciting excitatory
neurotransmission and promoting spine formation (Carpenter-Hyland, 2007). Therefore,
increased concentrations of NMDA receptors, along with the presence of dynamic
microtubules and their associated proteins within dendritic spines, may suggest an
increased likelihood of interactions between Nin and NMDA receptors at the synapse or
an association between Nin levels and synaptic plasticity. Interestingly, within the NAc,
the brain region where Nin expression is thought to mediate acute ethanol’s anxiolyticlike response, Nin and Grin2b (NMDA, NR2B subunit) basal mRNA levels were found to
be significantly inversely correlated (Figure 7.1, a). In fact, non-centrosomal Nin has
been found in much higher concentrations in neuronal cells than centrosomalassociated Nin, and levels were higher in processes actively undergoing axonal
retraction or “pruning”, a process that serves to eliminate inappropriate axonal
projections (He, 2002; Baird, 2004). Thus, Nin may perform a protective role during
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Figure 7.1 - Basal NAc Nin mRNA correlations with Grin2b and ethanol
consumption. Across the BXD panel of mice, basal mRNA expression of Nin and
Grin2b were found to be significantly inversely correlated, a. (Pearson’s r= -0.385,
p=0.01982, n=36 strains). Basal Nin levels in the NAc were also significantly correlated
with two-bottle choice drinking behavior following three rounds of ethanol vapor in the
CIE model, b. (Pearson’s r= -0.702, p=0.0212, n=10 strains).
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neurogenesis, disease, and/or injury to ensure “proper” synapse formation. Even more
striking, the basal mRNA expression of Nin significantly correlates to two-bottle choice
drinking following three bouts of ethanol vapor in the chronic-intermittent ethanol model
of alcohol dependence (Figure 7.1, b), implying that low Nin transcript abundance in the
NAc may be a risk factor for later drinking behavior.
!

Chronic administration of ethanol and other drugs of abuse has been shown to

decrease dendritic spine density (Robinson, 1997; Chandler, 2006; Kauer, 2007) and
investigation of alcoholic brain tissue samples revealed that chronic drinking
significantly decreased both the number of dendritic spines in the NAc and caused
dysmorphology of spines (Zhou, 2007), revealing a neurotoxic effect of ethanol. It has
been shown that ethanol, a known negative allosteric modulator of the NMDA receptor
with its allosteric site on the NR2B subunit (Wright, 1996), acutely potently inhibits
NMDA signaling (Engberg, 1992), but chronically upregulates these receptors
(Chandler, 1999). Furthermore, acute ethanol increases dendritic spine density in the
CeA (Moonat, 2011), suggesting that increased excitatory neurotransmission remains
intact. The ethanol-induced upregulation of NMDA receptors is thought to occur as a
homeostatic compensation to counteract the inhibition of NMDA receptor activity in
order to maintain an intact neural network (Carpenter-Hyland, 2007). In fact, one of the
three clinically-prescribed medications used to treat alcohol withdrawal symptoms,
acamprosate, antagonizes the NMDA receptor to reduce glutamatergic surge and
increased excitability leading to symptoms of delirium tremens following alcohol
cessation (DeWitte, 2005). Thus, it appears that predisposition to genetic variants of Nin
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could result in alterations of a glutamatergic amygdalar-striatal circuit following acute
and/or chronic ethanol use.
!

Taken altogether, acute ethanol, although a potent inhibitor of NMDA receptors,

has been shown to increase dendritic spines in the CeA, suggesting homeostatic
counteraction of this NMDA inhibition through enhancement of excitatory output to a
target brain region, such as the NAc. Perhaps because individuals with high basal Nin in
the NAc also have low levels of Grin2b in the NAc, this excitatory neurotransmission
from the CeA may result in an anxiolytic-like response of lower magnitude compared to
individuals with the opposite Nin/Grin2b gene expression pattern. Chronically, ethanol
and other drugs of abuse indirectly decrease dendritic spine densities and this
dysregulation might contribute to altered and/or inappropriate synaptic connections. As
the localization of Nin in retracting axons indicates that it may play a role in correcting
faulty dendritic spines, individuals with low Nin levels may be at risk for an enhanced
neurotoxic effect due to chronic ethanol. As these neural connections become rewired
with chronic ethanol use, local concentrations of Nin may not be high enough to
maintain regulation, thus predisposing an individual toward addiction. A model of the
interplay between Nin, ethanol, and anxiety is illustrated in Figure 7.2.
Overall, these studies strongly implicate both a role for neuronal Nin in an acute
anxiolytic-like response to ethanol and suggest that genetic variants of Nin may be risk
factors for chronic ethanol use. Additional studies discussed at length in Chapter 3
strongly implicate Chrna7-mediated regulation of insulin signaling as a potential
mechanism for eliciting nicotine’s reward-like phenotype. We report that genetic
variation within Chrna7 might be a risk factor for smoking initiation and/or relapse. The
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Figure 7.2 - Proposed interactions between Nin, ethanol, and anxiety. Acute
ethanol has been shown to increase dendritic spines in the CeA, which would be
expected to enhance excitatory output to the NAc. Perhaps this excitatory
neurotransmission underlies the decreased anxiolytic-like response in individuals with
high basal NAc Nin. Chronically, ethanol decreases dendritic spine densities and this
dysregulation might contribute to altered and/or inappropriate synaptic connections. As
Nin may play a role in correcting faulty dendritic spines, individuals with low Nin levels
may be at risk for an enhanced neurotoxic effect due to chronic ethanol. As these neural
connections become rewired with chronic ethanol use, Nin may not be abundant enough
to maintain regulation, thus leading toward addiction.
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genetical genomics approach taken here illustrates the utility of inbred mice as model
organisms in the study of disease phenotypes.

Future Studies
!

This dissertation work has just begun to unravel the complex, yet intriguing,

relationship between alcohol use disorders and anxiety, thus future studies are
warranted to further investigate these interactions. For example, we report that NAc Nin
transcript levels might be important in the synaptic remodeling events which occur
following both acute and chronic ethanol use. Although that mechanism is supported by
Nin neuronal localization studies and a large body of literature connecting spine
densities with anxiety and drug use, we have yet to provide direct evidence for this. To
do so, a series of studies examining dendritic spine densities and/or type of spines after
acute and chronic ethanol treatment might be performed in mice with either high or low
basal NAc Nin levels, such as B6 and D2 mice. However, the diverse genetic
backgrounds of these two strains may confound the results if epistatic interactions
involved in spine remodeling or between Nin and another gene occur, so a better
approach may be to use viral constructs, sh-Nin-lentivirus (or Cre-recombinase), to
knockdown Nin in a strain (or a Nin-floxed mouse) with high basal NAc levels, such as
were performed with D2 mice herein.
!

Currently, there is no Nin knockout mouse available and since genetic variants in

Nin were found to be associated with skeletal dysplasia (Grosch, 2013) and dwarfism
(Dauber, 2012), one might predict these mice may either not be viable or have severe
cranial and limb abnormalities. Alternatively, congenic strains of mice could be utilized in
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which B6 mice are created with the D2 form of the Nin gene and vice versa. The B6 Nin
genotype should increase the anxiolytic-like response to acute ethanol, as measured by
PTS and PDT in the light. However, congenic strains of mice require years of breeding,
the genomic changes are global rather than region-specific, and with the
commercialization and ease of making viruses, it is simply more feasible to inject a virus
stereotaxically to alter the expression of a gene. Furthermore, the viral approach can be
used in strains of varied genetic background and multiple brain regions can be
interrogated.
!

We have thus far, shown that knocking down Nin in the NAc increases acute

ethanol’s anxiolytic-like response, manifested as a decreased latency to enter the light,
a measure routinely interpreted as anxiolytic-like, as discussed previously. However,
drinking behavior was not tested because D2 mice do not routinely self-administer
ethanol (Le, 1994). Knocking down NAc Nin in the B6 mouse strain and subsequently
testing chronic drinking paradigms would solidify a link between basal Nin and drinking
susceptibility. Although this dissertation work suggests a role for neuronal Nin,
potentially at the synapse, it may be important to determine the downstream effectors of
Nin in the NAc which may contribute to dysregulation leading to the possibility of alcohol
addiction. One way to do so would be to perform microarray expression analysis or
RNA-Seq analysis on the NAc tissue of four groups of mice following the treatments:
basal Nin + saline, Nin knockdown + acute ethanol, basal Nin + chronic ethanol, Nin
knockdown + chronic ethanol. Comparisons within acute, chronic, and between acute
and chronic would elucidate genetic perturbances and perhaps networks of genes
responsive to Nin in each of those instances. Alternatively, as we are hypothesizing that
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synaptic Nin may be the primary driver for the acute and chronic ethanol-responsive
behaviors mentioned and Nin is expressed both within and outside of the synapse,
synaptoneurosome preparations might be performed on the aforementioned groups
prior to gene expression analyses to link the genetic changes observed with synapse
expression of Nin. It may be important to understand the gene network(s) being
modified by Nin, as altered basal expression patterns of genes may respond to ethanol
differently (Farris, 2010), and may ultimately lead to a new therapeutic approach of
targeting a central network hub gene or simply, a hub of one node of a network which
responds to a drug.
!

If these experiments reveal a solid role for Nin in modulating ethanol-responsive

behaviors, then studies ought to be performed to elucidate the mechanism of Nin
regulation. As discussed in Chapter 5, B6 and D2 mice displayed different pools of NIN
isoforms in the NAc, suggesting functional differences between the two isoforms and/or
enhancement of alternative splicing in the D2 strain. The smaller, ~150 and ~160KDa
isoforms which were found at higher levels in D2 NAc, likely from an alternative splicing
event in which exon 16 is skipped. As mentioned earlier, D2 mice have two nonsynonymous SNPs in exon 16 of the Nin gene, one of which is suggested to alter an
ESE site and one which creates a new site, compared with the B6 gene. Together,
these data suggest that D2 mice have increased alternative splicing activity, resulting in
a greater concentration of NIN isoforms missing exon 16. To determine whether these
SNPs are responsible for the alternative splicing events predicted, an experiment in
which site-directed mutagenesis of Nin and subsequent cloning into an expression
vector to create sequences having the B6 or D2 SNPs may be performed. Transfection
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into a cell line, followed by immunoblotting, may reveal whether these SNPs are
responsible for generating the altered pools of NIN isoforms between B6 and D2 mice.
Alternatively, Nin expression may be differentially regulated by an intronic enhancer
polymorphism, variant in the promotor region, or the 3‘UTR region, which may affect
miRNA binding.
!

The relationship between Nin and Grin2b is intriguing. As acute ethanol is a

negative allosteric modulator of NMDA receptors, one might predict that an antagonist
of Grin2b, for example, ifenprodil, should result in an anxiolytic-like phenotype in the
LDB. In fact, this antagonist was shown to increase social interaction in rats (Morales,
2013). It follows then, that the magnitude of the responses should differ in B6 and D2
mice in the same manner as ethanol, in which B6 mice might be expected to have a
greater anxiolytic-like response to the drug.
!

Some followup studies for the acute nicotine reward-like phenotype should

certainly include site-specific modulation of Chrna7 levels, followed by CPP testing. As
the relationship between its basal expression in the NAc and CPP phenotype were
inverse, one would predict that knocking down Chrna7 in the NAc would produce an
enhancement in nicotine CPP. That is, at the 1.0mg/kg dose which does not regularly
produce CPP, knockdown of Chrna7 in the NAc should produce a preference
phenotype. Additionally, based on our studies, further investigation into the interplay
between Chrna7 and the insulin pathway is warranted. A neuronal role for insulin in not
only disease, but substance abuse disorders, is newly emerging, suggesting a role
separate from its major peripheral role in glucose homeostasis (Ghasemi, 2013).
Furthermore, as the heritability of nicotine dependence is modest, additional BXD
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mapping studies for other relevant phenotypes should be pursued in order to better
understand the genetic underpinnings of the disease.
!

Altogether, this body of work has significant implications for both the nicotine and

alcohol fields. We have not only confirmed roles for new QTGs in acute phenotypes for
each drug, but we also propose that these acute behavioral responses are very
important in the progression from acute to chronic drug use and as such, warrant
adequate and careful investigation. By doing so, along with many others, we have
demonstrated the validity of the “genetical genomics” approach to studying substance
use disorders. With both the mouse and human genomes sequenced and now actively
being characterized in terms of regulatory elements, the future of genetical genomics
promises to be exciting and will ideally enhance our understanding of the molecular and
genetic mechanisms of disease so that treatment by genotype may be the effective
practice.
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A2 - Diagram of the CPP test

center partition

193

A3 - Diagram of the Marble Burying Task
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A5 - Restriction enzyme digests of lentiviral plasmids
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A6 - Gsk3b binding site amino acid sequence similarity between human and
mouse NINEIN

Query: human NIN isoform 2, NP_065972.3
Subject: mouse NIN isoform 1, NP_001074922.1
[

[ ] C-ter
- Gsk3

N isoform 2, NP_065972.3
IN isoform 1, NP_001074922.1
[

]

[ ] C-terminal domain
- Gsk3b binding site
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